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 Summary 
The world health organization (WHO) declares cancer as one of the leading 
causes of mortality worldwide and reported 14 million new cases and 8.2 million 
cancer-associated deaths in 2012. The term cancer summarizes a broad spectrum 
of diseases reflecting the common feature of uncontrolled cell proliferation and 
systemic dissemination of tumor cells. Systemic dissemination of cancer cells 
requires in principle the invasion of tumor cells into the body’s circulation and their 
outgrowth at a distant site. In breast cancer, which is one of the top five diagnosed 
cancers among women, as in most cancer types metastatic outgrowth is the leading 
cause of death. 
Epithelial to mesenchymal transition (EMT) is an essential developmental 
process and comprises the gradual remodeling of epithelial cell architecture and 
functional capabilities. More precisely, cells lose epithelial cell characteristics like 
strong cell-cell junctions and an apical-basal cell polarity, which retain cells in a 
functional epithelial layer. During EMT, cells convert to a low proliferation state and 
acquire a spindle-like cell shape enabling single cell migration, invasion and 
increased cell survival. The aberrant activation of EMT promotes breast tumor cell 
invasion and dissemination, furthermore, its reverse process, mesenchymal to 
epithelial transition (MET), is believed to support metastatic outgrowth. Hence, we 
need to better understand the underlying molecular mechanisms controlling the 
dynamic nature of cell (de)differentiation and its consequences during malignant 
tumor progression. 
In the past years, intensive research has demonstrated that EMT/MET plasticity 
and its functional implications can be orchestrated by interconnected molecular 
networks consisting of transcription factors, epigenetic regulators, splicing factors 
and non-coding RNAs, which can be activated by a plethora of extracellular signals. 
However, we are just at the beginning to understand the role and regulation of such 
factors during EMT. Therefore, during my studies I aimed to identify critical players, 
in particular transcription factors and miRNAs implicated and conserved during 
normal and cancer-associated cell dedifferentiation and characterized their 
contribution to cancer progression in vitro and in vivo.  
We established different in vitro EMT systems to examine the stepwise 
morphological transition of epithelial mouse mammary cells by transforming growth  
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factor β (TGFβ), a potent EMT inducing cytokine. Subsequent global gene 
expression profiling of various cell dedifferentiation states allowed us to monitor the 
transcriptomic alterations in a time-resolved manner. In combination with a 
bioinformatic analysis for DNA-binding motifs, we identified the transcription factor 
Tead2 as a potential EMT regulator. Tead2 is a transcriptional effector of the Hippo 
pathway, which tightly controls cell proliferation and organ growth. Upon EMT 
induction, the nuclear levels of Tead2 increase, which upon direct binding induces a 
predominantly nuclear localization of its cofactors Yap and Taz. Furthermsore, 
Tead2 is required during EMT and promotes tumor cell migration, invasion and lung 
colonization in vivo. Genome-wide chromatin immunoprecipitation/next generation 
sequencing in combination with gene expression profiling revealed the direct 
transcriptional targets of Tead2 during EMT in epithelial tumor cells. Among other 
EMT-relevant genes, we identified Zyxin an Actin remodeling and focal adhesion 
component important for Tead2-induced cell migration and invasion. 
Aside from transcriptional control non-coding RNAs can regulate EMT/MET 
processes. Analyzing global transcriptomic alterations of different cell 
dedifferentiation states by deep sequencing analysis, we identified a pool of strongly 
differentially regulated miRNAs. In a combination of screens, we tested their 
functionality during EMT and mesenchymal tumor cell migration and identified miR-
1199-5p as a novel EMT-regulatory miRNA. MiR-1199-5p is transcriptionally 
downregulated during EMT, and forced expression of miR-1199-5p prevented TGFβ-
induced EMT and decreased mesenchymal mammary tumor cell migration and 
invasion. Furthermore, we report a new double-negative feedback regulation 
between miR-1199-5p and the EMT transcription factor Zeb1, exemplifying the close 
interconnections of transcriptional and post-transcriptional networks facilitating 
epithelial plasticity. In summary, both studies provided new insights into the 
molecular mechanisms orchestrating EMT and its functional consequences.	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1 General Introduction 
1.1 Epithelial to mesenchymal transition 
Almost 50 years ago, Elizabeth Hay described the concept of epithelial to 
mesenchymal transition (EMT) for the first time. She observed dramatic 
morphological changes of epithelial cells within the chick primitive streak and 
proposed that these epithelial cells “transformed” into mesenchymal cells and would 
migrate and form mesodermal and endodermal epithelia during early vertebrate 
development [1]. Since this process is highly plastic and mesenchymal cells can 
convert back to an epithelial cell state by a mesenchymal to epithelial transition 
(MET), the term “transformation” has been replaced by “transition” [2]. 
1.1.1 Basics of EMT 
Epithelial cells are positioned and tightly packed within epithelial layers and are 
characterized by intercellular junctions, an apical-basal cell polarity and their basal 
connection to a basement membrane in an epithelial monolayer. These cells display 
a low migratory potential and sometimes a high proliferation rate. Upon EMT various 
structural changes occur to remodel epithelial cell architecture and functional 
capabilities [3, 4] (Figure 1). 
(a) Epithelial cell-cell junction disassembly: Epithelial cells are connected by tight 
and adhesion junctions, desmosomes and gap junctions. Tight junctions mainly 
function as impermeable barriers within an epithelium. Furthermore, they facilitate 
mechanical connections between epithelial neighboring cells, which are also 
reinforced by adhesion junctions and desmosomes. Gap junctions bridge the 
intercellular space and connect the cytoplasm of epithelial cells. They allow the 
exchange of small molecules and ions between cells and represent cell 
communication channels. All four cell-cell junctions are either delocalized and/or 
degraded during EMT [5]. Epithelial Cadherin (E-cadherin) belongs to the classical 
type of Cadherins and forms calcium-dependent, trans-membrane adhesion junctions 
with neighboring epithelial cells. Its cytoplasmic domain builds a multiprotein 
adhesion complex, which connects E-cadherin with the Actin cytoskeleton via 
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different Catenins (α, β, δ (p120)) [6]. E-cadherin is required for epithelial cell-cell 
adhesion and its loss is a hallmark of an EMT [7]. During an EMT, E-cadherin is 
replaced by neural Cadherin (N-cadherin) an event termed “Cadherin switch” which 
is important for cell dissemination, migration and invasion [4, 8]. Furthermore, E-
cadherin delocalization from the membrane and degradation induces the release and 
thus nuclear accumulation of β-catenin and p120 where these proteins serve as 
transcriptional cofactors [9]. Similar to adhesion junctions, epithelial tight junctions 
are disassembled during EMT and a downregulation of Claudin and Occludin 
expression and diffuse cytoplasmic localization of ZO-1 (zonula occludens 1) have 
been described [5]. Desmosomes consist of Plakoglobin, Plakophilin, Desmocollin, 
Desmoglein and anchor and connect Keratin filaments between neighboring 
epithelial cells. EMT initiation leads to the disruption of desmosomes and 
transcriptional downregulation of desmosome proteins [10] 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: Schematic representation of structural and functional changes during EMT. Epithelial cells 
within an epithelium are connected via cell-cell junctions and via cell-matrix junctions to the basement 
membrane via Integrins. Epithelial cells display an apical-basal polarity and cortical actin organization. Upon 
EMT, cells acquire a fibroblast-like morphology with front-rear polarity and resolve strong cell-cell junctions. 
Cortical F-Actin is reorganized to Actin stress fibers. Secretion of MMPs and ECM components lead to the 
remodeling of the surrounding ECM to facilitate single cell migration and invasion, which is further promoted 
by the dynamic formation of cell-matrix adhesions through Integrins. Additionally, mesenchymal cells switch 
to a rather low proliferation rate, exhibit increased cell survival and resistance to apoptotic signals. 
 
 
b) Loss of apical-basal cell polarity: The apical polarity complexes PAR (aPkc-
Par3-Par6) and Crumbs (Crumbs-Pals1-Patj) and the basolateral complex Scribble 
(Scrib-Lgl-Dlg) are localized and connected to tight and adhesion junctions in 
epithelial cells. The loss of epithelial cell-cell junctions during EMT induces the 
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dissolution of an apical-basal polarity and promotes a front-rear directional polarity in 
mesenchymal cells [3].  
c) ECM remodeling and cell-matrix interactions: Integrins are type I trans-
membrane proteins, they connect the extracellular matrix (ECM) with the cell 
cytoskeleton and mediate cell adhesion and signal transduction [4]. Integrins form 
heterodimers composed of a non-covalently bound α and β subunit. In humans 24 
types of alpha and 9 types of beta subunits exist and the combination of α/β subunits 
in heterodimers determines the specific binding to different ECM substrates. 
Epithelial cells express α6/β4 Integrins, which mediate the interaction with basement 
membrane proteins such as Laminins. However, the expression of α6/β4 is 
transcriptionally repressed during EMT and replaced by α5/β1 Integrins promoting 
dynamic focal adhesion assembly, cell migration and survival by selective binding for 
instance to Fibronectin [11, 12]. Fibronectin is an ECM glycoprotein highly secreted 
by mesenchymal cells to facilitate cell migration [13]. Matrix metalloproteinases 
(MMPs) like MMP2 and MMP9 are endopeptidases secreted by mesenchymal cells 
to degrade ECM proteins and to facilitate mesenchymal cell invasion [14]. In addition, 
MMP-mediated ECM degradation liberates/activates a broad spectrum of ECM-
trapped growth factors and cytokines, for instance, transforming growth factor β 
(TGFβ), a potent inducer of EMT [15, 16]. 
d) Cytoskeleton rearrangements: Epithelial cells display cortical Actin filaments, 
anchored at cell-cell and cell-matrix junctions and thereby interconnect an epithelial 
cell layer with an Actin belt. Upon EMT, the Actin cytoskeleton is drastically 
rearranged to highly dynamic Actin stress fibers, which allows mesenchymal cell 
contractility and directional movements [2, 4, 9]. In particular, Rho GTPases (RhoA, 
Rac1, Cdc42) control Actin polymerization and rearrangements in mesenchymal cells. 
RhoA enforces the formation of Actin stress fibers and Rac1 and Cdc42 mediate the 
formation of lamellipodia and filopodia, respectively [17]. Apart from Actin 
cytoskeleton remodeling, the intermediate filament cytoskeleton composition also 
changes during EMT. Intermediate filaments (IFs) provide cells with mechanical 
strength and facilitate the trafficking of organelles and other proteins within cells. 
Upon cell dedifferentiation, epithelial Keratins are replaced by type III Vimentin IFs, 
which is crucial for mesenchymal cell shape, increased cell motility and focal 
adhesion dynamics [18]. 
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These structural changes during EMT lead to an elongated cell shape going 
along with increased migratory and invasive capabilities. Furthermore, mesenchymal 
cells have been shown to display a lower proliferation rate, increased cell survival, 
resistance to apoptotic signals and stem cell-like properties [2]. Various extracellular 
stimuli can induce EMT or MET in a time and context-dependent manner (see 1.2). 
Networks of transcriptional, post-transcriptional and post-translational mechanisms 
seem to orchestrate such gradual changes in cell morphology and behavior (see 1.3). 
 
1.1.2 EMT in biological contexts 
Based on the biological context, EMT has been subcategorized in three different 
types: developmental EMT (type I), EMT in wound healing and fibrosis (type II) and 
oncogenic EMT (type III) [19]. All three types display similar underlining molecular 
mechanisms causing cellular remodeling events as described above. However, they 
differ in their biological consequences [2, 20, 21].  
Type I - Developmental EMT: Several rounds of cell dedifferentiation and 
differentiation are essential during embryogenesis to allow the formation of tissues 
and organs, thereby, illustrating the plasticity of epithelial cells. A primary EMT 
occurs during gastrulation, an event forming the three embryonic germ layers (Figure 
2). Epithelial cells from the epiblast (a single epithelial layer) undergo EMT and 
ingress from the primitive streak in the interior of the embryo and generate the 
mesoderm and endoderm. Remaining epithelial cells in the epiblast form the 
ectoderm. Mesenchymal cells of the mesoderm undergo MET and form the 
notochord, somites, the primordium of the urogenital system, the splanchnopleure 
and the somatopleure. In a second round of EMT/MET processes, cells for instance 
from the dorsal half of the somite give rise to components of the dermis, muscle and 
satellite cells. Notably, the generation of the cardiac valves requires three repeats of 
cell dedifferentiation and subsequent differentiation events. In conclusion, a type I 
EMT goes hand in hand with its reversal process and aims to generate new tissues 
with distinct functions during development. 
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Figure 2: Reversible EMT 
processes during 
embryogenesis. (1) Primary 
EMT allows the migration of 
cells from the primitive streak 
to the interior of the embryo 
and thereby forms the 
mesoderm and endoderm. 
(2) MET of the mesenchymal 
mesoderm cells leads to the 
formation of the notochord, 
somites, primordium of the 
urogenital system, 
splanchnopleure and 
somatopleure. (3) Subsequently, cells for instance from the dermomyotome perform another round of 
EMT/MET to generate the dermis, muscle and satellite cells (adapted from [20]). 
 
 
Type II - EMT in wound healing and fibrosis: The second type of EMT displays 
cell (de)differentiation processes in the adult. EMT is induced upon tissue injury and 
inflammation in adjacent epithelial cells. The generated mesenchymal cells are able 
to migrate into the wound, reconstruct and repair the tissue. However, chronic tissue 
inflammation induces the formation and maintenance of a mesenchymal cell 
phenotype eventually leading to organ fibrosis. 
Type III - Oncogenic EMT: Type III EMT describes the aberrant activation of 
(partial) dedifferentiation processes in epithelial tumor cells. Oncogenic EMT 
promotes primary tumor cell dissemination and invasion into the surrounding tissue 
to eventually seed metastasis in distant organs. The reversion of cell differentiation 
during tumor progression is thought to be a crucial event to promote cancer cell 
colonization and the establishment of secondary tumors. Aside from invasive 
properties, oncogenic EMT seems to endow tumor cells with resistance to anoikis 
and chemotherapy, evasion of immune surveillance and stem cell-like properties [20]. 
In summary, epithelial cell plasticity facilitated by EMT and MET processes, is an 
indispensable feature during physiological processes such as embryogenesis and 
tissue homeostasis. However, aberrant and uncontrolled activation of EMT correlates 
with pathological patterns, such as organ fibrosis and promotes malignant tumor 
progression. 
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1.1.3 EMT and the metastatic cascade 
Genetic and epigenetic instability can induce tumor formation in a multistep 
process. The malignant form of tumor progression and the cause for more than 90 % 
of cancer-associated deaths is characterized by a tumor cell`s ability to invade into 
the surrounding tissue, spread and reestablish secondary tumors at distant organs 
[22]. However, when metastasis occurs during tumor progression is still debated and 
has raised two cancer progression models. The linear progression model describes 
the dissemination of tumor cells from advanced, higher graded tumors and claims 
metastasis is a rather late event during tumor progression. On the other hand, the 
parallel progression model suggests an early cell dissemination event and 
metastases evolve independently of the primary tumor [23]. So far, final proof for one 
or the other model has not yet been obtained. On a side note, it has been estimated 
that only 0.01 % of tumor cells entering the systemic circulation are able to form 
macrometastases, demonstrating that metastases formation is a rather inefficient 
process [24]. 
The “invasion metastasis cascade” (Figure 3) describes the sequential processes 
leading to metastases outgrowth and includes tumor cell migration and invasion into 
the surrounding tissue. Subsequently, cells brake through the basement membrane 
and intravasate into the systemic circulations like the lymphatic and blood vascular 
system. Tumor cells disseminate in the body and have to survive the harsh 
conditions in the bloodstream and cope with shearing forces, anoikis and immune 
cells. At a secondary site, cells extravasate, migrate into the organ parenchyma and 
either enter a dormant cell state and remain there for a long time [25] or start to 
proliferate, an event termed colonization, and form macrometastases [26]. In the past 
years, more and more evidence accumulated demonstrating that EMT/MET plasticity 
of epithelial tumor cells promotes malignant tumor progression. In vitro and in vivo 
studies have revealed that EMT of epithelial tumor cells promotes cell migration and 
invasion into the stroma [2]. Additionally, cells at the invasive tumor front often 
display a dedifferentiated morphology that is accompanied with a loss of the cell-cell 
junction protein E-cadherin [27, 28]. Furthermore, circulating tumor cells (CTCs) 
isolated from the bloodstream of patients with metastatic breast cancers exhibited 
mesenchymal cell marker expression relative to primary tumor cells [29, 30]. These 
findings are also consistent with a previous in vivo lineage tracing study in a 
Kras/p53-driven pancreatic tumor mouse model [31]. Here, invading and circulating 
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pancreatic tumor cells exhibited a rather mesenchymal cell phenotype. Finally, the 
tumor differentiation status correlated with the clinical outcome, where less 
differentiated tumors gave a poorer survival prognosis for breast cancer patients [32]. 
These results indicate that EMT might help tumor cells to overcome the initial steps 
of the metastatic cascade. 
 
Figure 3: EMT/MET and the metastatic cascade. (1) Hyperproliferative epithelial primary tumor (brown) (2) 
Some tumor cells undergo EMT (reddish) and gain mesenchymal characteristics and (3) start to invade the 
surrounding ECM and break through the basement membrane (BM). (4) Tumor cells intravasate into the 
blood circulation. (5) Circulating tumor cells with mesenchymal characteristics disseminate through the blood 
system and (6) extravasation at a distant site. (7) Cells invade the parenchyma of the target organ and either 
enter a dormant state or undergo MET, (8) start proliferating (colonization) and (9) establish macrometastasis. 
 
 
Tsai and colleagues have demonstrated the importance of EMT/MET dynamics 
for metastatic outgrowth. In a squamous cell carcinoma mouse model the authors 
have shown that activation of Twist1, a classical EMT inducer, in the primary tumor 
induced tumor cell intravasation and dissemination in vivo. More importantly, Twist1 
inactivation and thereby MET induction at a metastatic site was crucial for tumor cell 
outgrowth [33]. Similar observations have been reported for other EMT/MET inducing 
factors, such as Prrx1 [34], Id1 [35] and Snail [36]. Furthermore, such MET events at 
secondary sites would explain why metastatic lesions often display a differentiated 
phenotype similar to their primary tumors [37, 38]. Accordingly, Thomas Brabletz has 
highlighted two potential types of metastasis formation [39]. Within the “Plasticity type 
I” metastasis model, tumor cells are susceptible for signals from the 
microenvironment and dynamic EMT/MET processes drive metastasis formation. In 
detail, initial cell dedifferentiation promotes tumor cell dissemination, intravasation 
and extravasation into/from the bloodstream. Afterwards, the reversion to a 
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differentiated cell state promotes tumor cell proliferation and colonization at the 
metastatic site. Thomas Brabletz has pointed out that metastases can also have a 
dedifferentiated morphology independent of the morphology of the primary tumor. 
This phenotype can be explained by the “Genetic type II” metastasis model. Here, 
tumor cells undergo a permanent, irreversible EMT, exhibit stem-like properties and 
loose their phenotypic plasticity upon genetic alterations. Such genetic alterations 
force cancer cell metastatic colonization and outgrowth without the need for an MET 
[39]. 
The existence and relevance of EMT during human tumor progression was long 
debated and its transient nature did and does complicate the search for proof [40]. 
However, new sophisticated technologies helped and provided evidence that an EMT 
and maybe more importantly a partial EMT (characterized by the coexistence of 
epithelial and mesenchymal markers) is indeed implicated in cancer progression [29, 
41-43]. Nevertheless, further investigation is needed to pinpoint the function and 
further dissect the molecular mechanisms of EMT/MET processes during cancer 
progression. 
 
1.1.4 EMT in breast cancer 
Breast cancer is a heterogeneous disease and the most commonly diagnosed 
cancer in women. The pathological and molecular heterogeneity is reflected in the 
diverse clinical outcomes demonstrating the importance of breast cancer 
classification for both patient treatment and prognosis [44]. 
Histopathologically, invasive breast cancers are divided into different subtypes 
depending on their morphology. The most common type is the “invasive carcinoma of 
no special type” and was previously known as “invasive ductal carcinoma”. Less 
frequently diagnosed are invasive lobular carcinomas or others like metaplastic, 
tubular, cribriform, mucinous, medullary carcinomas [45]. However, more importantly 
for breast cancer treatment is their immunopathological classification based on the 
expression of specific markers: estrogen receptor (ER), progesterone receptor (PR) 
and human epidermal growth factor receptor 2 (HER2, also known as Neu or ErbB2). 
Generally spoken, ER- and PR-positive (ER+, PR+) primary tumors have a 
differentiated morphology, respond well to endocrine therapy and are predictive for a 
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good clinical prognosis for patients. HER2 gene amplification and overexpression is 
observed in 20 – 25 % of breast carcinomas. HER2-positive (HER2+) tumors are 
rather dedifferentiated and aggressive but can be treated by targeted therapies such 
as HER2 specific tyrosine kinase activity blocking antibodies or small-molecule 
inhibitors. Tumors negative for all three receptors (ER-/PR-/HER2-) are summarized 
in the triple-negative breast cancer (TNBC) subtype and display the worst prognosis 
also because of the lack of successful therapies [46]. 
In addition to immunopathological classifications invasive breast cancers can be 
subdivided according to gene expression profiles generated by microarray gene 
expression analysis [47-49]. This classification distinguishes five subtypes: luminal A, 
luminal B, basal-like, HER2-enriched and normal breast-like. Latter exhibits a similar 
expression profile like non-cancerous tissue. The luminal subtypes are often ER+ 
and resemble a rather differentiated tumor morphology since they express E-
cadherin and epithelial Cytokeratins (CK8, CK18). Gene expression profiles of basal-
like tumors overlap in part with the TNBC. Later, a sixth subtype, claudin-low, has 
been added to the molecular classification of breast cancers [50]. Both, basal-like 
and claudin-low subtypes often assemble metaplastic mammary carcinomas, a 
histologically mesenchymal, aggressive and chemoresistant tumor [51, 52]. Claudin-
low tumors lack expression of luminal, epithelial and proliferation-associated markers 
and, even more than the basal-like subtype, display an EMT gene signature and 
stem cell-like features [32]. Of note, hormone and chemotherapy treatment of 
patients with different breast cancers induced recurrent tumors with an 
undifferentiated claudin-low gene signature [53]. However, it remains unclear, 
whether the tumor cells were induced for a claudin-low signature or whether they 
existed before and have been selectively enriched during cancer treatment. 
Nevertheless, the study has demonstrated that dedifferentiated tumors with a 
claudin-low EMT gene signature go hand in hand with chemoresistance and tumor-
initiating capacities. Along this line, claudin-low tumors are also predictive for a worse 
patient survival prognosis than differentiated luminal A tumors. Surprisingly, the 
prognosis is not worse than for basal-like and other tumor subtypes, which could 
have been expected if a full EMT cell phenotype goes along with tumor cell 
invasiveness and metastatic potential [32]. 
In summary, sub-classifications of human breast cancers clearly helped us to 
dissect the heterogeneous nature of this cancer type and provided valuable 
GENERAL	  INTRODUCTION	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Epithelial	  to	  Mesenchymal	  Transition	  	  
	   10 
advantages for breast cancer treatment and prognosis. EMT-like features can be 
found in certain subtypes of breast cancers, where a dedifferentiated morphology is 
predictive for poor relapse free survival and overall survival compared to 
differentiated tumors [32]. 
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1.2 Inducers of EMT 
Various extracellular stimuli can activate signaling cascades that mediate EMT 
progression during development, tissue regeneration and malignant tumor 
progression. Growth factors, such as fibroblast growth factor (FGF), epidermal 
growth factor (EGF), insulin-like growth factor (IGF), hepatocyte growth factor (HGF), 
platelet-derived growth factor (PDGF), vascular endothelial growth factor (VEGF) 
and transforming growth factor β (TGFβ) can induce EMT in a context-dependent 
manner. Cells release growth factors into the extracellular microenvironment where 
they bind to tyrosine kinase receptors (RTKs) located on cells. These receptors 
transmit and activate MAP kinase and PI3 kinase intracellular signaling pathways 
inducing cell proliferation and survival. Depending on the growth factor, other 
signaling pathways such as TGFβ, Wnt, Notch, Hedgehog, JAK-STAT, NF-κB and 
Hippo signaling can be activated by different stimuli, crosstalk and influence the EMT 
process. Tissue metabolic and mechanical stresses can also act as powerful 
inducers of EMT and tumor cell invasion [3]. 
 
1.2.1 Canonical and non-canonical TGFβ signaling in EMT 
TGFβ signaling in normal tissues regulates cytostasis, cell apoptosis and 
differentiation and therefore tightly controls tissue development and homeostasis. 
The cytokine TGFβ belongs to the TGFβ superfamily and consists of three members 
(TGFβ1-3). TGFβ homodimers bind to TGFβ receptor II (TGFβRII) to eventually form 
heterotetrameric complexes with TGFβRI. Phosphorylated TGFβRII acts as 
serine/threonine kinase receptor and trans-phosphorylates serine and threonine 
residues within the intracellular domain of TGFβRI. TGFβRI recruits, phosphorylates 
and activates receptor Smads (R-Smads), Smad2 and Smad3, which in turn complex 
with Smad4, a common Smad (Co-Smad). In the nucleus, the trimeric Smad complex 
binds to specific DNA motifs, however to achieve high DNA binding and specificity 
they need to interact with other transcriptional cofactors to activate or repress gene 
transcription in a context-dependent manner. TGFβ signaling via Smads describes 
the canonical TGFβ pathway (Figure 4) and controls cell proliferation, apoptosis and 
differentiation during development and tissue regeneration [3, 54, 55]. 
GENERAL	  INTRODUCTION	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Inducers	  of	  EMT	  	  	  
	   12 
TGFβ signaling induces the transcription of Snail, Zeb1 and Twist transcription 
factors (TFs) [56-58], which can together with Smads repress or activate the 
transcription of other epithelial or mesenchymal genes, respectively [16]. For 
instance, Snail interacts with Smad3/4 to repress transcription of the epithelial 
junction proteins E-cadherin and Occludin [59]. Similarly, Zeb1 and Zeb2 complex 
with Smad3/4 to repress E-cadherin transcription, thereby, promoting EMT [57]. Of 
note, Smad3 and Smad4 are crucial mediators of TGFβ-induced EMT, whereas 
Smad2 can also function as an EMT suppressor [56]. Several groups have 
demonstrated that TGFβ-induced EMT is a sequential process. Epithelial cells can 
dedifferentiate into mesenchymal cells through a partial or hybrid cell state, which is 
characterized by the coexistence of epithelial and mesenchymal markers. This 
stepwise transition and its (ir)reversibility is tightly controlled by double negative 
feedback loops of Snail/miR-34 and Zebs/miR-200, depending for instance on the 
concentration and duration of TGFβ treatment [60-62]. 
Non-canonical TGFβ signaling via Rho-like GTPases, PI3K and MAPK signaling 
pathways can contribute to EMT and its functional outputs. Activation of these 
pathways occurs on the level of TGFβRI and II, which interact and activate certain 
adaptor proteins. For example, RhoA, Rac and Cdc42 GTPases drive Actin 
cytoskeleton reorganization and promote the formation of lamellipodia and filopodia 
[63, 64]. Par6, a cell polarity complex protein, is phosphorylated by TGFβRII and 
promotes cell-cell tight junction disassembly during EMT [65]. TGFβ signaling can 
phosphorylate Akt through PI3K activation, which leads to the activation of 
mammalian target of rapamycin (mTOR) and subsequently S6 kinase 1 (S6K1). 
Activation of PI3K-Akt has been shown to be required for cell migration and tight 
junction disassembly [66]. Furthermore, TGFβ activates p38 and c-Jun N-terminal 
kinase (JNK) via TRAF6/TAK1/MKK signaling. p38 has been shown to be required 
for TGFβ-induced EMT and apoptosis [67]. JNK induces the expression of the 
mesenchymal marker Fibronectin and is a critical regulator of cell migration [68]. 
Finally, TGFβ activates Erk1/2 through the Ras/Raf/Mek1/2 cascade, and Erk1/2 are 
required for cell-cell adhesion junction disassembly and cell motility [69]. In summary, 
TGFβ is a potent inducer of EMT and modulates cell dedifferentiation through Smad-
dependent and independent pathways. 
 
Inducers	  of	  EMT	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  GENERAL	  INTRODUCTION	  	  
 13 
      
Figure 4: Canonical and non-
canonical TGFβ signaling. Binding 
of TGFβ dimers to TGFβRII induces 
the assembly of the heterotetrameric 
receptor complex build by TGFβRII 
and TGFβRI. Transphosphorylation 
of TGFβRI phosphorylates Smad2/3, 
which upon binding to Smad4 
translocate to the nucleus and 
activate or repress gene 
transcription (canonical signaling). 
Activated TGFβRs can also transmit 
the signal to other factors 
independently of Smads. TGFβ 
mediates the activation of p38 and 
JNK through receptor associated 
TRAF6 and TRAK1. ShcA activates 
the Ras-Raf-MEK-ERK MAP kinase 
pathway. RhoA at tight junctions is 
degraded by the proteasome upon activation of Par6-Smurf1 by TGFβRII. In parallel, RhoA is activated by 
TGFβ and promotes Actin cytoskeleton rearrangements via ROCK. TGFβ induces PI3K and 
activates/suppresses S6K1/4EBP1 via AKT. 
 
 
1.2.2 TGFβ signaling in cancer 
In normal tissue and early stages of tumorigenesis TGFβ mainly induces a G1 
cell cycle arrest and apoptosis and functions therefore as a tumor suppressor. In 
advanced carcinomas, tumor cells lose such growth-inhibitory restrictions and 
accumulate invasive and metastatic properties in response to TGFβ, which can be 
accompanied by an EMT phenotype [70]. Loss-of-function mutations or deletions of 
core TGFβ pathway components, such as TGFβRs or Smad4, have been observed 
in many human cancers like colon, gastric, ovarian, head and neck, esophageal and 
pulmonary carcinomas [71]. Interestingly, TGFβR mutations are rarely seen in breast 
cancer. Here, only the tumor suppressive branch of TGFβ signaling (anti-proliferation 
and pro-apoptosis) seems to be lost while the cancer promotive function is still intact. 
During tumorigenesis, TGFβ signaling can switch from a tumor suppressor to a tumor 
promoter, a phenomenon known as the “TGFβ paradox” [70]. In this case, TGFβ 
promotes tumor growth, cell dedifferentiation, invasion and dissemination and in turn 
generates a pro-inflammatory and pro-tumorigenic microenvironment by stimulating 
the release of autocrine mitogens and cytokines. Like a self-activating loop, TGFβ is 
produced and released by tumor cells and tumor stromal cells [72]. Not surprisingly, 
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increased TGFβ levels have been found in cancer cells and in the tumor 
microenvironment of breast cancer patients [73]. Furthermore, high plasma levels of 
TGFβ in cancer patients are predictive for poor prognosis [71]. 
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1.3 Molecular networks regulating EMT  
EMT-inducing stimuli such as various growth factors, other receptor ligands, 
hypoxia or ECM constitution can induce intracellular signaling cascades, which in 
turn activate or inactivate various components of interconnected regulatory networks. 
These networks consist of splicing factors (see 1.3.1), epigenetic regulators (see 
1.3.2), TFs (see 1.3.3) and non-coding RNAs (ncRNAs; see 1.3.4). They can 
orchestrate transcriptional, post-transcriptional and post-translational processes 
essential for EMT/MET plasticity. Their aberrant regulation can cause oncogenic 
EMT/MET events and promote malignant tumor progression [74] (Figure 5). 
 
Figure 5: EMT/MET regulatory networks. 
Various extracellular stimuli activate or inactivate 
intracellular signaling pathways, which influence 
the behavior of components of interconnected 
regulatory networks. Transcription factors, 
splicing factors, epigenetic modifiers and non-
coding RNAs control the dynamic regulation of 
EMT on the transcriptional, post-transcriptional 
and post-translational level. Extracellular matrix 
(ECM), sonic hedgehog (SHH), transforming 
growth factor β (TGFβ), epidermal growth factor 
(EGF), hepatocyte growth factor (HGF), vascular 
endothelial growth factor (VEGF), insulin-like 
growth factor (IGF), platelet-derived growth factor 
(PDGF). 
 
 
 
1.3.1 Alternative splicing and EMT 
Alternative splicing is a post-transcriptional mechanism of gene regulation and 
facilitates the generation of several (functionally) different RNAs per gene. Genome-
wide RNA analysis revealed that approximately 95 % of human multi-exon genes are 
alternatively spliced. This emphasizes that alternative splicing contributes and 
expands the RNA and protein diversity encoded by the eukaryotic genome [75, 76]. 
Shapiro and coworkers have examined the changes in RNA splicing during EMT [77]. 
Deep sequencing analysis of the transcriptome of human mammary epithelial 
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(HMLE) versus Twist-induced mesenchmyal HMLE cells has revealed global 
changes in mRNA splicing patterns during EMT. Several of the EMT-associated 
alternative splicing events are also conserved in luminal versus basal-like breast 
cancer cell lines. These results indicate that alternative splicing is tightly regulated 
during EMT and breast cancer progression. Furthermore, the authors have 
suggested that an EMT-associated splicing signature could be used as potential 
biomarkers for breast cancer metastasis [77]. 
The RNA-binding proteins epithelial splicing factor regulatory protein 1 and 2 
(ESRP1 and ESRP2) have been identified as fibroblast growth factor receptor 2 
(FGFR2) splicing regulators [78]. Expression of FGFR2 splice variant with exon IIIb 
(FGFR2-IIIb) is observed in epithelial cells, whereas FGFR2 splice variant with exon 
IIIc (FGFR2-IIIc) is exclusive in mesenchymal cells. These distinct FGFR2 splice 
variant expression patterns are essential during development where they control cell 
proliferation and differentiation [79-81]. Expression of ESRP1 and 2 is strongly 
downregulated during EMT and are direct targets of EMT TFs such as Snail, Zeb1 
and Zeb2 [77, 82, 83]. Loss of ESRP1 or ESRP2 expression induces a switch from 
FGFR2-IIIb to FGFR2-IIIc isoform in human prostate epithelial cells [78]. Furthermore, 
stable knockdown of ESRP1 or ESRP1/2 in epithelial mammary cells promotes 
mesenchmyal cell morphology, accompanied with increased expression of 
mesenchymal markers and cell motility. However, loss of ESRP2 expression only, 
does not induce mesenchymal characteristics, suggesting that epithelial cell 
morphology is predominantly regulated by ESRP1 [84]. Warzecha and colleagues 
have further identified other known splice isoforms of CD44 [85], p120/Catenin 
(CTNND1) [86] and Mena (ENAH1) [87] to be regulated by ESRP1/2 and are typical 
for an epithelial or mesenchymal cell morphology [78] (Figure 6). 
A switch in the cell surface marker CD44 from variant isoforms (CD44v) to the 
standard isoform (CD44s) has been observed to be required during EMT and tumor 
formation. High expression of CD44s further correlated with high-grade human breast 
tumors [85]. p120 stabilizes adhesion junctions between epithelial cells [88] and has 
four different splice isoforms. The shorter isoforms (isoform 3 and 4) lack N-terminal 
sequences and their expression has been observed in epithelial cells, whereas 
mesenchymal cells mainly expressed the full-length p120 splice variant. p120 
isoforms bind RhoA via a central Armadillo domain site (amino acids 622-628). 
However, only full-length p120 is able to suppress RhoA activity via the N-terminal 
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domain and increases tumor cell invasion [86, 89]. Mena is a member of the 
Ena/VASP family and its isoform Mena+11a is specifically expressed in epithelial 
pancreatic tumor cell lines [87]. These results suggested that ESRP1/2 regulate a 
broad spectrum of epithelial gene isoforms on the post-transcriptional level to 
maintain an epithelial cell morphology and behavior. 
 
Figure 6: ESRP1/2 regulate EMT/MET plasticity via 
alternative splicing. Epithelial splicing factor regulatory 
proteins 1 and 2 (ESRP1/2) are highly expressed in 
epithelial cells and are transcriptionally downregulated 
during EMT. ESRP1/2 facilitate alternative splicing of 
factors specific for epithelial cell morphology: Fibroblast 
growth factor receptor 2 (FGFR2) with exon IIIb (splice 
variant with exon IIIc is expressed in mesenchymal cells); 
CD44 variant isoform (CD44v; CD44 standard (CD44s) 
isoform is expressed in mesenchymal cells); p120 short 
isoforms (p120 full length in mesenchymal cells) and Mena 
with exon 11a (Mena+11). 
 
 
In addition to ESRP1/2 other RNA-binding splicing factors have been identified to 
regulate EMT-specific RNA splicing patterns, for instance members of the RBFOX 
(RNA binding protein FOX1 homologue), CELF (CUGABP Elav-like family), MBNL 
(muscleblind-like protein) and hnRNP (heterogeneous nuclear ribonucleoprotein) 
families [77]. RBFOX2, for instance, is moderately upregulated during EMT and 
regulates mesenchymal tumor cell invasion [90]. 
In conclusion, alternative splicing is coordinated by RNA-binding splicing factors 
and adds another layer of dynamic gene expression regulation during EMT. Aside 
from transcriptional, epigenetic and ncRNA-mediated post-transcriptional control, 
alternative splicing events regulate cellular plasticity and are associated with tumor 
progression. 
 
1.3.2 Epigenetic regulation of EMT 
Epigenetic mechanisms globally regulate gene expression and cause cell 
phenotype alterations without affecting the order of nucleotides in DNA sequences. 
Here, stable but reversible DNA methylation and post-translational histone 
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modification marks alter and remodel the chromatin architecture. Euchromatin 
describes open, lightly packed chromatin and genes can be actively transcribed. On 
the other hand, heterochromatin is rather characterized as closed, tightly packed 
chromatin and gene expression is repressed. Moreover, epigenetic marks control the 
On/Off-state of gene transcription in a context-dependent manner [91, 92]. 
Alterations in DNA methylation and histone modification patterns are commonly 
observed and lead to aberrant gene expression in cancer [93, 94]. Additionally, 
several studies have demonstrated global epigenetic chromatin remodeling and 
reprogramming processes during epithelial cell dedifferentiation. These processes 
include DNA methylation and histone modifications such as methylation and 
acetylation marks [95-98]. 
 
1.3.2.1 DNA methylation during EMT 
DNA methylation implies the covalent attachment of a methyl group to cytosines 
of CpG di-nucleotide sites within DNA sequences. Such marks usually induce 
repression of gene transcription and are established by DNA methyltransferases 
(Dnmts) [99]. The CDH1 gene promoter region has been found to be 
hypermethylated in breast and prostate carcinoma cell lines, which correlated with a 
loss of E-cadherin expression. Treatment with 5-aza-2-deoxycytidine, a 
demethylation agent, partially restored E-cadherin expression [100]. Furthermore, 
CDH1 promoter hypermethylation correlated with malignant breast cancer 
progression [101]. A dynamic and reversible regulation of gene promoter 
hypermethylation during EMT has been reported recently. TGFβ-induced EMT of 
epithelial MDCK cells induced promoter hypermethylation and transcriptional 
downregulation of the miR-200 gene cluster - a mechanism also observed in 
metastatic cancer cell lines. Interestingly, TGFβ-withdrawal reversed such 
methylation marks and induced a MET [102]. These studies suggest that individual 
DNA promoter (de)methylation events are a critical epigenetic mechanism for gene 
silencing during EMT/MET and can drive malignant tumor progression. In contrast, 
McDonald et al. have reported that genome-wide DNA methylation was unchanged in 
a TGFβ-induced in vitro EMT model.  Nonetheless, the authors demonstrated a 
global reduction in heterochromatin induced by histone modifications, which might 
have been crucial for cell dedifferentiation [97]. 
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1.3.2.2 Histone modifications during EMT 
Histones organize genomic DNA into structural units (nucleosomes) and can be 
post-translationally modified, for instance by acetylation or methylation of lysine (K) 
or arginine (R) residues on histone 3 or 4 (H3, H4). Such covalent modifications open 
or close the chromatin and make it accessible for factors controlling gene 
transcription. While, generally spoken, histone acetylation usually activates adjacent 
gene promoters, methylation can activate or repress gene transcription depending on 
the lysine residue: K4, K36 or K79 – activation of transcription; K9 or K27 – 
inactivation of transcription [103]. 
 
Polycomb group (PcG) complexes 
The mammalian PcG complexes consist of two classes of multiprotein 
complexes, namely polycomb repressor complex 1 (PRC1) and 2 (PRC2). PRC2 
consists of three core components: Ezh (enhancer of zeste 1 or 2 (Ezh1 or Ezh2)), 
Eed (embryonic ectoderm development) and Suz12 (suppressor of zeste 12). PRC2 
exhibits histone methyltransferase activity and is initially recruited to target genes to 
catalyze mono-, di- or trimethylation of H3K27. Subsequent recruitment of PRC1 to 
H3K27me3 sites is required for the stabilization of such repressive marks [104, 105]. 
The core PRC1 consists of chromobox-domain (Cbx) proteins, members of the Pcgf 
family (Pcgf1-6), Ring1 family (Ring1a and Ring1b) and Hph family (Hph1-3) [106]. 
Both, PRC1 and PRC2, participate in promoting EMT and cancer progression. 
Bmi1 (B lymphoma Mo-MLV insertion region 1 homolog, also known as Pcgf4) is part 
of the PRC1 and was the first PcG protein associated with cancer. Bmi1 collaborates 
with c-Myc and H-Ras to induce cell proliferation and directly represses the Ink4a/Arf 
locus, which encodes for the tumor suppressors and cell cycle inhibitors p16 and 
p19Arf. Overexpression of Bmi1 induces neoplastic transformation of mouse 
embryonic fibroblasts and lymphomas [107-109]. Later, Bmi1 has been connected to 
EMT. Twist has been shown to induce the expression of Bmi1, which interacts with 
Ezh2 and Twist1 to repress CDH1 promoter activity and promotes EMT [110]. 
Additionally, Bmi1 can be post-transcriptionally repressed by miR-200c and miR-203 
[111] (Figure 7). 
PRC2 can induce EMT by collaborating with factors guiding the complex to 
certain target genes. Snail has been reported to silence the CDH1 promoter in tumor 
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cells by recruiting the PRC2 components Ezh2 and Suz12, which mediate 
H3K27me3 and thus repression of CDH1 expression [112]. Of note, the epithelial 
cell-specific miR-200 family can post-transcriptionally repress Suz12 expression, 
which in turn triggers the stabilization of E-cadherin levels [113]. Ezh2 expression is 
post-transcriptionally controlled by miR-101. Upon EMT induction expression of Snail 
and Slug represses miR-101 transcription, which in turn leads to the stabilization of 
Ezh2 levels, EMT and increased migration of oral tongue squamous cell carcinoma 
(OTSCC) cells [114]. Furthermore, Sox4 directly induces the transcription of Ezh2 
during TGFβ-induced EMT of normal mammary epithelial cells, and Sox4 executes 
its EMT and metastasis promoting function at least in part via Ezh2. Interestingly, 
many EMT-relevant genes are regulated by H3K27me3 marks during TGFβ-induced 
EMT and overlap with Ezh2 function during EMT [98]. Snail has been reported to 
interact with the methyltransferases Suv39h1 (suppressor of variegation 3-9 homolog 
1) and G9a to repress CDH1 transcription [115, 116] (Figure 7). Additionally to TFs, 
long non-coding RNAs (lncRNAs) can act in cis and trans to recruit PRC2 to specific 
genomic regions [117-121]. For instance, lncRNA HOTAIR recruits the PRC2 in trans, 
which triggers the generation of H3K27 methylation and subsequent gene silencing 
of HOX genes in fibroblasts [117]. 
Interestingly, H3K27me3 marks mediated by polycomb group proteins are often 
found in combination with activating histone modifications, such as H3K4m3. In this 
case, nearby gene promoters are transcriptionally repressed, but can be easily 
activated when the repressive mark is removed [122, 123]. It is believed that such 
bivalent marks could allow a dynamic gene regulation and might be important for 
epithelial-mesenchymal cell plasticity. Chaffer and colleagues have recently reported 
a bivalent Zeb1 promoter configuration in basal CD44low non-cancer stem cells 
(CSCs). Upon TGFβ stimulation, the repressive K27 mark was removed, the Zeb1 
promoter was activated and cells rapidly entered a CD44high stem cell-like state [124]. 
However, additional research is needed to test whether poised gene promoters are 
fundamental for rapid and reversible EMT cell plasticity. 
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Figure 7: Histone modifiers collaborate with EMT TFs to silence the CDH1 promoter during EMT. 
Members of the polycomb group complex (red), histone acetyltransferases and deacetylases (green) and 
histone demethylases (blue) regulate E-cadherin expression during EMT. Their (post)-transcriptional 
regulation by TFs or miRNAs is depicted. 
 
Histone (de)acetylation 
Histone acetylation results in euchromatin and active gene transcription. Histone 
acetyl transferases (HATs) mediate the covalent binding of an acetyl group, for 
instance to lysine histone residues. Histone deacetylases (HDACs) revert such 
modifications and induce transcriptional repression of genes [125]. Recruitment of 
the HDAC1/2-containing NuRD (Mi2/nucleosome remodeling and deacetylase) 
repressor complex by Snail results in CDH1 gene silencing [126] (Figure 7). Twist1 
together with the NuRD complex also represses E-cadherin expression and loss of 
Twist1 or complex components reduced the metastatic behavior of mouse mammary 
cells [127]. HDAC3 is essential during hypoxia-induced EMT and metastasis. It is a 
direct target of Hif1α and represses E-cadherin transcription in collaboration with 
Snail and Twist1. Additionally, it promotes expression of N-cadherin and Vimentin 
[128]. The deacetylase Sirt1 is another example for epigenetic CDH1 gene silencing. 
EGF-induced EMT in epithelial prostate cells upregulates Sirt1 and is recruited by 
Zeb1 to the proximal CDH1 promoter. H3 deacetylation suppressed CDH1 
transcription [129]. Interestingly, in a TGFβ-induced mammary EMT model, Sirt1 is 
embedded in a double negative feedback loop with miR-200a [130]. Similarly to Sirt1, 
Zeb1 can also recruit HDAC1/2 to the CDH1 promoter, mediate H3 and H4 
deacetylation and induced its transcriptional repression in pancreatic tumor cells 
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[131] (Figure 7). Surprisingly, only a class I HDAC inhibitor (mocetinostat) 
consistently restored E-cadherin expression and Zeb1-induced drug resistance to 
gemcitabine of pancreatic cells in vivo [132]. 
 
Histone methylation 
Histone methylation or demethylation is catalyzed by lysine methyltransferases 
or demethylases, respectively. Depending on the lysine residue and cellular context, 
histone methylation marks can either activate (H3K4, H3K36 and H3K79 marks) or 
repress gene transcription (H3K9, H3K27 and H4K20 marks) [125]. Lysine specific 
demethylase 1 (Lsd1) has been the first histone demethylase identified, it removes 
methyl groups of H3K4m2/3 sites to reduce gene transcription [133]. Lsd1 interacts 
directly with the SNAG domain of Snail and both collaborate to reduce the H3K4m2 
mark on epithelial gene promoters, such as CDH1, CLDN7 and KRT8 (encoding for 
Claudin 7 and Cytokeratin 8, respectively) in human mammary epithelial cells [134]) 
(Figure 7). Furthermore, Lsd1 is highly expressed in estrogen-negative breast tumors, 
which display a rather dedifferentiated gene signature [135]. Enzymatic inhibition of 
Lsd1-Snail interaction triggers the re-expression of epithelial genes and suppressed 
cancer cell invasion [136]. Of note, Lsd1 can also remove methyl groups of 
repressive H3K9m3 marks and reactivate gene transcription [137]. McDonald et al. 
have shown a reversible reduction in heterochromatin and an increase in 
euchromatin during TGFβ-induced EMT, measured by H3K9me2 and H3K4me3 
marks. The same group has further reported that the changes in chromatin 
reprogramming were in part dependent on Lsd1 [97]. These results, underline the 
importance of Lsd1 activity on different histone marks during epithelial cell 
dedifferentiation processes. 
Taken together, epigenetic modifications, such as DNA methylation and different 
histone modifications, contribute to epithelial cell plasticity and malignant tumor 
progression by regulating global chromatin architecture and the expression of 
individual genes. 
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1.3.3 Transcriptional control of EMT 
A plethora of extracellular stimuli can activate cellular signaling pathways (Wnt, 
NFkB, Notch, Ras-ERK1/2, Hif1/2, TGFβ), which are known to induce EMT (Figure 5). 
The majority of them converge on the level of EMT-regulatory TFs, which can initiate 
and/or maintain the overall transcriptomic changes during EMT in a tissue- and 
developmental-dependent manner [138]. 
 
1.3.3.1 EMT transcription factors – drivers of a cell dedifferentiation 
program 
The TF families Snail (zinc finger proteins Snail and Slug), Zeb (zinc finger and 
homeodomain proteins Zeb1 and Zeb2) and Twist (basic helix-loop-helix proteins 
E12, E47, Twist1, Twist2 and ID) play a central role during developmental and 
oncogenic EMT and are considered master EMT TFs [139]. 
EMT TFs are potent inducers of the epithelial cell dedifferentiation process and 
act as transcriptional suppressors and activators. They coordinate the expression of 
cell architecture proteins, other transcriptional remodelers and even control the 
expression of each other to drive EMT [139]. The gene promoter of the cell adhesion 
junction protein E-cadherin is a common target of all EMT TFs. In cooperation with 
epigenetic modifiers, Snail [112, 115, 116, 126, 134], Zeb [129] and Twist [127] 
directly silence the CDH1 gene promoter and inhibit E-cadherin expression (see 
1.3.2; Figure 7) – a crucial event during EMT [16]. In addition to E-cadherin, the EMT 
TFs further suppress the expression of other epithelial genes encoding for cell-cell 
adhesion (Occludin, ZO-1, Claudins, Desmoplakin, Plakoglobin) and polarity complex 
proteins (Crumbs3, Pals). At the same time, they promote the transcription of 
mesenchymal genes encoding for N-cadherin, MMPs or ECM proteins to induce and 
maintain EMT, cell motility, invasion and survival [3] (Figure 8). 
Various cellular signaling pathways can trigger the transcription/activation of 
EMT TFs [139]. Snail and Slug can be activated by TGFβ, Wnt, Notch, PI3K, NFκB 
signaling. Zeb TFs are activated by TGFβ, Wnt and, like Twist1, by MAPK signaling. 
Importantly, post-translational modifications like phosphorylation and sumoylation 
determine their cellular localization, activity and degradation (Figure 8). Moreover, 
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miRNAs such as members of the miR-200 and miR-34 families post-transcriptionally 
bind and negatively regulate Zeb and Snail cellular levels [39]. 
 
 
 
 
 
 
 
 
 
 
 
Figure 8: EMT TFs – regulation and downstream targets during EMT. (a) Snail can be phosphorylated by 
the glycogen synthase kinase 3β (GSK3β) and protein kinase D1 (PKD1), which induces the nuclear export 
and transcriptional inactivation of Snail. A second phosphorylation by GSK3β leads to its ubiquitylation and 
proteasomal degradation. Phosphorylation of Snail by p21 activated kinase 1 (PAK1), large tumor 
suppressor 2 (Lats2) or dephosphorylation by small C-terminal domain phosphatase 1 (SCP1) triggers Snail 
nuclear localization. Slug (also called Snail2) cellular localization is controlled by p53. Both TFs activate or 
repress gene transcription of various factors involved in EMT (purple box). (b) Phosphorylation of Twist by 
p38, JUN N-terminal kinase (JNK) and ERK induces Twist nuclear translocation, where it functions as 
transcriptional activator and repressor (red box). (c) Zeb2 controls the transcription of various structural 
proteins involved in EMT (green box). Zeb2 can be sumoylated by the polycomb group repressor complex 2 
(PRC2), which leads to its cytoplasmic localization (adapted from [3]). 
 
 
Knockout of Snail, Zeb or Twist family members in mice are embryonic lethal 
since their loss induces defects, for instance in gastrulation, neural tube closure or 
mesoderm differentiation [140-142]. In addition, abnormal activation of the EMT TFs 
has been observed in various human cancers. For instance, aberrant stimulation of 
signaling pathways (TGFβ, Wnt, Notch) or failure of their post-transcriptional or –
translational control can cause their reactivation in cancers and often correlate with a 
poor clinical outcome [139, 143]. Yang and coworkers have demonstrated for the first 
time that suppression of Twist1 expression in orthotopically transplanted mouse 
mammary cells inhibited lung metastasis formation in mice. Conversely, forced 
expression of Twist 1 in epithelial MDCK or HMEC cells induced a mesenchymal cell 
morphology accompanied with a downregulation of E-cadherin and increased cell 
migration in vitro. Elevated levels of Twist1 have been found in different human 
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metastatic breast cancer cell lines and in lobular breast cancer tissues, a breast 
cancer type that usually lacks E-cadherin expression [110]. Furthermore, Twist1 
expression correlates with high-grade ductal carcinoma [144], Slug expression is 
increased in primary breast cancer tissues and both correlate with poor clinical 
outcome [145]. Twist1 and Snail expression are associated with E-cadherin 
repression, metastasis of breast carcinoma [146, 147] and a poor prognosis [148]. 
Forced expression of Zeb1 promotes metastasis in a mouse xenograft model for 
colorectal cancer [149]. High expression of Zeb1 is further linked to reduced E-
cadherin levels and increased aggressiveness of human breast carcinoma [148]. 
These results reveal that EMT TFs control epithelial cancer cell differentiation, cell 
invasiveness and their expression correlate with malignant tumor progression. 
Aside from Snail, Zeb, Twist EMT TFs other TFs have been shown to control or 
contribute to cell EMT/MET plasticity like Prrx1 [34], Sox4 [98], Klf4 [150], FoxC2 
[151], p53 [152] or Tead2 [153] and the list keeps growing. 
 
1.3.3.2 The Tead transcription factors 
Tead family, structure and function 
The TEA (transcriptional enhancer factors) domain TF family consists of four 
evolutionary conserved family members in mammals (Tead1-4) and belongs to the 
helix-turn-helix class of TFs. Tead2 gene expression can be detected already at the 
2-cell stage and it is the only family member expressed within the first seven days 
during mouse embryogenesis. At later developmental stages and in the adult, the 
other Tead family members are abundantly expressed in a tissue-specific but with 
overlapping patterns [154-156]. It has been shown that Teads are required for 
cardiogenesis [157], myogenesis [158], neural crest formation [159], notochord [160] 
and trophectoderm [161] formation. Furthermore, it should be noted that Tead1 and 2 
double-knockout mice exhibited more severe growth defects and developmental 
abnormalities on embryonic day 8.5 than the single knockouts, suggesting redundant 
and distinct functions for Tead1 and Tead2 [160]. Tead homologs are also found in 
invertebrates. For instance, Scalloped (Sd) is the Tead homolog in Drosophila 
melanogaster and is required for wing development [162, 163]. Egl-44 regulates the 
differentiation of touch-sensitive cells and egg-laying motor neurons in 
Caenorhabditis elegans [164, 165]. 
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All four mammalian Tead TFs have the same protein structure and share a high 
degree of sequence homology. The N-terminal DNA-binding domain is 99 % identical 
between the Teads [166] and binds to a DNA motif (5`-GGAATG-3`) found in the 
SV40 enhancer elements and in (proximal) promoter regions of target genes. Tead 
TFs lack a transactivation domain; therefore, their transcriptional activity depends on 
the interaction with transcription cofactors via their C-terminal cofactor-binding 
domain [155, 167, 168]. Here, several cofactors have been reported in mammals: (a) 
Yap (Yes-associated protein) [169] and Taz (transcriptional coactivator with PDZ-
binding motif) [170], both downstream effectors of the Hippo pathway (b) Vestigial-
like proteins 1-4 [171-173] and (c) p160 family of nuclear receptor coactivators [174]. 
 
Teads, transcriptional effectors of the Hippo pathway 
Yap and Taz are cofactors of Tead TFs. Tead TFs interact with nuclear Yap and 
Taz in mammals to regulate genes that are involved in cell proliferation, survival and 
anti-apoptosis [175]. In Drosophila, Sd binds to the Yap homologue Yorki (Yki) to 
facilitate cell growth [176]. Yap and Taz in mammals and Yki in Drosophila are 
conserved downstream targets of the Hippo pathway, which can control the 
subcellular localization of the Tead/Sd cofactors [175]. 
The core Hippo pathway members, Warts (Wts), Salvador (Sav) and Hippo (Hpo) 
were originally discovered by genetic mosaic screens in Drosophila and mutations in 
these factors lead to tissue overgrowth [177-183]. Homologues of these factors have 
been found in mammals: Mst1 and Mst2 (Hpo), Sav1 (Sav), Lats1 and Lats2 (Wts). 
Of note, expression of human Hippo pathway homologues are able to rescue the 
proliferation phenotype of mutant pathway members in Drosophila [184], underlining 
the high degree of functional conservation. The core Hippo pathway in mammals 
consists of a serine kinase cascade (Figure 9A). The STE20 kinases Mst1 and Mst2 
interact with the adaptor protein Sav1 and directly phosphorylate and activate Lats1, 
Lats2 and Mob1 (Drosophila homolog of Mats). Lats1/2 kinases complex with Mob1 
and phosphorylate Yap and Taz. The amino acid residues serine 127 and serine 89 
of Yap and Taz, respectively, generate a binding site for interaction with 14-3-3 
proteins and triggers their cytoplasmic localization and transcriptional cofactor 
inactivation. Furthermore, phosphorylation of serine 381 of Yap and serine 311 of 
Taz by Lats1/2 induce their proteasomal degradation [175, 185, 186]. 
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Figure 9: Regulation of Yap/Taz cellular localization. (a) The core mammalian Hippo pathway consists of 
a kinase cascade, which controls Yap/Taz (Yki; Yorki in Drosophila) nuclear and cytoplasmic localization. 
Phosphorylation of Mst1/2 (Hpo; Hippo) and Sav1 (Sav; Salvador) leads to the phosphorylation and 
activation of Lats1/2 (Wts; Warts) and Mob (Mats; Mob as tumor suppressor), which in turn phosphorylate 
Yap/Taz. Activation of the Hippo pathway leads either to the cytoplasmic retention of Yap/Taz bound to 14-3-
3 proteins or to their proteasomal degradation upon additional phosphorylation events. Inactivation of the 
Hippo pathway kinase cascade induces the translocation of Yap/Taz into the nucleus. They bind for instance 
to Tead (Sd; Scalloped) TFs to regulate genes involved in cell proliferation and survival. (b) Yap/Taz 
localization are further controlled by cell polarity complexes, cell-cell junctions and the cytoskeleton 
organization. In the nucleus, Yap/Taz bind to different TFs and control cell proliferation, survival, 
(de)differentiation and stemness. Mammalian STE20-like protein kinase 1/2 (Mst1/2), Salvador homologue 1 
(Sav1), larger tumor suppressor 1/2 (Lats1/2), Mob kinase activator (Mob), Yes-associated protein (Yap), 
transcriptional coactivator with PDZ binding motif (Taz or WWTR1), TEA domain TF family (Tead), 
Angiomotin family of proteins (AMOT). 
 
The regulation of Yap and Taz by the Hippo pathway has been shown to 
facilitate cell-contact inhibition, a mechanism fundamental in organ size control and 
maintenance [187]. In sparsely growing cells, the Hippo pathway kinase cascade is 
inactivated. This leads to hypophosphorylation of Yap and Taz and their nuclear 
localization, where they bind to Tead TFs to stimulate cell proliferation [188]. 
Conversely, the upstream pathway members are activated in densely growing cells. 
Lats1/2 phosphorylates Yap and Taz, which leads to their cytoplasmic localization 
and cell growth arrest [187]. Consequences of Hippo pathway deregulations are 
obvious. Inactivation of kinases Mst1/2 in hepatocytes induce cell proliferation, liver 
overgrowth and tumor formation in vivo [189]. Lats1-deficient mice develop ovarian 
and soft tissue tumors [190]. Conditional activation and subsequent inactivation of 
Yap induces reversible liver overgrowth in mice [191] and expansion of small 
intestine progenitor cells and their dedifferentiation [192]. Such organ overgrowth 
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defects have also been reported in Drosophila upon changing Yki-Sd transcriptional 
activities [176, 187, 191, 193]. 
Increasing evidence indicates that deregulation of Hippo pathway components 
are also implicated in human cancers. Downregulation of Lats1/2 and Mst1/2 
expression upon promoter hypermethylation has been reported in breast cancer, soft 
tissue sarcomas, colorectal cancer, astrocytomas and acute leukemia [194-197]. 
Mutations in Mob1 and Sav1 have been observed in renal cancer cell lines and in 
skin melanoma [180, 198]. The upstream hippo pathway members negatively control 
cell proliferation, their functions are mainly inhibited in human cancers and are 
therefore classified as tumor suppressors. Yap and Taz, on the other hand, are 
mainly acting as oncogenes. Yap gene amplification and/or increased expression has 
been seen in many human cancers [199]. Increased expression of Yap and Taz 
evokes their nuclear localization, which correlated with breast cancer tumor grade 
[200-202]. Taz is overexpressed in 20 % of human breast cancers [203] and higher 
levels of Taz are also found in colorectal cancer, glioblastoma, melanoma and non-
small cell lung cancer [199]. Such overgrowth defects triggered by Yap and Taz can 
be induced via Tead transcription factors [188]. Therefore, cancer therapy aims to 
disrupt the Yap-Tead or Taz-Tead interface to interfere with oncogenic cell 
proliferation. For instance, Verteporfin has been shown to inhibit Tead-Yap 
interaction and reduced liver overgrowth upon Yap overexpression or inactivation of 
Neurofibromin 2 (Nf2, also called Merlin; an activator of the Hippo kinase cascade) in 
mice [204]. Another compound, Dobutamine, has been identified in a drug screen to 
induce cytoplasmic localization of Yap and by this suppresses Yap-Tead 
transcriptional activity in the nucleus [205]. Recently, Statins, used for treatment of 
hypercholesterolemia, have been shown to inhibit the nuclear localization of Yap and 
Taz [206]. Ideally, such and future drugs will be tested in cancer patients with 
amplified or overexpressed Yap and Taz genes. 
 
Tead/Yap/Taz in cell (de)differentiation  
Several studies in human untransformed MCF10A cells have demonstrated that 
forced expression of Yap and Taz not solely induced cell proliferation, but also 
promoted EMT, cell migration, invasion and anchorage-independent growth via Tead 
transcription factors. The Yap/Taz/Tead complex induces tumorigenic cell properties 
and controls target genes like CTGF, CYR61, KI67, AXL, c-MYC and SURVIVIN [170, 
Molecular	  Networks	  of	  EMT	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  GENERAL	  INTRODUCTION	  	  
 29 
187, 191, 207-211]. Expression of Yap-Tead further promotes tumor formation and 
breast cancer metastasis in vivo [188, 212]. More and more evidence accumulated 
and reveal that the Yap/Taz/Tead complex is also important for stem cell 
maintenance. In undifferentiated embryonic, neural and hematopoietic cells the 
expression of Tead2 and Yap is enriched [213]. Additionally, Yap is activated in 
induced pluripotent stem (iPS) cells [214]. Similar reports in tissue-specific stem cells 
have shown that high levels of Yap and Taz induced stem cell expansion and 
blocked their differentiation [192, 215-217]. These results suggest that the 
Yap/Taz/Tead complex controls cell proliferation and (de)differentiation, processes 
enabling tissue development and homeostasis and can further force tumorigenesis if 
deregulated. In the past years, several research groups have investigated which 
stimuli can influence endogenous Yap/Taz localization and transcriptional activity 
aside from the control of the Hippo pathway. Interestingly, some of the factors or 
mechanisms are implicated in the EMT process: 
Apical epithelial polarity complex: The Crumbs polarity complex consists of 
Crumbs, Pals and Patj, is localized at the apical plasma membrane in epithelial cells 
and becomes delocalized upon EMT. It has been shown that this complex interacts 
with phosphorylated Yap and Taz and mediates their cytoplasmic localization in 
densely growing mammary epithelial cells [218] (Figure 9B). Additionally, Yap and 
Taz can also interact with Smad2/3/4, which in turn is required for nuclear localization 
of Smads upon TGFβ stimulation [219]. In confluent cultures, Smads are activated by 
TGFβ, however, fail to translocate to the nucleus. Subsequent Hippo pathway 
inactivation (loss of Lats1 or 2) or disruption of the Crumbs complex (loss Crb3 or 
Pals1) releases Yap/Taz from the membrane and induces their nuclear co-
localization with Smads upon TGFβ treatment [218]. These findings suggest that the 
Hippo pathway and epithelial cell polarity control Yap/Taz cellular localization and 
thereby interfere with canonical TGFβ signaling. 
Tight and adhesion junctions: α-catenin links the Actin cytoskeleton to Cadherin 
adhesion junctions in epithelial cells. It has been observed that α-catenin negatively 
controls the activity of Yap by binding to the phosphorylated cytoplasmic Yap/14-3-3 
complex and localizes it to cell adhesion junctions [217, 220] (Figure 9B). Loss of α-
catenin, β-catenin or disruption of adhesion junctions by calcium depletion induces 
the nuclear localization of Yap [221, 222] and hyperproliferation of human 
keratinocytes [217]. 
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Angiomotin (Amot) protein family members are important for tight junction 
assembly and epithelial cell polarity [223]. Amot1 and 2 can directly interact with Yap 
and Taz, localize them to tight junctions and thereby inhibit Yap/Taz transcriptional 
activity [224-226]. Downregulation of Amot2 in epithelial MDCK cells leads to 
Yap/Taz nuclear localization and transcriptional activation [224]. Furthermore, loss of 
Amot2 in epithelial MCF10A cells promotes nuclear localization of Yap and EMT 
thereby phenocoping an overexpression of Yap in MCF10A cells [226]. 
Actin cytoskeleton organization: Mechanical cues coming from cell 
stretching/crumpling and ECM elasticity influence cell shape. Cells can sense and 
adapt to such cues and stimulate proliferation, differentiation, apoptosis and 
migration [227]. Interestingly, all these physical stimuli affect Yap and Taz cellular 
localization and transcriptional activity [228-231]. For instance, cells plated on a stiff 
matrix display a nuclear localization of Yap and Taz. Conversely, Yap and Taz are 
excluded from the nucleus in cells grown on a soft matrix [228]. Additionally, round, 
compact cells display cytoplasmic Yap and Taz, whereas spreaded, stretched cells 
exhibit nuclear Yap and Taz [228, 229]. These findings suggest that mechanical cues 
coming from cell substrate stiffness and cell shape directly control Yap/Taz 
localization and activity. Interestingly, confluent, stretched epithelial cells display 
partial nuclear Yap and Taz. Here, mechanical signals partially uncouple Yap/Taz 
regulation from the Hippo pathway and overcome cell contact-mediated proliferation 
inhibition [229].  
Rearrangement of the Actin cytoskeleton can translate and adapt cell shape and 
behavior to the above-mentioned cellular mechanical cues [227]. Consequently, 
interfering with Actin cytoskeleton polymerization, more precisely with the Actin 
polymerization inhibitors CapZ, Cofilin and Gelsolin, seems to disrupt the regulation 
of Yap/Taz cellular localization and Yap/Taz/Tead transcriptional activity [229-231]. 
Surprisingly, the impact of Actin polymerization on Yki regulation seems to be 
conserved in Drosophila, since loss of Actin capping proteins in the wing disc 
promotes Yki transcriptional activity and tissue overgrowth [232, 233]. Additionally, 
Rho GTPases have been reported to trigger Yap dephosphorylation and nuclear 
localization. Aside Rac1 and Cdc42, RhoA strongly increased Yap transcriptional 
activity, however the mechanism behind this regulation is so far unknown [228, 231, 
234]. These findings suggest that the Actin cytoskeleton is a major regulator of 
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Yap/Taz/Tead activity (Figure 9B). However, the exact mechanism how F-Actin and 
Rho GTPases regulate Yap/Taz localization has to be investigated. 
Collectively, loss of epithelial polarity and cell junctions, Actin stress fiber 
formation and ECM remodeling are crucial events during EMT and facilitate cell 
migration and tumor progression [4]. One can speculate whether such events 
reinforce Yap/Taz/Tead transcriptional activity during EMT in addition to other EMT 
inducers (e.g. TGFβ signaling). In the past years, a broad collection of various stimuli 
and pathways has been discovered, which all influence Yap/Taz/Tead activity [235]. 
However, the physiological context of Yap/Taz/Tead activity during tissue 
development, homeostasis and disease has to be investigated in the future. 
 
1.3.4. Post-transcriptional control of EMT by ncRNAs 
More than 80 % of the human genome can be transcribed into RNA, however 
less than 2 % of the genome contains protein-coding capacity [236]. In the past 
decades, more and more evidence accumulated demonstrating that several non-
coding RNA (ncRNA) species are powerful regulators of gene expression and 
therefore heavily influence most cellular processes [237, 238]. 
 
1.3.4.1 miRNAs 
MicroRNAs (miRNAs) are a class of ncRNAs with an approximate length of 22 
nucleotides. They are ubiquitously expressed, conserved across species and control 
approximately 60 % of all human protein coding genes on the post-transcriptional 
level [239, 240]. 
 
Canonical miRNA biogenesis and function  
In 1993, the group of Victor Ambros has identified the first miRNA in 
Caenorhabditis elegans [241] and demonstrated an essential function for ncRNA lin-
4 during larval development. Lin-4 reduced the protein levels of lin-14, which 
possesses several lin-4 complementary sequence elements within its mRNA 3` 
untranslated region (UTR). Therefore, the authors have suggested an antisense 
RNA-RNA interaction of lin-4 and lin-14, where lin-4 negatively controls lin-14 
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translation. Since 1993, more than 2500 mature human miRNAs have been identified 
and annotated (miRBase version 21) [242]. Beside a few reports demonstrating an 
activation of mRNA translation, miRNAs are mainly described as post-transcriptional 
repressors of RNAs [243-246].  
MiRNAs are mainly located within intronic regions of coding or non-coding host 
genes or in intergenic regions, latter exhibiting their own gene promoter [240, 247]. 
Few miRNAs have been reported to be located in exonic regions of genes [248]. In 
the canonical miRNA biogenesis pathway (Figure 10), miRNAs are transcribed by 
RNA polymerase II (Pol II) either as monocistronic or polycistronic primary transcript 
(pri-miRNA) cluster. Pri-miRNAs contain a local hairpin structure, which exhibit the 
mature miRNA sequence. The nuclear RNase III Drosha binds to the double 
stranded RNA-binding protein DiGeorge syndrome chromosomal region 8 (DGCR8) 
to form the microprocessor complex, which endonucleolytically cleaves the pri-
miRNA to release an ~ 65 nucleotide long miRNA precursor molecule (pre-miRNA). 
Several non-canonical miRNA biogenesis pathways, leading to the production of pre-
miRNAs in a Drosha/DGCR8- or Dicer-independent manner, have been reported and 
reviewed [249]. Following Drosha/DGCR8 processing, Exportin 5 binds to pre-
miRNAs to actively transport them to the cytoplasm via the cofactor RAN-GTP. Here, 
the appropriate length and 3` overhangs of the miRNA precursors are essential for a 
successful nuclear export by Exportin 5. Dicer, a second RNase III enzyme in the 
miRNA biogenesis pathway, binds to the RNA-binding cofactor TRBP and cleaves 
the pre-miRNA close to the terminal loop to generate a double stranded 
miRNA:miRNA* complex. Subsequently, only one strand (guide strand) of the 
miRNA:miRNA* complex is loaded into the miRNA-induced silencing complex 
(miRISC). The mature miRNA binds via imperfect or perfect base pairing to the 3` or 
5` UTRs of the target RNA and induces its translational repression or deadenylation 
and degradation, respectively [250, 251]. More precisely, the nucleotides 2-7 within 
the 5` end of a miRNA are termed as seed sequence and bind the target RNA. The 
group of David Bartel has extensively studied miRNA:RNA interactions and their 
contextual features. They have presented four types of canonical miRNA:RNA 
recognition sites, which have different efficacies on target repression: 6-mer site 
(miRNA positions 2-7), 7-mer-A1 site (miRNA positions 1-7), 7-mer-m8 site (miRNA 
position 2-8) and 8-mer site (miRNA positions 1-8) (order of recognition sites displays 
increased target repression potential). Additional recognition sites or base pairing of 
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nucleotides 12-17 in the mature miRNA can further enhance 7mer-8 site-mediated 
target repression [252]. 
Figure 10: miRNA biogenesis. MiRNAs are 
transcribed from intergenic or intronic 
genomic regions by RNA polymerase II 
(RNAPII). During canonical miRNA 
processing, the microprocessor complex 
consisting of DiGeorge syndrome 
chromosomal region 8 (DGCR8) and nuclear 
RNase III Drosha, binds and cleaves the pri-
miRNA to release a ~ 65 nucleotide pre-
miRNA, which is transported to the 
cytoplasm via Exportin 5. The RNase III 
Dicer bound to the RNA-binding cofactor 
TRBP cleaves the pre-miRNA to generate 
the ~ 20 nucleotide double stranded 
miRNA:miRNA* complex. The guide strand 
(red) of the miRNA duplex is loaded into the 
miRNA-induced silencing complex (miRISC) 
and binds to a complementary RNA 
sequence in the target RNA and induces its 
translational repression or deadenylation 
and degradation (adapted from [261]). 
 
 
 
 
 
 
 
 
 
An important aspect of miRNA function is that one miRNA can control the 
transcripts of several RNAs (pleitropy) and one RNA can be targeted by different 
miRNAs [239, 246, 253, 254]. Furthermore, miRNAs are often positioned within gene 
regulatory networks such as feedback or feedforward loops with TFs [255, 256]. 
Therefore, miRNAs are thought to function as molecular switches in cells to allow 
fine-tuning of essential cellular processes such as proliferation, (de)differentiation 
GENERAL	  INTRODUCTION	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Molecular	  Networks	  of	  EMT	  	  
	   34 
and survival during normal development and homeostasis. They further endow these 
processes with the required robustness [257-259] and, consequently, deregulation of 
miRNAs is implicated in diseases such as cancer [260]. 
 
miRNAs in EMT 
In order to identify new EMT-regulatory miRNAs, several research groups have 
profiled global miRNA expression in various cellular EMT models mainly using 
microarray analysis. They have either extracted and characterized individual 
differentially expressed miRNAs during EMT or generated a miRNA signature 
specific for an epithelial or mesenchymal cell phenotype. Since there is an imperfect 
miRNA expression profile overlap comparing different studies, one can conclude that 
miRNA expression and regulation is highly cell context dependent [254, 262-267]. 
 
miR-200 family: the guardian of an epithelial morphology 
Strikingly, one miRNA family has appeared in most of the previously mentioned 
miRNA expression profiling studies. Members of the miR-200 family are associated 
with an epithelial cell morphology and their expression is decreased upon 
dedifferentiation across various cell types and EMT-inducing stimuli [254, 262-264]. 
The miR-200 family consists of five family members and is organized as two gene 
clusters on chromosome 1 (miR-200a/b, miR-429) and chromosome 12 (miR-200c, 
miR-141) in the human genome [265]. Ectopic expression of individual family 
members blocked TGFβ-induced EMT in normal murine mammary gland cells 
(NMuMG) [268] or induced MET in mesenchymal canine kidney cells (MDCK) cells in 
vitro [254]. In both studies, forced expression of miR-200s led to a stabilization of E-
cadherin adhesion junctions and transcriptional downregulation of the EMT TFs Zeb1 
and Zeb2. Here, miR-200 family members directly repress the transcripts of Zeb1/2 
on the post-transcriptional level by binding to specific recognition sites in their 3` 
UTRs [269]. Conversely, TGFβ-induced Zeb1 binds to specific motifs in the miR-200 
promoters to negatively control their transcription during EMT. This reciprocal 
regulation of Zeb1/2 and miR-200 family members not solely determines cell 
morphology but also controls cell migration and invasion in vitro, for instance, of the 
highly metastatic human MDA-MB-231 breast cancer cells [269, 270] (Figure 11). 
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Recently, a genome-wide analysis of direct mRNA targets of miR-200a and miR-
200b in MDA-MB-231 cells has been published [271]. MiR-200a/miR-141 and miR-
200b/c/miR-429 form two seed classes within the miR-200 family where the miRNA 
seed regions differ in only one nucleotide. In this way, the authors have covered both 
distinct sets of miR-200 mRNA targets in their analysis. Using Argonaute high-
throughput sequencing of RNA isolated by crosslinking immunoprecipitation (HITS-
CLIP) and subsequent barcoded cDNA analysis, Bracken et al. have identified 
around 2000 transcripts directly bound by miR-200a and miR-200b, which are mainly 
associated with cytoskeleton remodeling and genes implicated in EMT, TGFβ-, Wnt- 
and Rho-ROCK-signaling pathways. This study has demonstrated that the miR-200 
family can target multiple genes implicated in cell architecture and transcriptomic 
remodeling crucial during EMT and positioned the miR-200 family as a central 
regulator of epithelial cell plasticity [270-272]. 
 
miRNAs control cellular architecture during EMT 
The epithelial cell-cell adhesion junction protein E-cadherin facilitates normal 
epithelial tissue formation and its loss induces EMT in vitro and promotes tumor cell 
dissemination and local invasion in carcinomas [6, 28, 273, 274]. Several studies 
have shown that E-cadherin is directly targeted by several miRNAs during EMT and 
malignant tumor progression [275-278] (Figure 11). 
MiR-9 is induced by MYC/MYCN and reduces E-cadherin levels post-
transcriptionally, thus promoted breast cancer cell motility and invasiveness in vitro. 
Furthermore, loss of E-cadherin activated β-catenin signaling and VEGFA 
expression, which further triggered tumor angiogenesis and metastasis of the 
orthotopically transplanted human breast cancer cell line SUM149 in immune-
deficient mice [275]. 
The same group has identified miR-10b to be strongly expressed in metastatic 
breast cancer cell lines such as MDA-MB-231 compared to non-metastatic SUM149 
cells. Forced expression of miR-10b in SUM149 cells induced cell migration/invasion 
and lung metastasis in immune deficient mice [279]. In addition, E-cadherin is directly 
regulated by miR-10b and their expression is inversely correlated during human 
breast cancer development [276, 280]. 
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MiR-23a is induced by canonical TGFβ signaling and directly targets E-cadherin 
in human lung adenocarcinoma epithelial cells (A549). Ectopic expression of miR-
23a induced an EMT-like morphology of A549 cells [277]. Additionally, miR-92a 
belongs to the oncogenic miR-17-92 gene cluster and targets E-cadherin mRNA 
3`UTR. Their expression levels are inversely correlated in esophageal squamous cell 
lines (ESC) and ESC carcinoma (ESCC) tissues and high levels of miR-92a in ESCC 
is associated with lymph node metastasis and a poor survival rate of ESCC patients 
[278]. 
While E-cadherin is relocalized and downregulated during EMT, N-cadherin is 
often upregulated (Cadherin switch) to promote cell motility and migration [4]. MiR-
194 negatively controls N-cadherin expression and reduces liver metastasis of 
transplanted human liver cancer cells in immune deficient mice [281]. 
The small GTPase RhoA controls actin cytoskeleton organization and epithelial 
cell polarity during EMT. MiR-155 is transcriptionally upregulated by canonical TGFβ 
signaling in normal mouse epithelial cells and directly targets and reduces RhoA 
mRNA levels. Moreover, inhibition of miR-155 expression prevents TGFβ-induced 
EMT [262]. 
The mesenchymal intermediate filament Vimentin is a post-transcriptional target 
of miR-506. Overexpression of miR-506 blocks TGFβ-induced EMT in MCF10A cells 
and suppresses the migratory/invasive properties of MDA-MB-231 cells in vitro [282]. 
Additional miRNAs, such as miR-30a [283], miR-17-3p [284], miR-124 and miR-203 
[285], have been reported to negatively regulate Vimentin expression. 
 
Figure 11: MiRNAs control cell architecture and TFs during EMT. Top: Different miRNAs directly control 
the expression of epithelial and mesenchymal cell architecture proteins on the post-transcriptional level. 
Bottom: Double negative feedback loops between miRNAs and TFs regulate EMT plasticity. p53 induces the 
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expression of miR-200 family members, miR-34 and miR-15a/16-1 gene cluster in epithelial cells. TGFβ 
triggers the expression of Zeb1/2 and Snail during EMT initiation. 
 
miRNAs targeting EMT-regulatory TFs 
The TF families Zeb, Snail and Twist are expressed by different EMT-inducing 
stimuli and are considered EMT drivers (see 1.3.3.1). Importantly, these TFs are 
highly controlled on the post-transcriptional level by miRNAs. 
The key EMT TFs Zeb1 and Zeb2 are tightly controlled during EMT by the miR-
200 family as mentioned above [254, 265, 268, 269]. Similar to the regulation of miR-
200s, miR-203 is also downregulated during TGFβ-induced EMT in MDCK cells and 
in mesenchymal breast cancer cells [254]. Ectopic expression of miR-203 directly 
represses Zeb1 mRNA levels and, consequently, stabilizes E-cadherin junctions, 
however the effect is not as strong as for the miR-200 family. MiR-130b expression 
has been reported to be downregulated during p53 mutant-induced EMT in 
endometrial cancer cells. Restoration of miR-130b in mesenchymal endometrial 
cancer cells impairs cancer cell invasion by directly controlling the cellular levels of 
Zeb1 [286]. Snail is directly regulated by miR-30 in murine hepatocytes and TGFβ-
induced EMT in AML12 cells leads to a downregulation of miR-30b/c/d/e along with 
an upregulation of Snail. Overexpression of miR-30b triggers the repression of Snail 
protein levels and blocks TGFβ-induced EMT and AML12 cell migration [287]. The 
other TF family member Slug is post-transcriptionally regulated by miR-1 and miR-
200b. Both miRNAs are repressed upon TGFβ-induced EMT in a murine epithelial 
prostate cancer cell line. Forced expression of miR-1 and miR-200b prevents Slug 
expression, induces MET and inhibits invasion of human prostate cancer cells [288]. 
MiR-580 targets the 3` UTR of Twist1 mRNA and represses its expression in human 
mammary epithelial MCF10A cells [289]. These miRNAs are a few selected 
examples of a plethora of reports about post-transcriptional regulators controlling 
master EMT TFs. 
One important mechanism that might be (partially) responsible for the 
reversibility of cell differentiation and dedifferentiation are double-negative feedback 
loops between miRNAs and key EMT TFs, functioning as molecular switches (Figure 
11). Zeb1/2 and Snail TFs are induced upon TGFβ-signaling [139]. Both of them can 
directly target the promoter regions of miR-200 and miR-34 family members, 
inhibiting their transcription and inducing cell dedifferentiation, survival and stemness. 
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MiR-200 and miR-34 are embedded in a double-negative feedback loop with Zeb and 
Snail. Wildtype p53 can directly activate transcription of miR-200 and miR-34 family 
members, which in turn directly repress Zeb and Snail and subsequently initiate 
epithelial cell differentiation [143]. p53 has been reported to control another double-
negative feedback loop during EMT/MET plasticity in colorectal cancer. Upon DNA 
damage, p53 induces the downregulation of the TF AP4 via miR-15a and miR-16-1. 
Both miRNAs target the 3` UTR of AP4 and induce MET, decrease cell migration, 
invasion and metastasis of colorectal cancer cells in a xenograft model. Conversely, 
AP4 negatively controls the transcripts of miR-15a/16-1 by binding to two alternative 
transcriptional start sites within an intronic region [290]. 
Slug has been reported to regulate and to be regulated by miR-1 and miR-200 
during EMT-mediated progression of prostate adenocarcinoma [288]. Similarly, miR-
200b/c and Forkhead-box F2 (Foxf2) control their transcript levels in a reciprocal 
feedback loop to regulate EMT, invasiveness and metastasis of lung cancer cells 
[291]. 
Accumulating evidence reporting double-negative feedback loops between 
miRNAs and TFs suggest their importance during reversible (de)differentiation 
processes during embryonic development as well as in malignant tumor progression 
and are currently and in the future an area of active research. 
 
Regulation of miRNA expression during EMT 
Different extracellular signals can stimulate the activity of TFs, which initiate and 
maintain the overall transcriptomic changes during EMT [138]. Further, TFs can 
directly regulate the expression of individual miRNAs or miRNA clusters and either 
activate or repress their transcription. In the context of EMT, an important group of 
TFs like Zeb1/2, Snail, Slug and p53 controlling miRNA expression has been pointed 
out earlier [39, 288]. 
Epigenetic modifications can also control and organize miRNA expression during 
EMT and has been recently reported for the miR-200 family. The transcriptional start 
sites of the miR-200a/b/429 and miR-200c/141 gene clusters are located within 
canonical CpG islands and, therefore, exhibit potential sites for hypermethylation-
mediated gene silencing. It has been demonstrated that upon TGFβ-induced EMT of 
MDCK cells the promoter regions of the two miRNA clusters get hypermethylated 
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accompanied with a decrease in miR-200s expression. Interestingly, TGFβ 
withdrawal induces MET of MDCK cells and a reversion of the DNA methylation 
marks. Hypermethylation of miR-200 gene clusters is also observed in different 
human cancer cell lines and treatment with 5′-aza-2′-deoxycytidine, a Dnmt inhibitor, 
restores the expression of miR-200 family members in the cells [102]. These results 
indicate a dynamic epigenetic regulation of miR-200 expression during EMT/MET. 
A genome wide analysis of miRNA gene sequences has revealed that about half 
of the genes are associated with CpG islands [292]. Bisulfite genomic sequencing 
analysis has demonstrated that also the miR-34b/c cluster among others is strongly 
hypermethylated in metastatic tumor cells. Reintroduction of miR-34b/c represses 
cell migration in vitro and metastasis formation in a mouse xenograft model [293]. 
These findings further demonstrate the importance of epigenetic miRNA expressional 
regulation during EMT and tumor progression. 
 
miRNAs can exert tumor suppressive and oncogenic functions 
In 2002, Calin and coworkers have reported the first tumor suppressor miRNA 
implicated in chronic B-cell lymphocytic leukemia (B-CLL). They have found that the 
miR-15a/16-1 gene cluster on chromosome 13q14 is frequently deleted or 
downregulated in 68 % of B-CLL patients [294]. Subsequent miRNA expression 
analyses in tumor versus normal tissue has provided evidence that miRNAs are 
deregulated in cancer cells [295, 296] and can contribute to human cancer initiation 
and progression [260, 297]. Deregulation of miRNA expression has been shown to 
have different causes: (a) genomic miRNA gene amplifications, translocations, 
deletions [298]; (b) aberrant upstream TF activation [299-302]; (c) altered epigenetic 
modifications like promoter methylation [293] or histone acetylation at genomic loci of 
miRNA coding genes [303]; (d) deregulation of miRNA biogenesis pathway 
components (e.g. Dicer1) inducing impaired miRNA processing and a global 
reduction in mature miRNAs [304]. Furthermore, alterations in miRNA target site 
sequence (point mutations in the seed match, translocations or 3` UTR shortening of 
the mRNA sequence) [305-307] or aberrant expressed competitive endogenous 
RNAs (ceRNAs) [308, 309] can lead to an escape from miRNA repressive control in 
cancer. 
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Up to date, several studies have reported a deregulation of miRNAs in breast 
cancer analyzed by microarray or deep sequencing analysis [296, 310-313]. 
Together with the large amount of gene expression, genomic and clinical data from 
The Cancer Genome Atlas (TCGA), deregulated miRNAs have been further analyzed 
and linked to different breast cancer subtypes [313, 314]. 
One of the first human miRNAs discovered to affect breast cancer metastasis 
has been miR-335 [315]. MiR-335 is found to be lost in metastatic breast cancer cells 
caused by genetic gene deletion [316]. Loss of miR-335 induces expression of Sox4 
and Tenascin-C, which promotes cancer cell migration, invasion and metastasis 
[315]. Other identified “metastaMirs” (metastasis-regulating miRNAs) in breast cancer 
are for instance: let-7 [317], miR-10b [279], miR-9 [275], miR-21 [318] and they 
mainly control tumor cell invasiveness. 
A direct link coupling breast cancer metastasis and EMT/MET cell plasticity has 
been reported for a few miRNAs. The miR-200 family has been identified as EMT 
suppressor by directly targeting the TFs Zeb1 and Zeb2 to maintain an epithelial cell 
morphology and inhibit cell migration and invasion of breast cancer cells [254, 265, 
268, 269]. MiR-200 family members are transcriptionally downregulated in tumors 
enriched in an EMT signature such as mesenchymal endometrial carcinomas [267] 
and in the claudin-low breast cancer subtype [319]. Doxycycline-induced expression 
of the miR-200c/141 cluster in transplanted Claudin-low tumor cells induces a MET 
gene signature and decreases lung metastasis in vivo [320]. Additionally, forced 
expression of miR-200b in a mutant K-ras/p53 lung cancer model blocks TGFβ-
induced EMT, invasion and metastasis in vivo [321]. In these studies, the miR-200 
family has functioned as early suppressors of the tumor invasion metastasis cascade 
by controlling EMT/MET processes. 
However, another study has reported a pro metastatic role for miR-200s in breast 
cancer, as high expression of miR-200 family members is associated with decreased 
distant relapse-free survival in breast cancer patients [322]. Forced expression of 
miR-200s in mesenchymal, weakly metastatic mouse tumor cells (4TO7) has induced 
an epithelial phenotype in vitro, but enhanced lung colonization of 4TO7 cells injected 
intravenously in mice. These findings are consistent with a previous report [323] and 
support the notion that at later stages in the metastatic cascade miR-200 family 
members can induce a MET process favoring tumor cell colonization and lethal 
macrometastases formation at a secondary site. In addition, miR-200 family 
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members can promote breast cancer metastatic outgrowth by regulating other genes 
than the ones controlling EMT/MET cell plasticity. For instance, miR-200s target the 
COPII vesicle component Sec23a, leading to reduced secretion of the metastasis 
suppressing factors TINAGL1 and IGFBP4 [322], thereby, generating a pro-
metastatic niche for tumor cells. In summary, miR-200 family members seem to 
function as tumor suppressors and tumor promoters, which may depend on their 
activation in early or late events during the metastatic cascade. Clearly more 
investigations are required to dissect the function of miR-200s during breast cancer 
progression. 
Other miRNAs such as miR-29a and miR-103/107 have been described as 
crucial modulators of EMT in breast cancer progression. MiR-29a is upregulated in 
mesenchymal, metastatic mouse mammary cells compared to their epithelial 
counterparts. Overexpression of miR-29a in epithelial cells induces EMT and 
metastasis in vivo and its high expression is observed in metastatic human breast 
cancers [266]. MiR-103/107 expression is also associated with breast cancer 
metastasis and a poor prognosis for breast cancer patients [324]. MiR-103/107 
directly repress Dicer1 mRNA and induce EMT, migration/invasion and metastasis in 
human mammary epithelial cells in vivo. Inhibition of miR-103/107 blocked these 
cellular effects. Generally, a loss of the miRNA biogenesis component Dicer1 has 
been reported to promote tumorigenesis by decreasing global mature miRNA 
expression [325, 326], a phenomenon observed in human breast and other cancers 
[295, 314]. 
 
miRNAs in cancer therapy 
In the past, several studies have clearly demonstrated that miRNAs can function 
as oncogenes or tumor suppressors and, therefore, have a central role in the 
initiation and progression of various cancer types [327]. To interfere with the 
deregulation of specific miRNAs, two promising approaches have been established 
for miRNA-based therapies in cancer: 
(a) Sequence-specific inhibition of miRNAs to block their oncogenic function 
(targeting therapy). Antisense oligonucleotides bind with perfect sequence 
complementarity to endogenous mature miRNAs to inhibit their function. Ma and 
colleagues have demonstrated that systemic delivery of an anti-miR-10b 
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oligonucleotide reduced lung metastasis in a mouse orthotopic transplantation breast 
cancer model [328]. 
(b) Delivery of small double stranded RNAs to mimic mature miRNAs and restore 
their tumor suppressive function, which is reduced or lost in cancer cells 
(replacement therapy). MRX34 is the first miRNA mimic that has entered phase I 
clinical trials for miRNA-based cancer therapy. MRX34 replaces the function of miR-
34 in patients with primary liver cancer or liver metastasis [329]. 
Still, major challenges for miRNA-based therapies remain. For instance, enhance 
oligonucleotide stability and their effective delivery into target cells. For this purpose, 
oligonucleotides can be encapsulated in liposomes or polymer-based nanoparticles 
to protect them from serum nucleases. Additional chemical oligonucleotide 
modifications (2`-O-methyl (2`-O-Me), 2`-O-methyoxyethyl (2`-O-MOE) and locked 
nucleic acids (LNAs), 3` end cholesterol groups)) have also helped to increase their 
stability, delivery through cell membranes and their tissue distribution [330]. However, 
“unknowns” for miRNA-based therapy still remain, for instance, the levels of miRNA 
expression in cancer cells achieved by the replacement therapy is hard to estimate. 
Potential off-target effects evoked by introducing DNA/RNA inhibitors or mimics into 
cells are unexplored. Future investigations have to address these “unknowns” to 
utilize miRNA-based therapies in cancer treatment. 
 
1.3.4.2 piRNAs 
PIWI interacting RNAs (piRNAs) are a class of ncRNAs of 24-30 nucleotides in 
length, expressed as single stranded RNAs, produced in a dicer-independent manner 
and are involved in epigenetic regulation (DNA methylation) and transposon silencing. 
Two studies have revealed that piRNA expression can be deregulated in cancer cell 
lines and primary tumors [331, 332]. PiRNA-Hep1 (PiT-Hep1) expression was 
upregulated in hepatocellular carcinoma tumors compared to normal liver tissue and 
loss and gain of function experiments of piR-Hep1 in hepatocellular carcinoma cells 
induced a decrease or increase in cell migration and invasion, respectively [333]. 
These results indicate that piRNAs can be involved in cancer development, whether 
they regulate EMT in this context, has to be investigated in the future. 
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1.3.4.3 lncRNAs 
Long non-coding RNAs (lncRNAs) are a group of transcripts with a length of > 
200 nucleotides. They mediate gene expression by multiple (post)-transcriptional 
mechanisms and are involved in many biological processes and in tumorigenesis 
[334]. 
LncRNAs such as HULC [335], Malat1 [336] and HOTAIR [337] are aberrantly 
expressed in different human cancer types and affect tumor initiation and progression 
[335, 337-340]. Recently, the lncRNA lncRNA-ATB has been identified and 
characterized as post-transcriptional regulator of oncogenic EMT [341]. LncRNA-ATB 
is highly expressed in hepatoma cells undergoing TGFβ-induced EMT and functions 
as natural competitive endogenous RNA (ceRNA) for Zeb1 and Zeb2. LncRNA-ATB 
exhibits several miR-200 binding sites and expression of lncRNA-ATB reduces the 
levels of “free” miR-200 family members, therefore, stabilizing Zeb1/2 mRNAs during 
EMT. Forced expression of lncRNA-ATB induces EMT, invasion of hepatoma cells in 
vitro and metastasis in vivo. At the same time, lncRNA-ATB binds IL11 mRNA, 
stabilizes its expression and activates STAT3 signaling, which promotes tumor cell 
colonization at a secondary site [341]. In addition, an EMT lncRNA expression profile 
of normal mouse mammary cells (NMuMG) induced to undergo EMT upon TGFβ 
treatment has been recently published and the authors identified lncRNA-HIT as a 
new EMT-regulatory lncRNA. LncRNA-HIT expression has been further associated 
with invasive human breast carcinomas [342], however, the mechanisms by which 
lncRNA-HIT regulates EMT are still unknown. 
 
1.3.4.4 circRNAs 
Circular RNAs (circRNAs) have already been discovered in 1991 [343], however, 
novel bioinformatic approaches and deep sequencing technologies have identified 
these RNAs as new class of highly abundant, evolutionary conserved ncRNAs [344, 
345]. The group of Gregory J. Goodall has recently demonstrated that hundreds of 
circRNAs are regulated during TGFβ-induced EMT of human mammary epithelial 
cells (HMLE). The RNA binding protein and alternative splicing factor Quaking (QKI) 
binds to sites flanking circRNA-forming exons and promotes their generation during 
EMT [346]. Two circRNAs, Cdr1 and Sry, have been described to function as miRNA 
decoys, thereby, controlling miRNA inhibitory functions [347, 348]. Since circRNA 
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expression seems to be highly regulated during EMT, future questions should 
address their mechanistic function in EMT/MET cell plasticity and tumor progression. 
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2 Aim of the study 
The gradual and highly plastic process of an EMT is essential during 
embryogenesis to allow the formation of various tissues and organs. During 
malignant tumor progression, EMT induces epithelial tumor cell dedifferentiation and 
thereby promotes tumor cell invasion and dissemination into the surrounding tissue – 
the initial steps for metastatic spread. In the past years, intensive research has 
demonstrated that interconnected transcriptional, post-transcriptional and post-
translational networks can orchestrate the dynamic nature of EMT/MET processes in 
pathological contexts. These findings highlight the importance of a tight regulation of 
these networks and their aberrant activation can induce malignant tumor progression. 
This work has aimed at identifying and characterizing EMT-regulatory 
mechanisms, which are implicated and conserved during normal and cancer-
associated cell dedifferentiation and contribute to cancer metastasis in vivo. We have 
used normal and tumorigenic mammary epithelial cell lines, which undergo a 
stepwise EMT upon TGFβ-treatment, and have followed the morphological and 
transcriptional changes over time in order to: 
- Identify critical factors, particularly TFs and miRNAs, regulating EMT 
plasticity 
- Understand their molecular regulation during EMT, downstream targets 
and EMT-related functional outputs in vitro 
- Test their impact on tumor progression and metastasis in vivo  
Tumor metastasis is the main cause of cancer-related death in humans. 
Understanding the underlying cellular mechanisms of tumor cell dissemination and 
outgrowth at distant sites enables us to pharmacologically interfere and restrict these 
processes in the future. 
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3 Results 
3.1 Tead2 expression levels control the subcellular distribution 
of Yap and Taz, zyxin expression and epithelial-mesenchymal 
transition 
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3.1.1 Abstract 
The cellular changes during an epithelial–mesenchymal transition (EMT) largely 
rely on global changes in gene expression orchestrated by transcription factors. Tead 
transcription factors and their transcriptional co-activators Yap and Taz have been 
previously implicated in promoting an EMT; however, their direct transcriptional target 
genes and their functional role during EMT have remained elusive. We have 
uncovered a previously unanticipated role of the transcription factor Tead2 during 
EMT. During EMT in mammary gland epithelial cells and breast cancer cells, levels 
of Tead2 increase in the nucleus of cells, thereby directing a predominant nuclear 
localization of its co-factors Yap and Taz via the formation of Tead2–Yap–Taz 
complexes. Genome-wide chromatin immunoprecipitation and next generation 
sequencing in combination with gene expression profiling revealed the transcriptional 
targets of Tead2 during EMT. Among these, Zyxin contributes to the migratory and 
invasive phenotype evoked by Tead2. The results demonstrate that Tead 
transcription factors are crucial regulators of the cellular distribution of Yap and Taz, 
and together they control the expression of genes critical for EMT and metastasis. 
 
3.1.2 Introduction 
Epithelial–mesenchymal transition (EMT) is a cell-biological program that is 
required at various stages of embryonic development. Activation of EMT in epithelial 
cells induces a loss of cell–cell adhesions and apical-basal polarity, and promotes 
trans-differentiation into a mesenchymal state, which is characterized by a migratory 
and invasive phenotype [19, 349]. During solid tumor progression, a reactivation of 
some of these features in epithelial tumor cells (oncogenic EMT) is regarded as one 
of the mechanisms that can facilitate metastatic spread [2, 26]. Oncogenic EMT not 
only provides tumor cells with invasive properties that permit dissemination from the 
primary tumor, but also results in the acquisition of stem-cell-like traits, which has 
implications for cancer therapy and might also be important for colonization at distant 
organs [26, 350-352]. Among the many genes and signaling pathways active during 
EMT, transcription factors are the master coordinators of the EMT program [21, 349, 
353]. 
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The Hippo tumor suppressor signaling pathway plays a critical role in restricting 
organ size by antagonizing the oncogenic transcriptional co-activators Yap and Taz 
[224, 354]. A complex network of cell adhesion and signaling molecules, including 
the tumor suppressor neurofibromin-2/Merlin, regulates the Hippo kinase cascade, 
leading from the protein kinases Mst1 and Mst2 via the protein kinases Lats1 and 
Lats2 to the transcriptional co-factors Yap and Taz. When the Hippo pathway is 
active, Yap and Taz are phosphorylated by Lats1 and Lats2, and phosphorylated 
Yap and Taz are retained in the cytoplasm. In the absence of activated Hippo 
signaling, unphosphorylated Yap and Taz are imported into the nucleus where they, 
together with Tead DNA-binding transcription factors, activate the expression of 
proliferative and anti-apoptotic genes. 
In mammals, Tead transcription factors comprise a family of four members 
(Tead1–Tead4). They are ubiquitously expressed [155, 156] and exert partially 
redundant roles in regulating the development of various embryonic tissues, including 
neural crest, whose formation depends on EMT [2], notochord and trophectoderm 
[159-161, 355]. Transcriptional activity of the DNA-binding Teads requires their 
physical association with the transcriptional co-activators Yap or Taz [169, 356]. 
Upon Yap- or Taz-mediated activation, Teads can exert multiple functions. For 
example, they control proliferation in epithelial cells and fibroblasts [188, 209, 210]. 
Moreover, Yap and Taz are sufficient to induce EMT of MCF10A human breast 
epithelial cells in a Tead-dependent manner [208-210], and the nuclear accumulation 
of Yap and Taz in EpH4 murine mammary epithelial cells is required for these cells to 
undergo TGFβ-induced EMT [218]. Finally, elevated levels of Yap trigger increased 
tumor growth and a pro-metastatic phenotype through binding to Tead in breast 
cancer and melanoma cells [212]. Even though these studies clearly demonstrate a 
crucial role for Teads, Yap and Taz in mediating EMT induction and cancer 
progression, the mechanisms involved in the regulation of Tead transcriptional 
activity and the direct target genes during an EMT remain to be identified. 
To delineate the mechanisms underlying the transcriptional activities of Teads 
and to identify their transcriptional target genes during EMT, we have utilized cellular 
model systems of EMT in non-transformed murine mammary gland epithelial cells 
and in murine breast cancer cells. We report that the expression of Tead family 
members is upregulated during EMT, concomitant with an overall increase in Tead 
transcriptional activity. We demonstrate that elevated levels of Tead2 lead to 
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increased nuclear localization of Yap and Taz, where they form a complex with 
Tead2. As a result, increased Tead2 transcriptional activity provokes the induction of 
EMT and a malignant tumor phenotype. Conversely, knockdown of Teads in cells 
undergoing an EMT prevents efficient subcellular redistribution of Yap and Taz and 
blocks EMT. Genome-wide chromatin immunoprecipitation and next generation 
sequencing (ChIP-Seq) in combination with gene expression profiling identified 
several EMT-relevant genes as direct transcriptional targets of Tead2 during EMT. 
Among these, the gene encoding Zyxin, a component of focal adhesions and an actin 
cytoskeleton remodeling protein, is required for EMT-related migration and invasion. 
 
3.1.3 Results 
3.1.3.1 Formation of a nuclear Tead2–Yap–Taz complex and its 
transcriptional activity during EMT 
To identify crucial genes underlying the multiple stages of an EMT, we induced 
EMT in the untransformed normal murine mammary gland cell line NMuMG [357] by 
treatment with TGFβ for 0, 1, 4, 7, 10 and 20 days (data not shown). During this time 
course, the cells underwent progressive EMT and acquired a complete mesenchymal 
morphology [358]. Motif Activity Response Analysis (MARA) [359] of gene expression 
data derived from the EMT timecourse predicted that several transcription-factor-
binding motifs were important regulators of the EMT expression dynamics, including 
a motif bound by Tead transcription factors (supplementary Figure S1A). This 
analysis suggested that genes that contain a species-conserved Tead-binding MCAT 
motif are upregulated during an EMT of NMuMG cells (supplementary Figure S1A). 
To delineate the regulatory role of Tead transcription factors in the EMT process, 
we utilized NMuMG cells and Py2T murine breast cancer cells derived from a tumor 
of MMTV-PyMT transgenic mice [360], both of which underwent EMT upon treatment 
with TGFβ (Figure 1A). MTflECad cells have been established from a mammary 
tumor of a MMTV-Neu transgenic mouse carrying conditional (floxed) alleles of the E-
cadherin gene (Cdh1). These cells undergo EMT upon Cre-mediated genetic ablation 
of the E-cadherin gene (MTΔECad) [358] (Figure 1A). 
Gene expression profiling and quantitative RT-PCR revealed that the transcripts 
of all four Tead family members could be detected in the three model systems 
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before, during and after EMT, and that only Tead2 mRNA levels were upregulated 
across all model systems analyzed (supplementary Figure S1B). Based on the robust 
and reproducible expression of Tead2, we chose to focus on Tead2 and generated 
polyclonal antibodies specifically detecting Tead2 (supplementary Figure S1C-E). 
Analysis of endogenous Tead2 expression levels in all three EMT model systems by 
immunoblotting revealed that Tead2 protein levels increase upon EMT induction 
(Figure 1B). EMT-associated increased Tead2 expression was solely observed in 
Py2T cells stimulated with TGFβ, whereas other growth factors like EGF, FGF, HGF, 
IGF, PDGF or IL-6 were not able to induce Tead2 expression (supplementary Figure 
S1F). Furthermore, small interfering RNA (siRNA)-mediated ablation of Smad4 
expression during TGFβ-induced EMT in NMuMG cells did not affect Tead2 
expression levels, suggesting that TGFβ-induced Tead2 expression is independent 
of canonical TGFβ signaling (supplementary Figure S1G). Notably, siRNA-mediated 
ablation of Sox4 expression, a transcription factor known to be a crucial regulator of 
EMT [98], revealed that Tead2 expression is strictly dependent on Sox4 activity 
during TGFβ-induced EMT in NMuMG and Py2T cells (supplementary Figure S1H). 
Immunofluorescence analysis showed that low levels of nuclear Tead2 were 
present in epithelial cells, yet a much stronger nuclear staining could be observed in 
cells that were in the process of undergoing EMT (Figure 1C; NMuMG and Py2T) or 
had undergone EMT (Figure 1C; MTΔEcad). Immunofluorescence staining of the 
Tead transcriptional co-activators Yap and Taz revealed that they were distributed 
throughout the cytoplasm and in the nuclei of epithelial cells, as expected in sparsely 
growing, proliferating cells [175] (Figure 1C). Conversely, NMuMG and Py2T cells 
undergoing TGFβ-induced EMT or stably mesenchymal MTΔEcad cells displayed 
predominantly a nuclear localization of Yap and Taz, highly similar to that of Tead2 
(Figure 1C). 
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Figure 1: Tead2 upregulation and Yap and Taz subcellular redistribution during EMT. (A) 
Morphological differences between epithelial and mesenchymal counterparts of the three different cellular 
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EMT model systems used. Epithelial NMuMG and Py2T cells were treated with TGFβ for 13 days to induce 
EMT. Stably mesenchymal MTΔEcad cells were derived from epithelial MTflEcad cells by Cre-recombinase-
mediated knockout of the E-cadherin gene. Scale bars: 50 µm. (B) Immunoblotting analysis of Tead2 and E-
cadherin expression levels before, during and after TGFβ-induced EMT in NMuMG and Py2T cells, and by 
genetic deletion in MTflEcad cells. Actin served as a loading control. (C) Immunofluorescence staining of 
Tead2 and its co-factors Yap and Taz before and after induction of EMT. Yap and Taz were stained with an 
antibody that detects both proteins. E-cadherin staining served as a control, DAPI was used to visualize 
nuclei. Scale bar: 25 µm. (D) Interaction of Tead2 with Yap and Taz. Cells were treated with TGFβ for 4 days 
(NMuMG) or 7 days (Py2T). Co-immunoprecipitation (IP) was performed with an antibody against Tead2 or 
irrelevant IgG as a negative control. Levels of Yap, Taz and Tead2 were determined by immunoblotting 
analysis. Gapdh served as loading control. 
 
We next investigated whether Tead2 binding to Yap and/or Taz was subject to 
change during an EMT. Co-immunoprecipitation experiments in total cell lysates 
(Figure 1D; Py2T, NMuMG) or in cytoplasmic and nuclear cell extracts 
(supplementary Figure S1I) revealed that, indeed, the binding of Yap and Taz to 
Tead2 increased exclusively in the nucleus upon TGFβ stimulation. Similarly, both 
Yap and Taz only bound to Tead2 in mesenchymal MTΔEcad cells and not in 
epithelial MTflEcad cells (Figure 1D; MT). From these data we conclude that 
formation of a nuclear Tead2–Yap–Taz complex is increased during EMT, even 
though total levels of Yap and Taz decrease upon EMT induction (Figure 1D; 
supplementary Figure S1I). 
Consistent with these observations, we found that pan-Tead transcriptional 
activity increased upon EMT induction in a Sox4-dependent fashion (supplementary 
Figure S2A-C). Tead transcriptional activity in cells undergoing EMT was assessed 
by Tead-responsive luciferase reporter constructs bearing either MCAT core motifs 
(CATTCCT; supplementary Figure S2A) [361] or GTIIC core motifs (ACATTCCAC; 
supplementary Figure S2B) [188]. In addition, the transcriptional activity of a 
previously described Cyr61 promoter reporter containing a Tead-responsive MCAT 
motif [362] was induced during EMT of NMuMG cells, whereas mutation of the Tead-
binding site resulted in a complete loss of the reporter activity (supplementary Figure 
S2D). 
Taken together, these data demonstrate that, upon EMT induction, Tead2 
expression levels are increased in a Sox4-dependent manner concomitant with 
enhanced formation of the Tead2–Yap–Taz complex in the nucleus. In accordance 
with these observations, overall Tead transcriptional activity increases during EMT. 
 
Tead2	  in	  EMT	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  RESULTS	  	  
 53 
3.1.3.2 Nuclear localization of Yap and Taz is mediated by Tead2 and is 
required for EMT 
From the data presented above, we hypothesized that binding of the increased 
levels of Tead2 to Yap and Taz in the nucleus is required to activate Tead2-mediated 
transcriptional activity during EMT. To test this hypothesis, we first investigated 
whether overexpression of Tead2 in epithelial cells can provoke a subcellular 
redistribution of Yap and Taz. Immunofluorescence microscopy analysis revealed 
that Yap and Taz were evenly distributed between the cytoplasm and nucleus in 
control cells (Figure 2A, Vector) or in cells transfected to express a Tead2 mutant 
(Figure 2A, Tead2 Y440H), which is incapable of binding to Yap or Taz (Figure 2A) 
[210, 363-366]. Conversely, the forced expression of wildtype Tead2 (Tead2-WT) in 
NMuMG cells resulted in a marked concentration of Yap and Taz in the nucleus and 
reduced levels of cytoplasmic Yap and Taz, suggesting that Tead2 controls Yap and 
Taz subcellular distribution by direct binding. Consistent with these observations, 
Tead transcriptional activity was increased by the expression of wildtype Tead2 but 
not by the expression of mutant Tead2 Y440H (supplementary Figure S3A). 
We next assessed whether upregulation of Teads during EMT is required for Yap 
and Taz redistribution and for EMT. NMuMG cells were transfected with control 
siRNA (siCtr) or with siRNAs against Tead1, 2 and 3 (siTead1-3) whose expression 
were upregulated during EMT in these cells (supplementary Figure S1B). As 
expected, TGFβ-treated cells transfected with control siRNA displayed predominantly 
nuclear localized Yap and Taz in response to TGFβ-treatment, whereas knockdown 
of Teads prevented this subcellular redistribution (Figure 2B). Importantly, depletion 
of Teads and the resulting failure of Yap and Taz subcellular redistribution also 
averted the disassembly of tight junctions and adherens junctions normally observed 
during EMT (supplementary Figure S3B). Moreover, immunoblotting analysis of EMT 
marker expression revealed an attenuation of EMT upon Tead ablation: 
downregulation of E-cadherin was inhibited and, conversely, upregulation of the 
mesenchymal markers fibronectin and N-cadherin were delayed (supplementary 
Figure S3C). Similarly, blocking Tead transcriptional activity by the inducible 
expression of a dominant-negative version of Tead2 (Tead2-EnR) attenuated the 
EMT process in TGFβ-treated Py2T cells (supplementary Figure S3D,E). These 
results indicate that Teads are crucial for regulating the cytoplasmic-nuclear 
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redistribution of Yap and Taz during EMT and that this regulatory process is required 
for EMT. 
 
Figure 2: Elevated Tead2 levels induce a predominant nuclear localization of Yap and Taz and induce 
EMT. (A) Yap and Taz cellular localization is dependent on their direct binding to Tead2. A vector control 
(Vector), type Tead2 (Tead2-WT) or a Tead2 point mutant defective in Yap and Taz binding (Tead2 Y440H) 
were stably expressed in NMuMG cells, and Yap and Taz and Tead2 localization was assessed by 
immunofluorescence staining. DAPI was used to visualize nuclei. Scale bar: 20 µm. (B) Depletion of Tead 
expression prevents the reduction in cytoplasmic levels of Yap and Taz during EMT. NMuMG cells 
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transfected or not with siRNA pools targeting Tead1-3 were induced to undergo EMT by TGFβ-treatment for 
4 days. Yap and Taz, and Tead2 were visualized as described in A. Scale bar: 25 µm. (C) Effect of acute 
Tead2 overexpression on Yap and Taz localization and epithelial differentiation. Tead2 was expressed in 
Py2T cells (Py2T-iTead2) in a doxycycline (Dox)-inducible fashion, and the localization of Tead2, Yap and 
Taz and E-cadherin were visualized by an immunofluorescence staining. Scale bar: 20 µm. (D) Effect of 
Tead2 gain-of-function on cell morphology and EMT. Py2T cells were stably transduced with constructs 
coding for Tead2 (Tead2-WT), a constitutively active version of Tead2 (Tead2-VP16) or an empty vector 
control. Overall morphological changes were visualized by phase-contrast microscopy and by 
immunofluorescence staining against E-cadherin, ZO-1, vimentin and the actin cytoskeleton (phalloidin 
staining). The insets show an enlarged view of F-actin staining. Scale bars: 15 µm. (E,F) Depletion of Yap or 
Taz expression prevents Tead2-induced EMT. Py2T cells stably overexpressing Tead2 were transfected with 
siRNA pools against Yap and Taz or with a control siRNA (siCtr). Overall cell morphology by phase-contrast 
microscopy (E) and immunoblotting analysis of E-cadherin, Yap and Taz expression (F) are shown. Scale 
bar: 15 µm. 
 
 
We next asked whether experimentally increasing Tead2 levels and 
transcriptional activity in epithelial cells is sufficient to induce EMT. We generated 
Py2T cells that expressed wildtype Tead2 under the control of the doxycycline-
inducible system. Treatment with doxycycline for 3 days led to a heterogeneous 
induction of Tead2 expression in these cells (Figure 2C). Non-induced cells 
expressing low endogenous levels of Tead2 showed Yap and Taz staining in the 
cytoplasm as well as in the nucleus. In doxycycline-treated cells, the elevated levels 
of nuclear Tead2 resulted in concentration of Yap and Taz in the nucleus (Figure 
2C). By 3 days after doxycycline induction, Tead2-expressing cells had already 
started to lose E-cadherin expression; this phenotype was enforced with a prolonged 
doxycycline treatment (supplementary Figure S3F), indicating that the elevation of 
Tead2 levels was sufficient to induce EMT. 
Yap and Taz nuclear localization, increased formation of Yap–Taz–Tead2 
complexes and heightened Tead transcriptional activity was also observed in Py2T 
cells stably expressing wildtype Tead2 (Tead2-WT) (supplementary Figure S3G,H) 
[188]. Notably, although overexpression of a constitutively active version of Tead2 
(Tead2-VP16) lacking a Yap- and Taz-binding site showed a transcriptional activity 
that was highly dependent on Tead (mediated by the Herpes simplex virus VP16 
transactivation domain), but no increased nuclear localization of Yap and Taz 
(supplementary Figure S3G,I). Furthermore, forced expression of both wildtype 
Tead2 and constitutively active Tead2-VP16 also resulted in the morphological 
changes consistent with EMT [i.e. the loss of the epithelial markers E-cadherin and 
ZO-1, increased expression of the mesenchymal markers vimentin, Zeb1/2 and Slug, 
and a shift of the cytoskeleton from displaying cortical actin to actin stress fibers 
(Figure 2D; supplementary Figure S3J). Transient siRNA-mediated ablation of Yap or 
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Taz in Tead2-WT (siYap and siTaz, respectively) cells led to a mesenchymal-to-
epithelial transition (MET), as indicated by an epithelial morphology and the 
increased expression of E-cadherin in Yap- or Taz-deficient cells (Figure 2E,F). 
Collectively, these results demonstrate that Tead2 is able to induce an EMT via the 
formation of transcriptionally active complexes with Yap and Taz. 
 
3.1.3.3 Tead2 promotes tumor cell migration, invasion and metastasis 
A hallmark of cells undergoing EMT is the acquisition of migratory and invasive 
properties [4, 349]. Consistent with their mesenchymal phenotype, cells expressing 
Tead2-WT exhibited an increased capability to migrate and to invade (Figure 3A). In 
contrast to control cells, which formed smooth spheres, Tead2-WT and Tead2-VP16 
cells invaded there-dimensional Matrigel and projected filopodia into the extracellular 
matrix (Figure 3B). These results indicate that, consistent with its EMT-inducing 
activities, Tead2 also promotes cancer cell migration and invasion. 
We next assessed whether Tead2-induced EMT, cell migration and cell invasion 
translated into a higher metastatic capability in Py2T murine breast cancer cells. 
Py2T cells stably expressing Tead2-WT, Tead2-VP16 or a control vector were 
injected into the tail veins of Balb/c nu/nu immune-deficient mice, and the formation 
of lung metastasis was scored 33 days after injection. Serial sectioning of paraffin-
embedded lungs and staining by hematoxylin and eosin revealed that only one out of 
six mice injected with epithelial control cells displayed macroscopically visible tumor 
cell clusters. Notably, these nodules were found encapsulated within blood vessels 
(Figure 3C,D). In contrast, half of the mice injected with Tead2-WT cells and five out 
of six mice injected with Tead2-VP16 cells developed macroscopic metastases 
(Figure 3C,D), with a higher incidence per mouse as compared to control cells 
(Figure 3E). 
Taken together, these results indicate that Tead2 promotes increased cancer cell 
migration/invasion and metastatic outgrowth of Py2T cells in the lung. 
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Figure 3: Tead2 promotes cell migration, invasion and metastasis. (A) Chemotactic migration and 
invasion of Py2T cells stably expressing Tead2-WT or an empty vector control. Transwell assays were 
performed utilizing cell culture inserts that were not coated (migration) or coated with Matrigel (invasion). 
Migrated and invaded cells were quantified. Data are shown as mean ± S.E.M. (n = 3; **P<0.01). (B) Cell 
invasion in a 3D extracellular matrix. Py2T cells stably expressing Tead2-WT or Tead2-VP16 were 
embedded in Matrigel and allowed to grow for 5 days. Empty-vector-transduced Py2T cells served as a 
control. Scale bars: 50 µm. (C) Experimental metastasis. Py2T cells as described in B were injected into the 
tail veins of female Balb/c nu/nu mice. Mice were killed 33 days post-injection and lungs were sectioned and 
stained by hematoxilin and eosin (H&E). Higher magnifications are also shown (right). Scale bars: 100 µm. 
(D,E) Quantification of lung metastasis incidence and number of lung metastasis per mouse as determined 
by serial sectioning and microscopic analysis of lungs as described in C. The metastatic incidence was 
calculated as mice harboring metastases/total number of mice per group. Data are shown as mean ± S.E.M. 
(n = 6 mice per group; *P<0.05). 
 
 
3.1.3.4 The transcriptional Tead2 target genes during EMT 
The results presented above suggest that Tead2 function is regulated differently 
during EMT, leading to a malignant cancer cell phenotype. To elucidate the 
corresponding downstream mechanisms we sought to identify genes that are 
transcriptionally regulated by Tead2 during the process of EMT. Using our Tead2 
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antibody we performed chromatin immunoprecipitation followed by next generation 
sequencing (ChIP-Seq) at 5 days of TGFβ-treatment, a time point at which Tead2 
expression and activity was robustly increased in Py2T cells (Figure 1B; 
supplementary Figure S2A). Detection of known overrepresented transcription factor 
binding motifs by Hypergeometric Optimization Motif EnRichment (HOMER) revealed 
that the MCAT Tead-binding motif (supplementary Figure S1A) is the most significant 
motif found in Tead2 bound regions, followed by a motif bound by Jun-AP1 (Figure 
4A). PhyloGibbs, an algorithm that de novo infers overrepresented and evolutionarily 
conserved sequence motifs from ChIP-Seq data, also revealed a motif that 
corresponds to the MCAT and to the highly similar GTIIC core Tead binding motifs 
(Figure 4B). These findings suggest that the known MCAT and GTIIC motifs are 
among the main sequence motifs targeted by Tead2 during TGFβ-induced EMT. 
To identify direct target genes of Tead2 that showed a change in their expression 
during EMT, we performed genome-wide gene expression profiling in epithelial Py2T 
cells and in Py2T cells treated with TGFβ for 5 days. Genes that had a different 
expression level, passing a cutoff of at least 1.5-fold (adjusted P<0.05), were 
selected for an overlay with Tead2-bound genes as determined by ChIP-Seq 
analysis (Figure 4C; supplementary Table S1). Tead2-bound genes were defined as 
showing a ChIP-Seq peak at a distance less than 10 kb to their transcriptional start 
sites (TSS). The overlay analysis identified 132 genes bound by Tead2 in their 
promoter regions and showing increased or decreased expression during TGFβ-
induced EMT (supplementary Table S2). Gene ontology analysis for cellular 
components by GOstats [367] revealed that Tead2 predominantly controls genes 
which encode for components of cell junctions and regulators of the actin 
cytoskeleton (Figure 4D). 
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Figure 4: Identification of direct Tead2 transcriptional target genes during EMT. (A) DNA-binding motifs 
that are overrepresented in Tead2-binding regions. Py2T cells treated with TGFβ for 5 days were subjected 
to ChIP using an antibody for Tead2 followed by next generation sequencing (ChIP-Seq; n = 2). The 
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sequencing data were subjected to Hypergeometric Optimization of Motif EnRichment analysis (HOMER). 
Shown are the motifs that are significantly enriched. (B) De novo generation of sequence motifs 
overrepresented in Tead2-binding regions using PhyloGibbs. Shown is the most significant Tead2-binding 
motif. (C) Determination of potential direct target genes of Tead2 during EMT. The Venn diagram depicts the 
number of genes from the Tead2 ChIP-Seq analysis, the number of genes that were regulated differently in 
Py2T cells before and after 5 days of TGFβ treatment and the number of overlapping genes. (D) Gene 
ontology analysis was performed on overlapping genes described in C using GOstats. The table shows the 
functional annotation clustering analysis for the top five cellular compartments, the associated genes per 
group and their P-values within the groups. (E) Validation of genes directly bound by Tead2 by quantitative 
PCR. Chromatin from the cells treated as described in A was subjected to qPCR using primer pairs spanning 
the Tead2-binding regions determined by ChIP-Seq. The data are presented as fold enrichment above 
background (IP over input) and were normalized to control IgG. An intergenic region was used as negative 
control. Data are represented as means ± S.E.M. (n = 2). (F) Expression of Tead2-bound genes during EMT 
as determined by RT-qPCR. Py2T and NMuMG cells were treated with TGFβ for 5 or 4 days, respectively. 
Fold changes in mRNA expression are presented as means ± S.E.M. (n = 3). *P<0.05, **P<0.01, 
****P<0.0001. 
 
 
Among these 132 genes, we validated known Tead target genes by ChIP-PCR, 
including CTGF and CYR61 [215], whose expression also increased upon TGFβ-
stimulation in the three EMT model systems investigated (Figure 4E,F; 
supplementary Figure S4A,B). Furthermore, we identified other candidate Tead2 
target genes that had been previously implicated in EMT and/or malignant tumor 
progression [74, 98, 350], such as AMOTL2, ESRP2, MAL, PDGFC, SERPINE1 and 
others (supplementary Table S2). We further ascertained that PARD6B, a gene 
encoding for a polarity complex protein, and ELMO3, a gene implicated in 
phagocytosis and cell migration, were Tead2 target gene candidates. The expression 
of these genes was decreased during TGFβ-induced EMT in Py2T and 
mesenchymal MTΔEcad cells, indicating that Tead2 is not exclusively a 
transcriptional activator but also a repressor of gene expression (Figure 4E,F; 
supplementary Figure S4B). 
Given that, during EMT, Tead2 formed nuclear complexes with Yap and Taz 
(Figure 1D; supplementary Figure S1I), we assessed whether some of the above-
mentioned Tead2-regulated genes were bound by a Tead2–Yap–Taz complex. ChIP 
experiments for Tead2, Yap and Taz in Py2T cells induced to undergo EMT and 
subsequent RT-PCR analysis revealed similar or increased binding of Yap and/or 
Taz to the same promoter regions targeted by Tead2, including the promoters of 
CTGF, CYR61, PARD6B, PDGFC (supplementary Figure S4C). 
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These results indicate that the Tead2–Yap–Taz complex regulates EMT-relevant 
genes by acting as a transcriptional activator or repressor, mainly by binding to 
promoter sequences containing Tead-specific MCAT or GTIIC motifs. 
 
3.1.3.5 Zyxin is a Tead2–Taz target gene critical for EMT 
ChIP-Seq also revealed a direct binding of Tead2 to an intronic region of the 
gene encoding for Zyxin (ZYX; supplementary Figure S4D). Close inspection of this 
region revealed the presence of a species-conserved MCAT motif (Figure 5A). Zyxin 
is an actin regulatory protein that localizes to sites of focal adhesions and stress 
fibers in response to mechanical cues to facilitate actin polymerization and 
generation of traction force [368-370]. In line with this functional role, Zyxin 
upregulation during EMT in NMuMG cells has been reported to be essential for cell 
migration [371], and given that forced expression of Tead2 promotes cancer cell 
migration or invasion, and metastatic outgrowth of Py2T cells in the lung (Figure 3), 
we decided to focus on Zyxin as a Tead2 target gene. 
ChIP-PCR on Py2T cells treated with TGFβ for 5 days confirmed the binding of 
endogenous Tead2 to an intronic region of the ZYX gene (Figure 5B). Concomitantly, 
mRNA and protein levels of Zyxin were substantially increased during EMT in Py2T 
cells (Figure 5C). Higher Zyxin expression was also found in mesenchymal MTΔEcad 
cells as compared to MTflEcad cells (supplementary Figure S4E). 
Immunofluorescence microscopy analysis confirmed increased levels of Zyxin 
localized along stress fibers that are formed during TGFβ-induced EMT in Py2T cells 
and at focal adhesion sites (Figure 5D), as previously reported [371]. 
To evaluate whether increased expression of Zyxin during EMT is dependent on 
Tead activity, we induced EMT in a pool of Py2T cells expressing a dominant-
negative version of Tead2 (Tead2-EnR) under the control of the doxycycline-
inducible system. Immunoblotting and RT-PCR analysis demonstrated that 
expression of Tead2-EnR significantly attenuated Zyxin upregulation during EMT 
(Figure 5E,F). Similarly, siRNA-mediated knockdown of Tead1, 2 and 3 in NMuMG 
cells and knockdown of Taz, not Yap, in Py2T cells prevented increased expression 
of Zyxin during EMT (Figure 5G,H). 
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Figure 5: Zyxin is a direct Tead2 target gene critical for cell migration. (A) Top: scheme of the zyxin 
gene (ZYX) showing the location of the Tead2-binding site (red). Arrows denote primers used in B. Middle: 
species conservation of the Tead2-binding region. The red box denotes the core MCAT motif. Bottom: 
mammalian conservation plot encompassing 32 species (derived from UCSC genome browser). (B) 
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Validation of Tead2-binding to the Zyx gene by ChIP-qPCR in Py2T cells treated with TGFβ for 5 days. The 
qPCR data (n = 3; mean ± S.E.M.; *P<0.05) indicate fold enrichment above background and were normalized 
to irrelevant IgG as negative control. (C) Zyxin expression during EMT. Py2T cells were treated with TGFβ 
for the indicated durations. Regulation of mRNA (top) and protein level (bottom) was determined by RT-
qPCR and immunoblotting analysis. Results are presented as means ± S.E.M. (n = 3). *P<0.05; **P<0.01. (D) 
Immunofluorescence staining of zyxin and F-actin in epithelial and mesenchymal Py2T cells. Cells were 
treated with TGFβ as indicated. F-actin was stained with phalloidin coupled to a fluorophore. Scale bar: 15 
µm. (E,F) Zyxin protein and mRNA levels in Py2T cells undergoing EMT without (−) or with (+) doxycycline 
(Dox)-induced expression of a HA-tagged dominant-negative version of Tead2 (Tead2-EnR) before and 
during a TGFβ-induced EMT. Results are presented as means ± S.E.M. (n = 2). **P<0.01. (G) Immunoblotting 
analysis of zyxin during TGFβ-induced EMT of NMuMG cells transfected with siRNA pools targeting Tead1, 
2 and 3 or control siRNA. Membranes shown in supplementary Figure S3C were reprobed with an antibody 
against zyxin. (H) Yap, Taz and zyxin mRNA expression levels in Py2T cells. Cells were transfected with 
siRNA pools against Yap, Taz or a control siRNA and cultured in the absence and presence of TGFβ. 
Results are presented as means ± S.E.M. (n = 2). *P<0.05, **P<0.01, ***P<0.001. (I,J) Immunoblotting 
analysis of zyxin expression in Py2T cells overexpressing HA-tagged wildtype Tead2 (HA–Tead2-WT), 
constitutively active Tead2 (HA–Tead2-VP16), and wildtype or Yap and Taz mutants (HA–TazS89A, HA–
YapS127A). (K) Contribution of zyxin to mesenchymal migration and invasion induced by Tead2 
overexpression (Tead2-WT; left panel) or by 20 day TGFβ-treatment (right panel). Py2T cells were 
transfected with siRNA pools against zyxin or control siRNA pools and subjected to chemotactic transwell 
migration and invasion assays as described in Figure 3A. Data are represented as means ± S.E.M. (n = 3). 
*P<0.05, **P<0.01. 
 
 
We next assessed whether Zyxin expression was indeed controlled by Tead2. 
We thus evaluated Zyxin expression in response to modulating Tead2 function by the 
expression of wildtype Tead2 and Tead2-VP16, by the expression of wildtype Yap 
and Taz and by the expression of Hippo-signaling-insensitive mutant versions of Yap 
and Taz [372]. Immunoblotting analysis revealed that Zyxin expression was induced 
by forced expression of Tead2-WT, Tead2-VP16 and both versions of Taz, but not by 
Yap (Figure 5I,J). These results demonstrate that Tead2 mediates Zyx gene 
expression via Taz co-activation. 
To determine the functional contribution of increased Zyxin expression levels to 
cell migration and invasion, we tested whether the increased migratory and invasive 
phenotype of Py2T cells treated with TGFβ (>20 days) or of Py2T cells forced to 
express Tead2-WT (Figure 3A) could be reversed by siRNA-mediated ablation of 
Zyxin expression (supplementary Figure S4G). Indeed, knockdown of Zyxin in cells 
expressing wildtype Tead2 or cells treated with TGFβ led to a reduction in cell 
migration and invasion (Figure 5K). Interestingly, knockdown of Zyxin in Py2T cells 
overexpressing wildtype Tead2 had no effect on the mesenchymal morphology of 
these cells (supplementary Figure S4H), indicating that Zyxin is only required for cell 
migration and invasion and not for the morphogenic process of EMT. The results 
demonstrate that Tead2 directly regulates Zyxin expression during TGFβ-induced 
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EMT via its co-factor Taz and thereby induces a Zyxin-driven migratory and invasive 
cell phenotype. 
 
3.1.4 Discussion 
The transdifferentiation of epithelial cells into a mesenchymal state involves a 
thorough remodeling of cell architecture, such as the loss of apical-basal cell polarity 
accompanied by a breakdown of tight and adherens junctions. Concomitantly, the 
establishment of mesenchymal traits involves the generation of front–rear polarity via 
remodeling of the actin cytoskeleton and the activation of cell migration. These 
changes largely rely on global changes in gene expression orchestrated by 
transcription factors [373]. Here, we have uncovered a crucial mechanistic role of 
Tead transcription factors, in particular Tead2, during the process of EMT. 
We demonstrate that Tead2 expression is increased during EMT and that 
elevated nuclear levels of Tead2 lead to nuclear complex formation with Yap and Taz 
and to increased nuclear localization of these cofactors. We further demonstrate that 
increased Tead2 expression during EMT is accompanied by enhanced Tead2-
mediated transcriptional activity. Notably, experimental elevation of Tead2 
transcriptional activity is sufficient to induce an EMT and the establishment of lung 
metastasis. The EMT-associated upregulated expression of Tead2 is independent of 
canonical TGFβ signaling, because the ablation of Smad4 during TGFβ-induced 
EMT had no substantial impact on Tead2 expression. Moreover, our studies indicate 
that the TEAD2 gene is a downstream target of the transcription factor Sox4, a 
crucial epigenetic regulator of EMT [98]. Whether TEAD2 gene expression is directly 
activated by Sox4 during EMT remains to be addressed. Recent studies on SoxC 
family members, which include Sox4, Sox11 and Sox12, demonstrate a direct 
regulation of the TEAD2 gene promoter by Sox4 and Sox11 in the fibroblast-like cell 
line Cos-1 [374]. Given that Sox4 controls the levels of Tead2, which are crucial for 
Tead2 binding to the Hippo downstream targets Yap and Taz in nucleus, it will be 
interesting to assess whether Sox4 is an integrator of non-canonical TGFβ signaling 
and Hippo signaling. 
Several recent studies have suggested that elevated Tead activity mediated by a 
gain-of-function of Yap or Taz can evoke a malignant phenotype. Indeed, Taz is 
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highly expressed in ∼20% of breast cancers, most of which represent invasive ductal 
carcinomas (IDCs), and expression of this Tead co-activator is responsible for 
migration and invasiveness of cultured breast cancer cell lines [203]. Recently, 
another study has demonstrated that overexpression of a Hippo-signaling-insensitive 
version of Yap (YapS127A) renders breast cancer and melanoma cells pro-
metastatic [212]. In accordance with our results, this effect depends on an intact 
interaction domain for Yap in Tead, and Tead transcriptional activity correlates with 
the metastatic potential of various cancer cell lines. Our results are also consistent 
with previous reports demonstrating that ectopic expression of Yap and Taz in 
MCF10A normal breast epithelial cells induces EMT via Tead transcriptional activity 
[208, 210]. 
As expected from cells that have undergone an EMT, we report that Tead2-
overexpressing cells display increased migration, invasion and metastasis in 
comparison to control cells. Conversely, an attenuation of TGFβ-induced EMT is 
observed when a dominant-negative version of Tead2 (Tead2-EnR) is expressed. 
This effect is also observed upon siRNA-mediated depletion of Tead family 
members. These results demonstrate that the presence and transcriptional activity of 
Teads is required for the proper execution of a TGFβ-induced EMT program. 
Tead transcriptional activity is mainly controlled by the direct binding of the co-
factors Yap and Taz [169, 209, 356, 375]. Here, we have investigated whether this is 
also true during EMT in normal mammary epithelial cells and in breast cancer cells. 
In epithelial cells, Yap and Taz are almost equally distributed between the cytoplasm 
and the nucleus. However, during EMT Yap and Taz are predominantly localized to 
the nucleus and this subcellular redistribution is dependent on their binding to Tead2. 
We also observe a membranous staining pattern of Yap and Taz in epithelial cells 
reminiscent of tight junctions (data not shown). This observation is consistent with a 
series of studies reporting that Yap and Taz clusters with apical junction proteins, 
such as Crumbs, PATJ, PALS, angiomotins and α-catenin, thereby counteracting 
their nuclear entry [218, 220, 222, 224-226]. On the basis of published observations 
and our own results, it is tempting to speculate that, in epithelial cells, membrane-
bound Yap and Taz are released by EMT-induced disassembly of junctional 
complexes, and increased nuclear levels of a Tead2–Yap–Taz complex in the 
nucleus to finally promote Tead transcriptional activity. 
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To the best of our knowledge, this is the first report on genes that are 
transcriptionally regulated by activated Tead2 during EMT. ChIP-Seq analysis has 
identified genes that are directly bound by Tead2 during TGFβ-induced EMT 
(supplementary Table S1). Our results indicate that in cells undergoing EMT, Tead2 
predominantly binds to regions harboring MCAT Tead-binding motifs [376]. A closer 
inspection of Tead2-bound genes and their changes in gene expression during EMT 
indicates that Tead2 acts as a transcriptional activator as well as a repressor. 
Because Tead transcription factors lack a transactivation domain, their function 
depends on transcriptional co-factors. Thus far, Yap and Taz have been reported to 
exclusively act as transcriptional co-activators of Teads, for example in regulating the 
expression of the CTGF and CYR61 genes [210, 215]. Our analysis identified new 
Tead2 target genes like PARD6B and ELMO3, whose expression are significantly 
reduced during EMT. The same promoter regions were also found to be bound by 
Taz upon TGFβ-treatment, which would implicate that the Tead2–Taz complex could 
also function as a transcriptional repressor. 
We further report that Taz but not Yap acts as a co-activator of the Tead2 target 
gene ZYX. Zyxin protein expression is upregulated during EMT in a Tead-dependent 
manner. Zyxin associates with the actin cytoskeleton and therefore can be localized 
at the apical membrane, in focal adhesions and on stress fibers [368]. Notably, Zyxin 
is required for the rearrangement of the actin cytoskeleton during TGFβ-induced 
EMT of NMuMG cells, thereby enabling cell migration [371]. Zyxin upregulation could 
therefore be at least one of the mechanisms by which Tead transcriptional activity 
controls the induction of a migratory and invasive cellular phenotype during EMT. 
In summary, our results establish a crucial regulatory role for Tead transcription 
factors during the process of EMT and suggest that Teads are not only mere 
executors of Yap and Taz functions in promoting EMT and metastasis, but also play 
a crucial regulatory role in controlling Yap and Taz subcellular localization and 
activity during these processes. 
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3.1.5 Materials and methods 
Antibodies and reagents 
Antibodies used were as against the following proteins: actin (Santa Cruz 
Biotechnology, Dallas, TX), E-cadherin (BD, San Jose, CA, USA), N-cadherin 
(Takara Bio, Otsu, Shiga, Japan), fibronectin (Sigma-Aldrich, St Louis, MO, USA), 
GAPDH (Sigma-Aldrich), vimentin (Sigma-Aldrich), ZO-1 (Zymed, San Francisco, 
CA), Yap and Taz (Santa Cruz Biotechnology), Taz (IMGENEX, San Diego, CA, 
USA), zyxin (Santa Cruz Biotechnology), HA (Covance, Princeton, NJ, USA). Affinity 
purified, polyclonal rabbit anti-Tead2 antibody was generated by immunizing rabbits 
with a peptide corresponding to the N-terminus of Tead2 (amino acids 16–32); 
phalloidin–Alexa-Fluor-568 was from Invitrogen (Carlsbad, CA). Reagents used 
were: recombinant human TGFβ1 (R&D Systems, Minneapolis, MN, USA); Matrigel, 
growth factor reduced (BD); Doxycycline (Clontech/Takara). 
 
Cell culture and cell lines 
The subclone of NMuMG cells (NMuMG/E9) was as previously described [357] 
and was originally obtained from the American Type Culture Collection (ATCC, 
Manassas, VA). MTflEcad and MTΔEcad cells and Py2T cells are as described 
previously [358, 360]. All cells were cultured in Dulbecco's modified Eagle's medium 
(DMEM) supplemented with glutamine, penicillin, streptomycin and 10% FBS 
(Sigma-Aldrich). Cells were treated with 2 ng/ml TGFβ. 
 
Plasmids 
The GTIIC reporter was generated by subcloning the GTIIC Tead response 
elements including the basal promoter from pδ51-LucII (kindly provided by Hiroshi 
Sasaki, RIKEN Center for Developmental Biology, Kobe, Japan) into pGL4 
(Promega, Madison, WI, USA) [167, 188]. The MCAT reporter was derived from this 
construct by replacement of 8×GTIIC with eight copies of the sequence 
CCTGACACACATTCCTCAGCT (8×MCAT), where the MCAT core motif is 
underlined, and flanking sequences were according to Larkin et al. [361]. The 
Cyr61prom WT and Cyr61prom TeadMut reporters were previously described [362] 
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and kindly provided by Xiaolong Yang (Pathology and Molecular Medicine, Queen's 
University, Ontario, Canada). The Renilla luciferase expressing vector (pRL-CMV) 
was from Promega. Murine Tead1-4 in pcDNA3.1 were kindly provided by Jaime 
Carvajal (The Institute of Cancer Research, London, UK). Retroviral Tead2-WT and 
Tead2-VP16 constructs were as described previously [188]. Retroviral HA-tagged 
Tead2, Tead2-VP16, Tead2-EnR, Taz and Yap were created by inserting the 
respective cDNAs into the pBabe-derived retroviral vector pRFTO containing an N-
terminal HA tag (kindly provided by Reto Kohler, FMI, Basel, Switzerland). Original 
cDNAs were kind gifts from H. Sasaki (Tead2, Tead2-VP16), R. Kohler (Yap, 
YapS127A) and Kun-Liang Guan (Department of Pharmacology and Moores Cancer 
Center, UCSD, La Jolla, USA) (Taz, TazS89A). The lentiviral, doxycycline-inducible 
HA–Tead2 and HA–Tead2-EnR constructs were generated by subcloning from 
pRFTO into pLVX-tight-puro (Clontech, Madison, WI, USA). Retroviral HA-tagged 
Tead2 Y440H was generated by PCR-mediated site-specific mutagenesis. 
 
RNA interference 
10 nM siGENOME smart pool siRNAs (Dharmacon, Lafayette, CO, USA) against 
murine Tead1, Tead2, Tead3, Tead4, Yap, Taz and Zyxin were used for transient 
knockdown experiments. Transfection was performed with Lipofectamine RNAiMax 
(Invitrogen) according to the manufacturer's instructions. 
 
RNA isolation and RT-PCR 
Total RNA was prepared using TriReagent (Sigma-Aldrich), reverse transcribed 
with M-MLV reverse transcriptase (Promega), and transcripts were quantified by 
PCR using SYBR-green PCR MasterMix (Invitrogen). Riboprotein L19 primers were 
used for normalization. PCR assays were performed in triplicate, and fold induction 
was calculated using the comparative Ct method (ΔΔ Ct). Primers used for 
quantitative RT-PCR are listed in supplementary Table S3. 
 
Luciferase reporter assay 
Cells were plated in triplicate in 24-well plates. At 1 day after plating, cells were 
transfected with 800 ng reporter and 10 ng of plasmids encoding Renilla luciferase 
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using Lipofectamine 2000 (Invitrogen). Cells were lysed using 1× passive lysis buffer 
(Promega) and lysates were analyzed using the Dual-Luciferase reporter assay 
system (Promega) and a Berthold Luminometer LB960. Firefly luciferase values were 
normalized to internal Renilla luciferase control values. 
 
Cell fractionation and co-immunoprecipitation 
Nuclear and cytoplasmic extracts were prepared with NE-PER nuclear and 
cytoplasmic extraction reagents (Thermo Scientific, Waltham, MA, USA) according to 
the manufacturer's instructions. Protein-G-coupled Dynabeads (Invitrogen) were 
used for co-immunoprecipitation experiments on total, nuclear and cytoplasmic cell 
extracts according to the manufacturer's instructions. Samples were analyzed by 
SDS-PAGE. 
 
Immunoblotting, immunofluorescence staining, retroviral infection and 
Affymetrix gene expression profiling 
These were performed as described previously [360]. 
 
Lentiviral infection 
Stable pools of cells expressing Tead2-WT or Tead2-EnR in a doxycycline-
inducible fashion were generated using the Lenti-X Tet-On Advanced system 
(Clontech). Lentiviral particles were produced according to the manufacturer's 
instructions using the helper vectors pHDM-HGPM2, pHDM-Tat1b, pRC-CMV-RaII 
and the envelope-encoding vector pVSV. For infection, viral supernatants were 
added to target cells in the presence of polybrene (8 µg/ml). Cells were spun for 1 
hour at 30°C at 1000 g and were subsequently incubated at 37°C under 5% CO2 in a 
tissue culture incubator for 2 hours. Viral supernatant was replaced by normal growth 
medium and after 1 day, antibiotic selection was performed. 
 
Transwell migration and invasion assay 
Trypsinized and washed cells were resuspended in growth medium containing 
0.2% FBS and 2 ng/ml TGFβ, where appropriate. 2.5×104 cells in 500 µl medium 
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were seeded into cell culture insert chambers (BD). Bottoms of the chambers 
contained 700 µl of growth medium supplemented with 20% FBS. After 24 hours in a 
tissue culture incubator at 37°C under 5% CO2, cells were fixed with 4% PFA in PBS 
for 10 minutes. Cells that had not crossed the membrane were removed with a cotton 
swab, and cells on the bottom of the membrane were stained with DAPI and 
quantified using a Leica DMI 4000 microscope. 
 
3D Matrigel culture 
Growth factor-reduced Matrigel (BD) was diluted to 4 mg/ml protein with serum-
free growth medium. 2500 cells in 10 µl Matrigel were transferred to one well of a µ-
slide angiogenesis microscopy slide (ibidi, Martinsried, Germany). After 20 minutes of 
gel solidification in a tissue culture incubator, 50 µl of normal growth medium was 
added. Growth medium was replenished after 3 days. After 5 days of growth, 
structures were photographed using a Leica DMIL microscope. 
 
Tail vein injection, tissue processing and H&E staining 
0.5×106 Py2T cells were injected orthotopically into the tail vein of three months 
old female Balb/c nude mice. Mice were killed at 33 days post injection and lungs 
were isolated. Tissue processing and H&E staining were performed as previously 
described [360]. All studies involving mice were approved by the Swiss Federal 
Veterinary Office (SFVO) and the regulations of the Cantonal Veterinary Office of 
Basel Stadt (licences 1878, 1907, 1908). 
 
Chromatin immunoprecipitation 
ChIP experiments were performed as previously described [377]. In brief, 
crosslinked chromatin was sonicated to achieve an average fragment size of 500 bp. 
Starting with 150 µg of chromatin and 5 µg of antibody, 1/40 of the ChIP sample and 
a 1∶100 dilution of input DNA were used for quantitative PCR per reaction. Fold 
enrichment of specific target genes was calculated by IP over Input samples and was 
normalized to IgG negative control. Primers used for ChIP-qPCR are listed in 
supplementary figure S4. 
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ChIP-Sequencing 
ChIP libraries were prepared using the ChIP-Seq sample Prep Kit from Illumina 
(San Diego, CA, USA) and were sequenced using Illumina HiSeq 2000 according to 
the manufacturer's protocol. ChIP-Seq data were processed as described [378, 379]. 
Briefly, reads were mapped against the Mus musculus genome (UCSC, mm9) using 
bowtie software (version 0.9.9.1) with parameters -v 2 -a -m 100, tracking up to 
hundred best alignment positions per read and allowing at most two mismatches. 
Each alignment was weighted by the inverse of the number of hits. All quantifications 
were based on weighted alignments. Chipcor software 
(http://sourceforge.net/projects/chip-seq) was used to estimate the fragment length. 
Alignments from ChIP-Seq experiments were shifted by half of the estimated 
fragment length towards their 3′ end. Clusters of ChIP-Seq read alignments were 
identified employing MACS software (v.1.3.7.1) [380] using IP and input samples with 
following parameters: nomodel, gsize = 2700000000, tsize = 50, pvalue = 1e-5 and 
shiftsize = (chipcor estimate)/2. Resulting peak candidates were further filtered based 
on the enrichment over the input chromatin and only peaks with at least 4-fold 
enrichment were used. 
 
Motif analysis 
For HOMER analysis, motif detection in the vicinity of Tead2-binding sites was 
carried out using the Hypergeometric Optimization of Motif EnRichment tools 
(HOMER; v4.1) [381]. For PhyloGibbs, de novo motif generation was used as 
described previously [382]. 
 
Motif activity response analysis 
Microarray raw data (.CEL files) were uploaded to 
http://ismara.unibas.ch/fcgi/mara for analysis. 
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Statistical analysis 
Statistical analysis and graphs were generated using the GraphPad Prism 
software (GraphPad Software Inc.). Statistical analyses were performed as indicated 
in figure legends. 
 
Accesssion numbers 
Gene expression data of Py2T untreated versus five days TGFβ-treated cells 
and ChIP-Seq data of Tead2 ChIP during TGFβ-induced EMT in Py2T cells are 
deposited at Gene Expression Omnibus (GEO accession number: GSE55711). 
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3.1.6 Supplementary data  
 
Figure S1. Tead activity and Tead2 levels are consistently upregulated in all 3 EMT models. (A) Motif 
Activity Response Analysis (MARA) predicts Tead activity during EMT in NMuMG cells. Shown is the Tead 
consensus binding motif (MCAT) used for the identification of Tead regulated genes and the increase in the 
expression of Teadregulated genes (activity) during TGFβ-induced EMT in NMuMG cells. (B) Changes in 
mRNA expression of Tead1-4 during EMT. Time course experiments of TGFβ-induced EMT were performed 
as described in Fig. 1B and mRNA levels were determined by quantitative RT-PCR. Results are presented 
as mean fold difference ± S.E.M. (n = 3; * = p < 0.05; ** = p < 0.01; *** = p < 0.001; Py2T and NMuMG). 
Expression changes in MT cells were determined once in triplicates. (C, D) α-Tead2 antibodies do not detect 
other family members than Tead2. Murine Tead 1-4 were transiently overexpressed in HEK293 cells (C) and 
siRNA pools against the different family members were transfected in NMuMG cells (D). Cell lysates were 
probed with α-Tead2 by immunoblotting. The asterisk marks a band that is not specific for murine Tead2. (E) 
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Quantification of siRNA efficiency in the experiment described in (D) by quantitative RT-PCR. The 
downregulation of Teads mRNA levels was specific for the targeted family members, with the exception of 
siTead3, which depleted the expression of Tead2 and Tead3. (F) Localization of Yap and Taz in epithelial 
NMuMG cells was visualized by immunofluorescence staining. A higher magnification of the boxed area in 
the left panel is shown in the right panel. Arrows indicate junctional localization of Yap and Taz. Scale bar, 20 
µm. (G, H) Measurement of Tead activity in the indicated EMT systems by luciferase reporter assays. 
NMuMG and Py2T cells were treated with TGFβ for the indicated durations prior to cell lysis and 
luminescence analysis. Reporter constructs were transfected along with a Renilla luciferase construct for 
normalization. Results are shown as mean ± S.E.M. (NMuMG: n = 3; * = p < 0.05; Py2T: n = 5; MT: n = 2; ** 
= p < 0.01). Top: Scheme of the luciferase reporter constructs. Eight repeats of the core MCAT (G) or GTIIC 
(H) Tead DNA binding motif was cloned in front of a basal promoter followed by the Firefly luciferase gene. A 
construct lacking a Tead-binding motif served as control. (I) Tead activity was determined using a luciferase 
reporter construct harboring the promoter of the Cyr61 gene (Cyr61prom WT). The same construct with a 
mutated Tead binding site (Cyr61prom TeadMut) was used as a control. Results are shown as mean ± 
S.E.M. (n = 3; * = p < 0.05). 
 
 
Figure S2. Tead2 transcriptional activity increase during EMT. (A,B) Measurement of Tead activity in the 
three cellular EMT systems by luciferase reporter assays. Top panels: Scheme of the luciferase reporter 
constructs. Eight repeats of the core MCAT (A) or GTIIC (B) Tead DNA binding motifs were cloned in front of 
a basal promoter followed by the Firefly luciferase gene. A construct lacking a Tead-binding motif served as 
control. Bottom panels: NMuMG and Py2T cells were treated with TGFβ for the indicated durations prior to 
luminescence analysis. Reporter constructs were transfected along with a Renilla luciferase construct for 
normalization. Results are shown as mean ± S.E.M. (NMuMG: n = 3; Py2T: n = 5; MT: n = 2; *p < 0.05; **p < 
0.01). (C) Analysis of Tead transcriptional activity after Sox4 depletion. Py2T cells were transfected with 
siRNA pools against Sox4 or a control and treated with TGFβ as indicated. Relative Tead activity was 
determined by using the Tead-responsive MCAT luciferase reporter construct as described in supplementary 
material Fig. S2A. Results are shown as mean ± S.E.M. (n = 3; **p < 0.01, ***p < 0.001). (D) Tead activity 
was determined using a luciferase reporter construct harboring the promoter of the Cyr61 gene (Cyr61prom 
WT). The same construct with a mutated Tead binding site (Cyr61prom TeadMut) was used as control. 
Results are shown as mean ± S.E.M. (n = 3; *p < 0.05). 
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Figure S3. Tead2 upregulation is required for EMT. (A) Effect of Tead2 WT or Tead2 Y440H 
overexpression on Tead activity. Measurement of Tead activity in NMuMG cells stably expressing wildtype 
Tead2 (WT) or a point mutant unable to interact with Yap/Taz (Y440H) using the Teadresponsive GTIIC 
luciferase reporter construct as described in supplementary Figure S2B. Data represent mean ± S.E.M. (n = 
2). (B) Effect of Tead knockdown on cell morphology and the disassembly of adherens and tight junctions. 
NMuMG cells were transfected with siRNA pools targeting each Tead1, 2, and 3. One day after transfection, 
cells were treated or not with TGFβ as indicated. Overall cell morphology (phase contrast) and 
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immunofluorescence staining of adherens junctions (E-cadherin) and tight-junctions (ZO-1) are shown. DAPI 
staining visualizes cell nuclei. Scale bars, 50 µm. (C) Immunoblotting analysis for the expression of the 
mesenchymal markers Fibronectin and N-cadherin and the epithelial marker E-cadherin in the experiment 
described in (B). Immunoblotting for Tead2 was used to assess knockdown efficiency, and immunoblotting 
for actin was used as a loading control. (D) Interference with Tead transcriptional activity in Py2T cells 
undergoing EMT. A HA-tagged, dominant-negative version of Tead2 (Tead2-EnR) was expressed in Py2T 
cells in a doxycycline-inducible fashion (Py2T-iTead2-EnR). The Tead2-EnR construct encompasses the 
Tead2 DNA-binding domain fused to the transcriptional repression domain of Drosophila Engrailed. Py2T-
iTead2-EnR cells were induced to undergo EMT by TGFβ treatment for five days in the presence or absence 
of doxycycline (Dox), and the expression of Tead2-EnR (HA) and of the EMT markers E-cadherin and N-
cadherin were analyzed by immunoblotting. Actin was used as loading control. (E) In the experiment 
described in (D), Tead transcriptional activity was determined by using the MCAT firefly luciferase reporter as 
described in supplemental Figure S1F. Results are presented as mean ± S.E.M. (n = 2). (F) Impact of 
prolonged Tead2 expression on E-cadherin protein levels. Py2T cells were induced to express HA-tagged 
Tead2-WT (iTead2) or firefly luciferase (iLuc) as a control upon doxycycline treatment for indicated periods. 
Tead2 (HA) and Ecadherin expression are shown by immunoblotting analysis. Actin served as loading 
control. (G) Analysis of Tead transcriptional activity in Py2T cells expressing wildtype Tead2 (Tead2-WT) or a 
constitutively active version of Tead2 (Tead2-VP16) using the GTIIC Tead-responsive Firefly luciferase 
reporter construct (supplemental Figure S1G). The results shown represent mean ± S.E.M. (n = 2; *p < 0.05). 
(H) Determination of the amount of Yap/Taz/Tead2 complexes in control (vector) and Tead2-expressing 
Py2T cells (Tead2-WT). Lysates were subjected to immunoprecipitation with a Tead2 antibody or with 
irrelevant IgG as negative control (IP). The presence of Tead2 and of co-immunoprecipitated Yap and Taz 
was analyzed by immunoblotting. The levels of these proteins in total cell lysates were also assessed (Input). 
Gapdh was used as loading control. (I) Immunofluorescence staining of Yap/Taz and Tead2 in Py2T cells 
expressing wildtype Tead2 (Tead2-WT), constitutively active Tead2 (Tead2-VP16) or transduced with an 
empty vector control in the absence of TGFβ. Scale bar, 25 µm. (J) Analysis of mRNA expression levels of 
vimentin and EMT transcription factors in Py2T cells stably expressing wildtype Tead2 (Tead2-WT), 
constitutively active Tead2 (Tead2-VP16) or the Hippo-insensitive mutants of Yap (Yap S127A) and Taz (Taz 
S89A). The results shown represent mean ± S.E.M. (n = 3; *p < 0.05, **p < 0.01, ***p < 0.001). 
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Figure S4. Identification and validation of direct Tead2 target genes. (A) Genome browser view of 
Tead2 ChIP-Seq data showing the binding of Tead2 at promoter regions of the known Tead target genes 
Ctgf and Cyr61. Py2T cells were treated with TGFβ for five days, chromatin was prepared and subjected to 
chromatin immunoprecipitation (ChIP) using a Tead2 antibody. Precipitated chromatin was then subjected to 
next generation sequencing. Data of two independent biological replicates are shown on separate wiggle-
tracks. (B) Expression of Tead2 target genes in the MTflEcad/MTΔEcad model of EMT as determined by 
quantitative RT-PCR. (C) Binding of Yap and/or Taz to direct Tead2 target genes. Py2T cells were treated 
with TGFβ for five days, chromatin was isolated and subjected to ChIP using a Tead2, Yap, Taz or IgG 
antibody as negative control. ChIP-qPCR analysis was performed as shown in Figure 4E. Data are 
presented as mean ± S.E.M. (n = 2, *p < 0.05; **p < 0.01). (D) Genome browser view of the Tead2 ChIP-Seq 
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data showing the binding of Tead2 at an intronic region in the zyxin gene (Zyx). (E) Immunoblotting analysis 
of zyxin expression levels in the MTflEcad/MT Ecad model. Actin served as a loading control. (F) 
Immunoblotting analysis of zyxin and Tead2 expression levels in Py2T cells transduced with an empty vector 
(Vector) or overexpressing wildtype Tead2 (Tead2-WT), and Py2T cells treated with TGFβ for at least 20 
days (> 20d TGFβ). (G) Efficiency of siRNA-mediated ablation of zyxin expression. Quantification of zyxin 
mRNA levels by quantitative RT-PCR in control Py2T cells (Vector) or cells expressing wildtype Tead2 
(Tead2-WT; left) and in Py2T cells treated with TGFβ for at least 20 days (> 20d TGFβ; right) and treated 
with siRNA against zyxin (siZyxin) or control siRNA (siCtr). Measurements were performed in parallel to the 
transwell migration/invasion assays shown in Figure 5K. (n = 3 mean ± S.E.M.; **p < 0.01, ***p < 0.001) (H) 
Cell morphology of Py2T cells stably overexpressing Tead2-WT after siRNAmediated depletion of zyxin. 
Phase-contrast images of Py2T cells overexpressing Tead2-WT two days after transfection of siRNA pools 
against zyxin or a control siRNA. Scale bar, 100 µm. 
 
Table S1 is available upon request 
 
Table S2. Genes that are directly regulated by Tead2 during EMT 
Listed are genes, which are directly bound by Tead2 and change their expression after five days of TGFβ-
induced EMT in Py2T cells. Genes are represented by their gene names, their log2 fold changes (log2FC) 
and by statistical significance (p-value). 
 
Gene log2 FC pValue 
Il11 5.56 9.21E-04 
Serpine1 3.35 1.51E-03 
Olfm2 3.04 5.49E-03 
Pdgfc 2.98 1.43E-03 
Pgf 2.84 1.58E-03 
Itga5 2.80 1.06E-03 
Marcksl1 2.54 5.21E-03 
Clu 2.53 2.12E-03 
Adamts4 2.07 1.47E-03 
9930111J21Rik2 2.01 6.11E-03 
Hbegf 1.89 2.94E-03 
Kctd11 1.87 1.13E-02 
Cyr61 1.82 1.71E-03 
Rhob 1.76 1.34E-02 
Sfn 1.73 3.53E-03 
Sfn 1.72 6.36E-03 
Ccrn4l 1.61 2.52E-03 
Mir181b-2 1.50 2.99E-02 
Nppb 1.47 1.90E-02 
Ctgf 1.36 2.49E-03 
Itpripl2 1.33 2.52E-03 
Tnfaip6 1.33 3.53E-03 
Rnf122 1.33 3.09E-02 
Cd97 1.32 1.21E-02 
Ctla2b 1.31 1.89E-02 
Tmprss11f 1.30 1.07E-02 
Myo7a 1.22 8.21E-03 
Smad7 1.21 4.44E-03 
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Limk1 1.21 7.45E-03 
Itpripl2 1.20 6.44E-03 
Atg4c 1.19 7.18E-03 
Creb3l2 1.12 2.01E-02 
Cttnbp2nl 1.08 4.88E-03 
Tmcc3 1.08 3.54E-02 
Zyx 1.04 2.84E-02 
Plaur 1.04 6.24E-03 
Ier3 1.03 6.21E-03 
Mfhas1 1.03 4.02E-03 
Cnn3 1.01 6.17E-03 
Podnl1 1.01 9.48E-03 
Klk9 0.99 2.75E-02 
Atp11a 0.99 5.39E-03 
Amotl2 0.96 1.21E-02 
Schip1 0.94 6.33E-03 
Fbln2 0.94 9.52E-03 
Sdcbp2 0.92 1.94E-02 
Klf6 0.91 8.44E-03 
Zfp451 0.90 2.90E-02 
Soga1 0.89 1.35E-02 
Egr3 0.89 1.41E-02 
Gne 0.87 3.17E-02 
Acvr1 0.86 8.82E-03 
Adcy7 0.86 2.19E-02 
Cnn3 0.83 5.74E-03 
Lrrc8c 0.82 1.19E-02 
Trim13 0.81 2.25E-02 
Mir22hg 0.80 3.80E-02 
B230120H23Rik 0.80 1.73E-02 
Zfp658 0.79 9.73E-03 
Ugdh 0.78 1.43E-02 
Loxl3 0.76 1.36E-02 
E030011O05Rik 0.75 1.69E-02 
Synpo 0.75 1.89E-02 
Ercc1 0.75 6.86E-03 
Ncor2 0.74 4.56E-02 
Csrp1 0.73 2.74E-02 
Atp6v1g1 0.72 4.26E-02 
H2-Ab1 0.72 1.30E-02 
Tmem150a 0.71 3.27E-02 
Ankrd1 0.71 9.96E-03 
Sept9 0.69 1.50E-02 
Zfp568 0.68 4.68E-02 
Mapk6 0.66 1.37E-02 
Atp6v1g1 0.66 3.74E-02 
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Fxr2 0.66 1.48E-02 
Lamb1 0.63 2.60E-02 
Mat2a 0.62 3.97E-02 
Cdc42ep1 0.61 2.42E-02 
Fpgt 0.60 1.45E-02 
Zkscan5 0.59 3.11E-02 
Dok1 0.58 2.64E-02 
Pcif1 -0.59 1.81E-02 
Ect2 -0.62 1.69E-02 
Tnfrsf1b -0.63 1.19E-02 
Zfp672 -0.67 2.64E-02 
Tnni2 -0.68 3.15E-02 
Ift80 -0.68 1.07E-02 
Cep68 -0.69 1.05E-02 
Tmem106b -0.70 1.90E-02 
Zcwpw1 -0.70 1.77E-02 
Ahnak -0.70 9.37E-03 
Unc13d -0.77 3.39E-02 
A430105I19Rik -0.78 7.18E-03 
Tspan4 -0.78 9.58E-03 
Ly6f -0.80 1.91E-02 
Rere -0.83 9.26E-03 
Arrdc1 -0.83 9.26E-03 
Sh3rf2 -0.88 1.91E-02 
Myo6 -0.91 1.83E-02 
Nbeal2 -0.93 4.17E-03 
Hist2h3c2 -0.99 4.65E-02 
Pkhd1l1 -1.00 1.56E-02 
Tnfrsf26 -1.02 1.82E-02 
Rnf13 -1.04 1.33E-02 
Malat1 -1.05 2.49E-02 
Yipf2 -1.11 4.02E-02 
March9 -1.14 4.55E-02 
Tmtc2 -1.15 4.09E-03 
Entpd3 -1.16 4.66E-02 
Jag2 -1.16 4.07E-03 
Tinagl1 -1.18 4.29E-03 
Airn -1.20 6.26E-03 
Prss22 -1.20 7.39E-03 
Pard6b -1.21 1.45E-02 
Syt8 -1.27 4.40E-03 
Capn5 -1.27 1.59E-02 
H1f0 -1.31 4.77E-03 
Emp2 -1.35 4.61E-02 
Clip4 -1.36 4.28E-03 
Tlr5 -1.40 3.10E-03 
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Table S3. Primer sequences used for RT-pPCR 
Name Sequence (5’- 
3’) 
Tead1 ccaggatcctcacaagacg 
gaatgggggctgtgactg 
Tead2 ctgaggacagggaagacgag 
cttcgagccaaaacctgaat 
Tead3 gagctgattgcccgctac 
tgtatgtggctggacacctg 
Tead4 tcaaaacacctaccctgtcca 
gccctgcaggagactcaa 
Zyxin aagagaagcagcacccaca 
ctctacctccttcagggtcaag 
E-cadherin cgaccctgcctctgaatcc 
tacacgctgggaaacatgagc 
Cyr61 ctggcatctccacacgagttac 
tgcccttttttaggctgctg 
Rpl19 ctcgttgccggaaaaaca 
tcatccaggtcaccttctca 
Vimentin ccaaccttttcttccctgaa 
ttgagtgggtgtcaaccaga 
Zeb1 gccagcagtcatgatgaaaa 
tatcacaatacgggcaggtg 
Zeb2 ggaggaaaaacgtggtgaactat 
gcaatgtgaagcttgtcctctt 
Twist gccggagacctagatgtcattg 
cacgccctgattcttgtgaa 
Dcaf4 -1.45 5.04E-03 
Atp6v0a1 -1.45 1.33E-02 
Esrp2 -1.54 6.11E-03 
Ckb -1.68 5.39E-03 
Uap1l1 -1.73 3.75E-02 
Atp1b1 -1.82 1.43E-03 
Blnk -1.84 2.04E-03 
Rbm47 -2.00 2.87E-02 
Mal -2.07 3.83E-03 
Gpr97 -2.08 1.34E-02 
Elmo3 -2.12 4.99E-03 
Tenc1 -2.18 1.43E-03 
Afap1l2 -2.39 2.30E-03 
Klk10 -3.24 3.83E-03 
Cldn9 -3.89 9.11E-04 
Cp -4.01 3.45E-02 
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Snail ctctgaagatgcacatccgaa 
ggcttctcaccagtgtgggt 
Slug tgtgtctgcaagatctgtggc 
tccccagtgtgagttctaatgtg 
Ctgf ctctcgtcgcctctgcac 
cagtcctggcccatagca 
Pard6b tgggctacgcagatatcca 
ggcactgtagtcagcttcttcc 
Elmo3 ctcagcactgccccagat 
gcacccttcacgacttgtatt 
Pdgfc tgtgtcccacgtaaagttacaaa 
tcagtgagtgacttatgcaatcc 
 
 
Table S4. Primer sequences used for ChIP-qPCR 
Name Sequence (5’- 3’) 
Intergenic region gctccgggtcctattcttgt 
tcttggtttccaggagatgc 
Ctgf caatccggtgtgagttgatg 
ggcgctggcttttatacg 
Cyr61 ctctgatggatctgagaagagg 
gccctttataatgcctgccta 
Pard6b ccacctactttccagcagaga 
gctattttgaggcattactcagc 
Elmo3 tgcctctgagaatagctgga 
ggagatccagaactgaaagagaa 
Pdgfc tgctctgtggattgcttcac 
ctccaagaagaagcctgtcc 
Zyxin ccctgtcctgagcagatgtt 
agaacgagccaggttgaaga 
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3.2 Identification and characterization of miR-1199-5p in EMT and 
mesenchymal migration 
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3.2.1 Abstract 
Epithelial to mesenchymal transition (EMT) is an essential developmental 
process, which in part is reactivated by epithelial tumor cells and enables them to 
convert into metastatic cancer cells. Upon diverse extracellular stimuli, EMT is 
initiated and driven by transcriptional and post-transcriptional alterations. 
Here we focused on post-transcriptional regulation of EMT by microRNAs 
(miRNAs) and their interaction with transcription factors mediating this dynamic 
process. We used normal murine mammary gland (NMuMG) cells to induce gradual 
EMT by exposing the cells to the cytokine transforming growth factor beta (TGFβ). 
Analyzing different cell dedifferentiation stages by deep sequencing allowed us to 
obtain detailed insights into global transcriptional changes during this transition in a 
time-resolved manner. We focused on highly differentially expressed miRNAs and, 
subsequently, tested their functionality during EMT and mesenchymal tumor cell 
migration. We identified miR-1199-5p as novel EMT-regulatory miRNA whose 
transcript levels and promoter activity were continuously downregulated during 
TGFβ-induced EMT. Ectopic expression of miR-1199-5p prevented TGFβ-induced 
dedifferentiation of mouse and human untransformed mammary gland cells and 
decreased the migratory and invasive behavior of mesenchymal breast cancer cells. 
We further report a negative reciprocal regulation of miR-1199-5p and the key EMT 
transcription factor Zeb1 during EMT. 
These results suggest that miR-1199-5p-Zeb1 interaction play a critical role 
during EMT and might control cell migration and invasion during breast cancer 
progression. 
 
3.2.2 Introduction 
Epithelial to mesenchymal transition (EMT) as well as its reversal process 
mesenchymal to epithelial transition (MET) reflect two gradual, well-controlled 
processes during embryogenesis and wound healing in adults to promote tissue and 
organ formation [2, 21]. The process is defined by a collapse of cell-cell adhesion 
and tight junctions, loss of apical-basal cell polarity, a rearrangement of the actin 
cytoskeleton and a gain of mesenchymal characteristics. These structural changes 
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further lead to increased cell motility, survival and decreased proliferation [13, 19, 
138]. Therefore, this process allows cells to switch forth and back between two 
different cell types and behaviors to endow the necessity of tissue plasticity. 
In the context of malignant tumor progression, epithelial tumor cells can revive 
an EMT upon diverse extracellular stimuli and consequently gaining metastatic 
properties [383]. This allows tumor cells to disseminate from the primary tumor, 
intravasate and survive in the blood circulation. At a distant organ, cells extravasate 
into the parenchyma and eventually grow out as lethal metastasis possibly promoted 
by a MET [26, 39, 384-386]. The cytokine TGFβ is an inducer and driver of EMT in 
transformed epithelial tumor cells. At the primary tumor site it stimulates tumor 
growth, cell invasion and metastasis [70]. High levels of TGFβ1 are often associated 
with malignant breast tumor progression [73, 387]. Epithelial tumor cells, once 
exposed to TGFβ, activate the dedifferentiation process, which involves global 
changes in the transcriptional and post-transcriptional network [98] [150, 153, 268]. 
The control and regulation of this highly dynamic process involves epigenetic 
and mRNA splicing alterations, transcription factor (TF) (in)activation as well as 
changes in the expression of non-coding RNAs, in particular microRNAs (miRNAs) 
[74]. MiRNAs represent a class of ~ 22 nucleotide-long RNAs which can regulate 
EMT-MET cell plasticity on the post-transcriptional level by either promoting mRNA 
target degradation or preventing mRNA translation [246]. Up to date, several studies 
have identified differentially regulated miRNAs during cell dedifferentiation. The miR-
200 family, which consists of five members (miR-200a/b/c, miR-141 and miR-429), 
was one of the first miRNA families discovered to play a critical role during EMT. 
Several research groups have demonstrated that miR-200 family members are 
required to maintain an epithelial cell morphology for instance by controlling the 
transcripts of the key EMT TFs Zeb1 and Zeb2. MiR-200 family members bind to 
specific seed sequences in the Zebs mRNA 3` untranslated region (3`UTR) via 
classical Watson-Crick base-pairing and thus destabilize Zeb1 and Zeb2 mRNA 
levels, consequently, strengthening epithelial cell-cell E-cadherin adhesion junctions. 
Upon activation of an EMT program, miR-200 family members are downregulated, 
which drives the expression of Zeb1 and Zeb2. In turn, both TFs are reported to 
directly suppress transcription of the miR-200 family by binding to E-box elements in 
their promoter region. In sum, these results describe a negative reciprocal regulation 
of a TF and a miRNA family, which tightly controls tumor-related EMT and breast 
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cancer progression [254, 265, 268, 269, 388]. These and other studies 
demonstrating the regulation of EMT/MET plasticity and tumor metastasis by 
miRNAs highlight the potential of this class of short, non-coding RNAs and illustrate 
once more their prognostic and therapeutic value for cancer treatment [389]. 
The regulation of EMT and MET seems to be highly context-dependent and 
various transcriptional and post-transcriptional changes may vary in the initiation and 
regulation of these processes. Therefore, analyzing the main checkpoints controlling 
EMT in physiological versus pathological context may deepen our understanding of 
cancer-associated pathways. Here we focused on the post-transcriptional regulation 
of EMT by miRNAs and their interaction with TFs mediating the initial steps of the 
metastatic cascade. As a model, we utilized normal murine mammary gland 
(NMuMG) cells and induced a gradual transition by treating the cells with TGFβ for 
different time points. Deep sequencing analysis of various dedifferentiation stages 
provided a detailed insight into the transcriptional changes during the initiation of 
EMT in a time-resolved manner. We focused on highly differentially expressed 
miRNAs during this dynamic process and, subsequently, tested their functionality in 
normal and breast cancer cells during EMT and mesenchymal tumor cell migration. 
We identified miR-1199-5p, which exhibited decreased expression and promoter 
activity during TGFβ-induced EMT. Forced expression of miR-1199-5p in mouse and 
human untransformed mammary gland cells blocked EMT and migration and 
invasion of mesenchymal breast tumor cells. We further report that miR-1199-5p 
controlled post-transcriptionally the mRNA levels of the key EMT TF Zeb1. Zeb1, in 
turn, regulated the promoter activity and transcript levels of miR-1199-5p during EMT. 
Our work demonstrates a new critical double-negative feedback loop between Zeb1 
and a miRNA during EMT, which might control EMT-derived metastasis in breast 
cancer. 
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3.2.3 Results 
3.2.3.1 Identification of new regulatory miRNAs in EMT and mesenchymal 
tumor cell migration 
In the context of malignant tumor progression epithelial tumor cells can gain 
metastatic properties via an EMT to allow dissemination from the primary tumor and 
extravasation at a distant organ followed by the outgrowth as a metastasis [26]. To 
identify new regulatory miRNAs involved in the gradual process of EMT, we 
performed RNA-sequencing on normal murine mammary gland cells (NMuMG 
subclone E9; NMuMG/E9) induced to undergo a gradual EMT upon treatment with 
the cytokine TGFβ. We cultured NMuMG/E9 cells in the presence of TGFβ and 
isolated total RNA at the following time points: 2, 6, 12, 24, 36, 48, 60, 72 and 96 
hours. We then analyzed the differential expression of miRNAs in TGFβ-treated 
versus epithelial, untreated cells (Figure 1A). This cellular model enabled us to obtain 
a detailed insight into the kinetic of transcriptional changes during normal epithelial 
cell transition in a time-resolved manner. We found 32 differentially regulated 
miRNAs, which displayed an at least 4-fold up- or downregulation (in at least one of 
the time points with p < 0.05) in their expression compared to untreated cells within 
four days of TGFβ treatment. Unsupervised hierarchical clustering illustrated that 
roughly half of these differentially expressed miRNAs showed a continuous increase 
in their expression, whereas the other half a continuous decrease in their expression 
(Figure 1A, D). 
To extract those differentially expressed miRNAs, which have a functional impact 
on TGFβ-induced EMT we came up with a combination of functional screens. First, 
we included these 32 differentially regulated miRNAs in an EMT phenotypic 
microscopy-based screen (Figure 1B). Here, mesenchymal cell characteristics like 
secretion of the extracellular matrix protein Fibronectin, formation of focal adhesions 
and actin stress fibers were monitored by fluorescence microscopy and quantified. 
Using miRNA mimics to overexpress individual miRNAs in NMuMG/E9 cells cultured 
in the absence or presence of TGFβ (four days) allowed us to test their contribution 
to EMT. With this screen we identified ten miRNAs which were able to block/delay 
EMT when overexpressed in cells treated with TGFβ: miR-125b-5p, miR-6944-3p, 
miR-181b-2-3p, miR-1247-3p, miR-200a-3p, miR-200b-3p, miR-429-3p, miR-1199-
5p, miR-145a-3p and miR-504-3p. One miRNA induced EMT in epithelial NMuMG/E9 
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cells: miR-145a-5p (Figure 1D). Additional analysis of cell morphology and 
localization of the epithelial adhesion junction protein E-cadherin further confirmed 
the impact of different miRNAs on EMT (supplementary Figure 1A, B). 
 
 
Figure 1: Identification of regulatory miRNAs during TGTβ-induced EMT and mesenchymal migration. 
(A) Expression profiling of miRNAs during TGFβ-induced EMT in NMuMG/E9 cells. NMuMG/E9 cells were 
treated with TGFβ for the indicated time points and total RNA was isolated for RNA-sequencing. The heat 
map summarizes the hierarchical clustering of differentially expressed miRNAs (fold change log2 > 2, p < 
0.05 compared to epithelial, untreated cells) during EMT according to the indicated color scale. Red 
represents increased expression; blue represents reduced expression. (B) Identification of miRNAs 
controlling EMT. NMuMG/E9 cells were transfected with miRNA mimics for individual miRNAs and analyzed 
for mesenchymal characteristics in the absence and presence of TGFβ (4 days). Formation of focal 
adhesions (green), actin cytoskeleton reorganization to actin stress fibers (red), Fibronectin secretion 
(yellow) and nuclei (brown) were visualized by high-content fluorescence screening microscopy and the 
different EMT read outs were quantified. (C) Identification miRNAs regulating mesenchymal migration. 
Mesenchymal, migratory Py2T cells (>20 days TGFβ) were transfected with different miRNA mimics and, 2 
days later, replated in a Boyden chamber migration insert within a FCS gradient and in parallel on an input 
plate (96-well plate formats). After 18 hours, cell nuclei were visualized with DAPI and the bottom of the 
migration inserts and the input plate were imaged using a fluorescence screening microscope. Nuclei were 
quantified and the number of migrated cells was normalized to the total cell number. (D) Overview of the 
functional miRNA screening process. Depicted are the different screening methods (A-C) along with the 
number of miRNAs showing differential expression during EMT and the number of miRNAs controlling EMT 
and mesenchymal migration. 
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Mesenchymal cell migration is one functional output of EMT, which allows tumor 
cell dissemination and invasion [20]. In a second screen, we focused on those 
miRNAs, which had an impact on EMT and tested whether their overexpression in 
mesenchymal migratory tumor cells, such as Py2T cells treated for > 20 days with 
TGFβ (long-term TGFβ treated; LT), would influence their trans-well migration 
behavior (Figure 1C). We transfected Py2T LT cells with different miRNA mimics, two 
days later, cells were replated within a FCS gradient in a 96-well plate Boyden 
chamber migration insert (migration plate) and in parallel in a 96-well input plate as a 
reference for total cell number. 18 hours later, migrated as well as total cell numbers 
were quantified and normalized to each other. Trans-well migration behavior of Py2T 
LT cells was significantly reduced (< 1.5-fold) by the expression of four out of eleven 
miRNAs: miR-200b-3p, miR-429-3p, miR-1199-5p and miR-125b-5p (< 1.35-fold) 
(Figure 1D; supplementary Figure 2 A, B). 
Our screen identified miR-1199-5p as entirely novel regulatory miRNA, which 
seemed to be involved in TGFβ-induced EMT and mesenchymal tumor cell migration 
(Figure 1A-D). Several groups have extensively studied the function of the two miR-
200 family members miR-200b-3p and miR-429-3p in EMT [254, 268]. The role of 
miR-125b-5p has also been investigated during tumor cell migration and invasion 
[390, 391]. Therefore, we decided to focus on the mechanistic function of miR-1199-
5p during EMT. 
 
3.2.3.2 Ectopic expression of miRNA-1199-5p inhibits TGFβ-induced EMT 
In the course of a TGFβ-induced EMT, miR-1199-5p transcripts were found to be 
continuously downregulated in NMuMG/E9 cells. This observation was additionally 
confirmed by a luciferase promoter reporter assay, showing a significant decrease in 
miR-1199 promoter activity during EMT (Figure 2A, Supplementary Figure 3A). 
Overexpression of miR-1199-5p in NMuMG/E9 cells verified a more epithelial 
morphology of cells cultured for four days in the presence of TGFβ compared with 
cells transfected with a miR-Ctr mimic (Figure 2B). These cells maintained their cell-
cell adhesion junction protein E-cadherin and tight junction protein ZO-1 at the 
plasma membrane while miR-Ctr transfected cells lose these epithelial 
characteristics (Figure 2C top, Figure 2D, E). The reorganization of filamentous actin 
from cortical to stress fibers as well as formation of focal adhesions are features of 
mesenchymal cells. In miR-1199-5p-overexpressing cells, these rearrangements 
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were mostly prevented, here analyzed with Phalloidin to stain filamentous actin and 
Paxillin, a focal adhesion complex protein (Figure 2C bottom). Additional structural 
mesenchymal markers like extracellular matrix protein Fibronectin and intermediate 
filament Vimentin are repressed on the mRNA (Figure 2E) and protein (Figure 2D) 
levels in miR-1199-5p mimic-transfected cells. We further examined the effect of 
miR-1199-5p on some key EMT TFs, drivers of the transcriptional changes occurring 
during EMT. We found that miR-1199-5p induced a decrease in Zeb1 mRNA levels, 
but did not affect the levels of the zinc-finger TF family member Zeb2 [392] or Sox4 
[98] (Figure 2E). 
A similar phenotype was observed in another cellular TGFβ-inducible EMT 
system, human untransformed MCF10A mammary epithelial cells. MCF10A cells 
also maintained their epithelial cell morphology and showed a strong sustained E-
cadherin expression at the plasma membrane in cells forced to express miR-1199-5p 
in the presence of TGFβ. The mesenchymal markers Fibronectin, N-cadherin and 
Zeb1 were repressed (supplementary Figure 3B-E). In order to test whether miR-
1199-5p affects EMT in transformed tumor cells, we ectopically expressed miR-1199-
5p in Py2T cells and cultured them for three days in the presence of TGFβ. As shown 
in supplementary Figure 3F-I, overexpression of miR-1199-5p stabilized E-cadherin 
expression on the mRNA and protein level. However, it had only minor effects on 
overall cell morphology and mesenchymal marker expression, such as Fibronectin 
and Vimentin. 
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Figure 2: Overexpression of miRNA-1199-5p inhibits TGFβ-induced EMT. (A) miR-1199-5p transcripts 
as well as miR-1199 promoter activity are reduced during TGFβ-induced EMT. Green: Expression profile of 
miR-1199-5p during EMT in NMuMG/E9 cells measured by RNA-sequencing (Figure 1A). Grey: miR-1199 
promoter activity during EMT. NMuMG/E9 cells were transfected with a miR-1199 Firefly luciferase promoter 
reporter (pGL4 miR-1199 promoter) or a control reporter (pGL4), which lacks a promoter cassette 
(supplementary Figure 3A). Additionally, cells were co-transfected with a Renilla luciferase reporter and 
treated with TGFβ for the indicated time points. Relative luminescence (Firefly/Renilla) was calculated and 
normalized to the vector control (pGL4). Results are presented as mean fold change +/- S.E.M. of two 
independent experiments. (B) Bright field images of NMuMG/E9 cells transfected with either a control miRNA 
mimic (miR-Ctr) or a miRNA mimic for miR-1199-5p. The cells were cultured in the absence (untreated) or 
presence of TGFβ for 4 days. Scale bar: 100 µm. (C) Immunofluorescence images of NMuMG/E9 cells 
transfected with miR-Ctr or miR-1199-5p mimic after 4 days of TGFβ treatment. Immunofluorescence 
analysis was performed to visualize differences in E-cadherin (green), ZO-1 (red) localization (top) and actin 
cytoskeleton reorganization (Phalloidin in red) and focal adhesion formation (Paxillin in green; bottom). DAPI 
was used to label nuclei (blue). Scale bar: 100 µm. (D) Immunoblot analysis for the expression of indicated 
EMT markers in NMuMG/E9 cells transfected with miR-Ctr or miR-1199-5p mimic and cultured in the 
absence (untreated) and presence (4 days) of TGFβ. GAPDH served as loading control. (E) mRNA 
expression levels of indicated EMT markers. NMuMG/E9 cells were transfected with miR-Ctr or miR-1199-5p 
mimic and cultured for 4 days in the presence of TGFβ. qRT-PCR was used to measure the expression of 
different mRNAs. Results are presented as mean fold change +/- S.E.M of six independent experiments. 
 
In summary, miR-1199-5p transcript levels and its promoter activity are reduced 
during TGFβ-induced EMT in NMuMG/E9 cells. Forced expression of miR-1199-5p 
preserved an epithelial cell morphology of NMuMG/E9 and MCF10A cells exposed to 
TGFβ. In tumor-derived Py2T cells ectopic expression of miR-1199-5p rather induced 
a delay than a complete block in EMT upon dedifferentiation. 
 
3.2.3.3 Expression of miR-1199-5p reduces mesenchymal tumor cell 
migration and invasion 
A gain in cell migration and invasion is one of the consequences of TGFβ-
induced EMT and allows tumor cells to leave the primary tumor and intravasate the 
blood circulation or extravasate at a distant organ [138]. 
We tested the influence of miR-1199-5p on mesenchymal tumor cell migration by 
using a trans-well Boyden chamber assay (Figure 1C). Only a few epithelial, TGFβ-
untreated Py2T cells transfected with miR-Ctr mimic were able to trans-migrate 
towards a higher FCS concentration. Their mesenchymal, TGFβ-treated counterparts 
on the other hand showed an around 4-fold increase in tumor cell migration. These 
migratory properties were in turn significantly reduced by an overexpression of miR-
1199-5p (Figure 3A, B). This inhibitory effect of miR-1199-5p on cell migration was 
also observed in 4T1 cells treated with TGFβ (LT) (Figure 3C), another migratory and 
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invasive breast cancer cell line with a high metastatic potential in vivo [393]. 
Moreover, forced expression of miR-1199-5p in Py2T LT and 4T1 LT cells also 
significantly decreased trans-well invasion of these cells (Figure 3D, E). 
 
 
Figure 3: Expression of miR-1199-5p reduces mesenchymal tumor cell migration and invasion. (A) 
Representative immunofluorescence images of migrated epithelial (untreated) and mesenchymal (long term 
(LT) TGFβ-treated (> 20 days)) Py2T cells. Cells were transfected with miR-Ctr or miR-1199-5p mimic and, 
after two days, replated within a FCS gradient in a 96-well Boyden chamber trans-well migration insert and a 
96-well reference plate. After 18 hours, cell nuclei were stained with DAPI and cells on the bottom of the 
inserts as well as the cells in the reference well were imaged and quantified. (B) Quantification of migrated 
Py2T cells from the experiment described in A. The graph represents the number of migrated cells per insert 
(fold change) normalized to the total cell number. Data are shown as mean +/- S.E.M. of three independent 
experiments. (C) Mesenchymal 4T1 cells were transfected with miR-Ctr or miR-1199-5p mimic and replated 
within a FCS gradient in a Boyden chamber trans-well migration insert (24-well plate format). After 18 hours, 
migrated cells were quantified. Graph represents the number of migrated cells per insert (fold change) and 
data are shown as mean +/- S.E.M. of three independent experiments. (D, E) Boyden chamber trans-well 
invasion assays with mesenchymal Py2T (D) and 4T1 (E) cells. Experiments were performed as described in 
C. Data represent the mean +/- S.E.M. of three (D) and four (E) independent experiments. 
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3.2.3.4 miR-1199-5p post-transcriptionally controls the expression of the 
key EMT transcription factor Zeb1 
To understand how miR-1199-5p is able to maintain an epithelial cell morphology, 
we utilized the online database miRWalk [394] to identify miR-1199-5p mRNA targets 
that might play a role during EMT. MiRWalk, which itself also predicts mRNA targets 
with its own algorithm, combines several established miRNA:mRNA databases in 
order to reduce unwanted false positive mRNA target predictions. Zeb1 turned out to 
be the top predicted target of mmu-miR-1199-5p in five of eight different databases 
(TargetScan, miRanda, miRDB, PITA and miRWalk). One potential miR-1199-5p 
binding site within the mouse Zeb1 3`UTR at position 239-246 was predicted by this 
in situ analysis. Additional sequence alignments of Zeb1’s 3`UTR region displayed a 
well-conserved 8-mer seed sequence in different species (Figure 4A). 
In our EMT systems, Zeb1 mRNA expression was increased in NMuMG/E9, 
Py2T and MCF10A cells within a TGFβ time course experiment (Supplementary 
Figure 4A). Furthermore, siRNA-mediated knockdown of Zeb1 conserved an 
epithelial cell morphology of MCF10A cells treated with TGFβ for five days 
(supplementary Figure 4B) and significantly reduced the migratory behavior of Py2T 
LT and 4T1 LT cells (supplementary Figure 4C). 
In order to examine whether miR-1199-5p indeed regulates Zeb1 levels during 
EMT, we overexpressed miR-1199-5p in NMuMG/E9 and Py2T cells and analyzed 
Zeb1 abundance in the absence and presence of TGFβ by immunofluorescence 
analysis. Ectopic expression of miR-1199-5p in NMuMG/E9 and Py2T cells treated 
with TGFβ for four or three days, respectively, resulted in the stabilization of cell 
junction protein E-cadherin, while nuclear levels of Zeb1 were reduced (Figure 4B, 
supplementary Figure 4D). This result was further confirmed by immunoblotting 
analysis for Zeb1 in NMuMG/E9, Py2T and MCF10A cells transfected with either 
miR-1199-5p mimic. Here, Zeb1 proteins levels were diminished upon forced 
expression of miR-1199-5p in all three cellular EMT model systems treated with 
TGFβ (Figure 4C, supplementary Figure 4E, F). 
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Figure 4: miR-1199-5p post-transcriptionally controls the cellular levels of the transcription factor 
Zeb1. (A) Top: Schematic presentation of the predicted mouse miR-1199-5p target site (red: position 239-
249 bps) and its conservation through different species within the 3`UTR of Zeb1 mRNA. Middle: Sequence 
alignment of mouse miR-1199-5p-Zeb1 seed sequence. Bottom: Mutated seed sequence (red) within mouse 
Zeb1 3`UTR. Exchanged nucleotides are underlined. (B) miR-1199-5p reduces Zeb1 protein levels. 
Immunofluorescence images of NMuMG/E9 cells transfected with miR-Ctr or miR-1199-5p mimic. Cells were 
cultured in the absence (untreated) or presence of TGFβ (4 days) and the localization of epithelial marker E-
cadherin (green) and levels of Zeb1 (red) were analyzed. Nuclei were stained with DAPI (blue). Scale bar: 
100 µm. (C) Immunoblot analysis of Zeb1 protein levels in NMuMG/E9 cells. Experiment was performed as 
described in B. GAPDH was used as loading control. Levels of Zeb1 in indicated samples were quantified 
and normalized to GAPDH. (D) Post-transcriptional regulation of Zeb1 by miR-1199-5p. NMuMG/E9 cells 
were transfected with the indicated miRNA mimics, with either a wild type (wt) or a mutated (mut) Zeb1 
3`UTR Firefly luciferase reporter construct (A) and further a Renilla luciferase reporter. After three days, 
relative luminescence intensities (Firefly/Renilla) were calculated and normalized to miR-Ctr transfected cells. 
Data are represented as mean +/- S.E.M. of three independent experiments. 
 
 
To proof a direct regulation of Zeb1 by miR-1199-5p on the post-transcriptional 
level, we generated two Zeb1 3`UTR luciferase reporters. One exhibited the wild type 
miR-1199-5p seed sequence (Zeb1 3`UTR wt) and the other one possessed a 
mutated seed sequence where five nucleotides have been exchanged (Zeb1 3`UTR 
mut; Figure 4A bottom). NMuMG/E9 cells overexpressing either miR-1199-5p or a 
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miRNA negative-control were transfected with the Zeb1 3`UTR luciferase reporters 
mentioned before. Expression of miR-1199-5p mimic in epithelial NMuMG/E9 cells 
transfected with Zeb1 3`UTR wt reporter led to a significant reduction in relative 
luminescence compared to miR-Ctr transfected cells. This reduction in luminescence 
was not observed in cells transduced with 3`UTR Zeb1 mut reporter (Figure 4D). 
In summary, we identified Zeb1 as a direct target of miR-1199-5p, which binds a 
conserved seed sequence in the Zeb1 3`UTR and, therefore, negatively regulates its 
expression on the post-transcriptional level during EMT. 
 
3.2.3.5 Zeb1 controls the expression of miR-1199-5p on the transcriptional 
level 
Zeb1 has been shown to be directly regulated by different miRNAs [254, 286, 
395, 396], and the interplay between Zeb1 and miR-200 family members is probably 
the best characterized during EMT. Several groups have shown that Zeb1 and miR-
200 family members control their transcripts in a double negative feedback loop [272]. 
To check whether Zeb1 also regulates expression of miR-1199-5p during EMT, 
we examined the mouse miR-1199 promoter region on chromosome eight. We found 
several E-box binding motifs (CANNTG; N = G or C) as potential binding sites for 
Zeb1 (Figure 5A). This encouraged us to test our hypothesis and utilized a miR-1199 
luciferase promoter reporter (supplementary Figure 3A). We performed a siRNA-
mediated knock down of Zeb1 in NMuMG/E9 cells cultured in the presence of TGFβ 
for four days and transfected the cells with either a miR-1199 promoter reporter 
(pGL4 miR-1199 promoter) or a control promoter reporter (pGL4). Luciferase activity 
analysis revealed a significant increase in miR-1199 promoter activity upon loss of 
Zeb1 (Figure 5B). Conversely, overexpression of 6xMyc-tagged Zeb1 in epithelial 
NMuMG/E9 cells significantly decreased miR-1199 promoter activity compared to 
miR-1199 promoter activity of cells transfected with 6xMyc-tag as negative control 
(Figure 5C). Furthermore, the regulation of miR-1199 promoter activity by loss or 
gain of function experiments of Zeb1 correlated with an increase or decrease in miR-
1199-5p transcripts, respectively (Figure 5D, E). 
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Figure 5: Zeb1 controls the expression of miR-1199-5p on the transcriptional level. (A) Schematic 
presentation of the mouse miR-1199 promoter region on chromosome eight. Grey: Localization of E-boxes 
(CANNTG, N = G or C) as potential binding sites for Zeb1. Red: Localization of primer pairs within the miR-
1199 promoter region used for ChIP-PCR analysis in F. (B, C) Zeb1 controls the promoter activity of miR-
1199. NmuMG/E9 cells were transfected with the Firefly luciferase reporter constructs described in 
supplementary Figure 3A, a Renilla reporter and further with either siRNAs against Zeb1 or a control (B) or 
6xMyc-tag-Zeb1 or 6xMyc-tag as negative control (C). Cells transfected with siRNAs were cultured for four 
days with TGFβ and cells transfected with 6xMyc-tag or 6xMyc-tag-Zeb1 were cultured in the absence of the 
growth factor. Relative luminescence intensities (Firefly/Renilla) were measured and normalized to the 
control reporter (pGL4). (D) miR-1199-5p expression increases upon loss of Zeb1. NMuMG/E9 cells were 
transfected with siRNAs against Zeb1 or a negative control and cultured in the presence of TGFβ for four 
days. miR-1199-5p levels were analyzed by qRT-PCR. Data are represented as mean +/- S.E.M. of three 
independent experiments. (E) miR-1199-5p expression decreases upon overexpression of Zeb1. NMuMG/E9 
cells were transiently transfected with 6xMyc-tag-Zeb1 or 6xMyc-tag as negative control and cultured in the 
absence (untreated) and presence of TGFβ (4 days). miR-1199-5p levels were analyzed by qRT-PCR. Data 
are represented as mean +/- S.E.M. of three independent experiments. (F) Schematic model depicting the 
mechanistic function of miR-1199-5p during TGFβ-induced EMT in mammary (tumor) cells. Upon EMT 
induction the transcript levels of miR-1199-5p (green) decrease, whereas Zeb1 levels (red) increase. MiR-
1199-5p and Zeb1 control each other in a double negative feedback loop. Expression of miR-1199-5p 
prevents TGFβ-induced EMT, particularly, stabilizes E-cadherin at the plasma membrane and reduces tumor 
cell migration and invasion. 
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These results suggested that Zeb1 functions as a transcriptional repressor of 
miR-1199, and that miR-1199-5p and Zeb1 indeed regulate each other in a reciprocal 
negative feedback loop during TGFβ-induced EMT. 
 
3.2.4 Discussion 
Cancer-associated EMT can drive early steps of the metastatic cascade by 
converting epithelial tumor cells into metastatic cancer cells. This developmental 
dedifferentiation process allows tumor cell dissemination and invasion at the primary 
site. Mesenchymal tumor cells can enter the blood circulation and extravasate at a 
distant organ to, eventually, grow out as lethal macro metastasis promoted by a MET 
[2, 13, 26]. In order to discover conserved EMT-regulatory mechanisms during 
normal and cancer-associated EMT we utilized the untransformed NMuMG cells, a 
frequently used model to study TGFβ-induced EMT [357]. A detailed TGFβ time 
course experiment and subsequent deep sequencing analysis displayed the kinetic 
transcriptional changes during EMT. Hereby, we established a basis to understand 
the molecular mechanisms during EMT to potentially interfere and prevent EMT-
driven cancer cell dissemination from tumors of an epithelial origin. 
In this study, we concentrated on post-transcriptional regulation of EMT by 
miRNAs and their interaction with transcription factors mediating this dynamic 
process. Using deep sequencing analysis, we extracted 32 highly differentially 
regulated miRNAs (> 4-fold; p < 0.05) during TGFβ-induced EMT in NMuMG/E9 cells 
(Figure 1A). We found transcripts of miR-200 family members (miR-200a-3p/-5p, 
miR-200b-3p/-5p and miR-429-3p) significantly downregulated which is consistent 
with other studies in NMuMG and other EMT model systems [254, 264, 268]. Kong 
and colleges have published a similar approach in 2008. They have profiled an EMT 
miRNA signature induced by canonical TGFβ signaling (24 hours) in NMuMG cells by 
microarray analysis. They have found miR-155 to be upregulated by the TGFβ/Smad 
pathway. The authors have convincingly demonstrated that elevated levels of miR-
155 promotes EMT through targeting RhoA GTPase, a regulator of cell polarity and 
tight junction stability [262]. In our deep sequencing analysis we used a very stringent 
cut-off to select for highly regulated miRNAs during TGFβ-induced EMT. Although 
miR-155 was not in our final miRNA list, we still observed an upregulation of miR-155 
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by 2-fold after 24 hours and almost 3-fold after 96 hours of TGFβ treatment (data not 
shown). However, comparing our miRNA EMT signature with other published 
signatures it is striking that we did not observe a complete overlap in miRNA 
expression within the different studies [254, 262-264, 266]. These discrepancies in 
miRNA expression during EMT might have diverse reasons. They can be due to, for 
example, different cell model systems, duration of TGFβ treatment, other EMT-
inducing stimuli or miRNA expression cut off stringencies. Additionally, it should be 
noted that the other published miRNA signatures were based on microarray 
technology. We utilized deep sequencing analysis to study miRNA kinetics during cell 
dedifferentiation. This method has the advantage to provide better specificity and 
sensitivity in miRNA detection and allows the identification of so far unknown 
miRNAs. To our knowledge, this is the first time-resolved miRNA profiling of TGFβ-
induced EMT based on deep sequencing analysis. However, these two different 
miRNA detection technologies can cause divergent miRNA signatures between the 
different studies. 
We further tested the functionality of the 32 highly differentially expressed 
miRNAs during EMT and mesenchymal tumor cell migration by two different 
approaches (Figure 1B, C). From this analysis, we extracted four miRNAs, which 
prevented cells to undergo EMT upon TGFβ stimulation and reduced mesenchymal 
tumor cell migration. We found the two miR-200 family members miR-200b-3p and 
miR-429-3p and confirmed their importance for an epithelial differentiated cell 
phenotype, which has been observed by several other groups before [254, 265, 268, 
269]. We also identified miR-125b-5p in our screen, which has been reported by 
others to facilitate tumor cell migration and invasion [390, 391]. Finally, we 
discovered miR-1199-5p as a novel EMT-regulatory miRNA with a functional impact 
on mesenchymal cancer cell migration (Figure 1D). 
The transcript levels of miR-1199-5p as well as its promoter activity were 
continuously downregulated during TGFβ-induced EMT in NMuMG/E9 cells (Figure 
1A, Figure 2A). Many studies have shown that epigenetic alterations, especially CpG 
island hypermethylation-associated miRNA siliencing, could be responsible for the 
observed deregulation of miRNAs in human cancers [260, 397]. In 2012, Davalos 
and colleges investigated the reversibility of CpG island hypermethylation of the two 
miR-200 family gene cluster promoters during EMT. Induction of EMT by TGFβ in 
MDCK cells correlated with increased CpG island hypermethylation and decreased 
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miR-200 family expression. Subsequently, TGFβ withdrawal led to MET and a 
removal of the methylation marks in the miR-200 promoter regions. Furthermore, 
these methylation patterns in the miR-200 family gene clusters correlated with 
epithelial or mesenchmyal cell morphology of different human cancer cell lines [102]. 
MiR-1199-5p and miR-200 family members seem to display a similar regulation and 
function during EMT. MiR-1199 is located on chromosome 8 in the mouse and on 
chromosome 19 in the human genome within CpG islands. Whether the expression 
of miR-1199 is indeed controlled by dynamic hypermethylation during TGFβ-induced 
EMT and/or metastatic breast cancer cells, will be investigated in the future. 
Forced expression of miR-1199-5p in untransformed mouse and human 
mammary cells prevented cells to undergo EMT upon TGFβ treatment (Figure 2B-E, 
supplementary Figure 3B-E). The epithelial adhesion junction protein E-cadherin was 
strongly stabilized in both untransformed cell lines. However, sustained E-cadherin 
expression upon miR-1199-5p overexpression in the breast cancer cell line Py2T did 
not prevent a mesenchymal cell morphology, it rather delayed this dedifferentiation 
process (supplementary Figure 3F-I). Nonetheless, forced expression of miR-1199-
5p in mesenchymal Py2T and 4T1 breast cancer cells significantly reduced their 
migratory and invasive cell behavior (Figure 3A-E). Increased mesenchymal tumor 
cell motility is an output of cancer-associated EMT, which promotes metastatic 
spread in vivo [138]. Whether gain or loss of function of miR-1199-5p would reduce 
or increase, respectively, the metastatic potential of orthotopically transplanted 4T1 
cells in vivo has to be investigated in the future. To address these questions, we plan 
to establish an inducible 4T1 cell line, which expresses miR-1199 upon doxycycline 
treatment. In parallel, genomic excision of the miR-1199 gene in 4T1 cells by using 
the CRISPR/Cas9 system (Clustered Regularly Interspaced Short Palindromic 
Repeats) will further help us to understand the role of miR-1199 in the context of 
malignant tumor progression. 
Transcriptional and posttranscriptional networks built by TFs and miRNAs 
represent two different yet interconnected mechanisms regulating EMT-MET 
plasticity [143, 269, 290, 291]. The well-described TF families of Snail, Zeb and Twist 
are considered as key EMT drivers guiding the initiation and maintenance of the 
cellular dedifferentiation process [138]. Here, we demonstrated a new negative 
reciprocal regulation of miR-1199-5p and Zeb1 during TGFβ-induced EMT in 
different breast model systems (Figure 4, Figure 5, supplementary Figure 4). Other 
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than miR-1199-5p, Zeb1 mRNA levels were upregulated during EMT (supplementary 
Figure 4A). RNAi-mediated knockdown of Zeb1 prevented TGFβ-induced EMT in 
MCF10A cells and reduced mesenchymal tumor cell migration of Py2T and 4T1 cells 
(supplementary Figure 4B, C). Zeb1, together with Zeb2, belongs to the zinc finger E-
box-binding homeobox TF family. They bind to E-box promoter elements and directly 
repress transcription of miR-200 family members or E-cadherin, whose loss is a 
hallmark of EMT [269, 398, 399]. Whether Zeb1 binds to existing E-box elements in 
the miR-1199 promoter region (Figure 5A) to directly repress its transcription has to 
be investigated. Like Zeb1, Zeb2 also inhibited miR-1199 promoter activity and 
reduced miR-1199-5p transcript levels (data not shown). However, Zeb2 was not a 
predicted downstream target of miR-1199-5p and its mRNA levels were unchanged 
upon miR-1199-5p overexpression in NMuMG/E9 cells (Figure 2E). Therefore, both 
Zeb1 and Zeb2 transcriptionally control miR-1199 expression, but only Zeb1 seems 
to be post-transcriptionally regulated by miR-1199-5p. 
In summary, we identified miR-1199-5p as a regulator of EMT in normal and 
mammary tumor cells. MiR-1199-5p is expressed in epithelial cells and is 
downregulated during cell dedifferentiation. Forced expression of miR-1199-5p 
prevented or delayed TGFβ-induced EMT and significantly reduced mesenchymal 
tumor cell migration and invasion. We further report a new negative reciprocal 
regulation of miR-1199 and Zeb1 during EMT (Figure 5F). Several research groups 
have described double negative feedback loops between different miRNAs and EMT 
master TFs like Zeb1/2, Snail and Slug, which together tightly control EMT and 
malignant tumor progression [139, 143, 269, 288, 400]. 
These feedback loops involving major TFs and miRNAs suggest a crucial role of 
post-transcriptional regulation during the highly dynamic process of EMT and 
perhaps cell fate. It is fascinating to think of this kind of regulation as a remnant of 
tissue development and embryogenesis, when this kind of cell plasticity is required. If 
so, are these superordinate functional units that facilitate the dynamic switch 
between an epithelial and mesenchymal cell type? Do they endow cells with a high 
degree of cellular plasticity, which is necessary during embryogenesis and revived or 
disturbed during malignant tumor progression? To fully understand the function and 
regulation of TF-miRNA interactions in EMT-associated tumor progression, additional 
investigation is required. However, as this study demonstrates cell fate is highly 
dynamic and is closely regulated on the post-transcriptional level. 
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3.2.5 Materials and methods 
Reagents and Antibodies 
Antibodies  
The following antibodies were used: E-cadherin (BD Transduction Labs, 610182), 
N-cadherin (Takara, M142), ZO-1 (Zymed, 617300), Paxillin (BD, 610052), 
Fibronectin (Sigma-Aldrich, F3648), Vimentin (Sigma-Aldrich, V2258), GAPDH 
(Sigma-Aldrich, G8795), Zeb1 (Cell Signaling, 3396 or Santa Cruz Biotechnology, sc-
25388), Alexa-Fluor 488 and 568 (Molecular Probes), secondary HRP-conjugated 
antibodies against mouse and rabbit (Jackson ImmunoResearch) 
Reagents  
Recombinant human TGFβ1 (R&D Systems, 240-B), 4',6-diamidino-2-
phenylindole (DAPI, Sigma-Aldrich), Phalloidin Alexa-Fluor 568 (Molecular Probes, 
A12380) 
 
Cell lines and cell culture 
A subclone of normal murine mammary gland cells (NMuMG/E9) has been 
described previously [357]. The human epithelial mammary gland cells MCF10A 
have been described earlier [401]. Py2T cells have been established from a MMTV-
PyMT mammary tumor and have been described previously [360]. The murine 
metastatic cell line 4T1 has been described earlier [393]. 
NMuMG/E9, Py2T and 4T1 cells were cultured in Dulbecco`s modified eagle 
medium (DMEM; Sigma-Aldrich) supplemented with fetal calf serum (FCS, 10 %; 
Sigma-Aldrich), glutamine (2 mM; Sigma-Aldrich), penicillin (100 U; Sigma-Aldrich) 
and streptomycin (0.2 mg/l; Sigma-Aldrich). MCF10A cells were cultured in 
DMEM/F12 medium supplemented with horse serum (5 %; Bioconcept Amimed), 
insulin (10 µg/ml; Sigma-Aldrich), hydrocortisone (0.5 µg/ml; Sigma-Aldrich), human 
EGF (0.02 µg/ml; Invitrogen) and cholera toxin (0.01 µg/ml; Sigma-Aldrich). All cell 
lines were grown at 37 °C, 5 % CO2, 95 % humidity. 
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Transient transfections 
miRNA mimic transfection 
miRNA mimics are chemically modified, double-stranded RNA molecules and 
were used for ectopic expression of mature miRNAs. NMuMG/E9, MCF10A, Py2T 
and 4T1 cells were transfected with 20 nM or 50 nM of mouse or human pre-miR 
miRNA precursors (Ambion; mmu-miR-1199-5p: PM13577; hsa-miR-1199-5p: 
PM26554) by using Lipofectamine RNAiMax (Invitrogen) according to the 
manufacture`s instructions. A random sequence has been used as negative control 
(Ambion, AM17110 control #1). To maintain overexpression of miR-1199-5p, the 
transfection was repeated every third day. 
siRNA transfection 
20 nM of siRNA against murine/human Zeb1 (AM16708) or a scrambled control 
siRNA (Ambion) was used for transient knock down experiments in NMuMG/E9 and 
MCF10A cells. Lipofectamine RNAiMax (Invitrogen) was used for the transfection 
according to the manufacture`s instructions and the transfection was repeated every 
third day to maintain a knock down of gene transcripts during the experiments. 
 
Plasmids  
6xMyc-tagged Zeb1 
pCS3-6xMyc-tag-Zeb1 was a kind gift from T. Brabletz (Friedrich-Alexander-
Universität Erlangen-Nürnberg, Germany). The proper control plasmid pCS3-6xMyc-
tag was generated by digesting pCS3-6xMyc-tag-Zeb2 with EcoRI/XbaI, thereby 
removing the Zeb2 gene but retaining the 6xMyc tag. pCS3-6xMyc-tag-Zeb2 was 
also a gift from T. Brabletz (Friedrich-Alexander-Universität Erlangen-Nürnberg, 
Germany). 
miR-1199 promoter reporter 
The genomic promoter region of miR-1199 (800 nucleotides upstream of TSS) of 
NMuMG/E9 cells was PCR-amplified with the following primers: 5`-
tcgactcgaggaccggggaaacactctgta-3` and 5`-tcgaaagcttgcgtctccatctgcaattccgc-3`, 
which exhibit restriction enzyme sites for XhoI and HindIII, respectively (underlined). 
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The PCR amplicon was digested with XhoI and HindIII and subcloned into the 
pGL4.10[luc2] firefly luciferase reporter vector purchased from Promega. 
Zeb1 3`UTR reporter 
A mouse Zeb1 3`UTR reporter was generated by subcloning the Zeb1 3`UTR 
sequence (166-302 bps) containing a wild type (wt: GACTCAGA) or mutated miR-
1199-5p binding site (mut: GTGACTCA) into the pMIR-REPORT Firefly luciferase 
vector (Applied Biosystems) via SpeI/HindIII sites. Integrated DNA Technologies 
synthesized the different DNA fragments. 
 
Luciferase reporter Assay 
A Dual-Luciferase reporter assay (Promega) was used to measure the miR-1199 
promoter activity and posttranscriptional repression of Zeb1 3`UTR by miR-1199-5p. 
miR-1199 promoter reporter: 
In a TGFβ time course experiment, NMuMG/E9 cells were plated in triplicates in 
a 24-well plate and treated with TGFβ for zero, one, four, seven and ten days. Three 
days before measuring the luciferase activity, cells were transfected with 0.5 ug of 
pGL4-miR-1199 Firefly luciferase promoter reporter or pGL4 reporter (lacking a 
promoter cassette) by using Lipofectamine 3000 (Invitrogen). Additionally, cells were 
transfected with 10 ng of pRL-CMV (Promega), which encodes a Renilla luciferase 
and was used for subsequent cell number normalization.  
To test miR-1199 promoter activity upon Zeb1 gain and loss of function studies, 
NMuMG/E9 cells were plated as described before and reverse transfected with 20 
nM of siRNAs against Zeb1 or a negative control (loss of function). On the next day, 
cells were transfected with the different reporter constructs mentioned above and 
treated with TGFβ for three days. For Zeb1 gain of function studies, NMuMG/E9 cells 
were forward transfected with 50 ng of pCS3-6xMyc-tag or pCS3-6xMyc-tag-Zeb1 
along with the different luciferase reporters. 
Zeb1 3`UTR reporter: 
NMuMG/E9 cells were plated as described above and reverse transfected with 
20 nM of miR-1199-5p or a negative control mimic. On the next day, cells were 
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transfected with 0.2 µg of pMIR-Report-Zeb1 3`UTR wt or pMIR-Report-Zeb1 3`UTR 
mut along with 10 ng of pRL-CMV by using Lipofectamine 3000 (Invitrogen). 
Three days after reporter plasmid transfection, cells were washed twice with PBS, 
100 µl of 1x passive lysis buffer (Promega) was added per well and incubated for 30 
minutes at room temperature. 6 µl of supernatant was transferred to a 96-well plate 
and Firefly/Renilla luciferase activity was measured with a luminometer (Berthold 
Technologies; Centro LB 960). 
 
Quantitative RT-PCR 
In order to quantify gene transcripts, total RNA was isolated using Tri Reagent 
(Sigma-Aldrich) following the manufacture’s instruction. cDNA was generated by 
reverse transcription of RNA using M-MLV reverse transcriptase (Promega) and was 
quantified by real-time PCR using Mesa Green qPCR MasterMix plus (Eurogentec). 
Riboprotein L19 was used as internal normalization control. Fold changes were 
calculated using the comparative Ct method (∆∆Ct). 
Primers used for quantitative RT-PCR: 
Table 1: List of oligonucleotides used for quantitative RT-PCR 
Name fwd. primer (5`- 3`) rev. primer (5`- 3`) 
Murine genes 
mRpl19 ctcgttgccggaaaaaca tcatccaggtcaccttctca 
mCdh1 cgaccctgcctctgaatcc tacacgctgggaaacatgagc 
mFibronectin cccagacttatggtggcaatt aatttccgcctcgagtctga 
mVimentin ccaaccttttcttccctgaa ttgagtgggtgtcaaccaga 
mCdh2 caatgacgtccaccctgttct ctgccatgactttctacggaga 
mZeb1 gccagcagtcatgatgaaaa tatcacaatacgggcaggtg 
mSox4 cctcgctctcctcgtcct tcgtcttcgaactcgtcgt 
Human genes 
hRpl19 gatgccggaaaaacaccttg tggctgtacccttccgctt 
hCdh1 agaacgcattgccacatacact tctgatcggttaccgtgatcaa 
hFibronectin gaactatgatgccgaccagaa ggttgtgcagatttcctcgt 
hCdh2 tagtcaccgtggtcaaaccaat gtgctgaattcccttggctaat 
hZeb1 gccaacagaccagacagtgtt tcttgcccttcctttcctg 
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For quantitative miRNA analysis, total RNA was isolated using miRNeasy kit 
(Qiagen). Mature miRNAs were reverse transcript and measured by using the 
miRCURY LNA Universal RT microRNA PCR kit from Exiqon. U6 snRNA was utilized 
as internal normalization control during quantitative RT-PCR. Fold changes were 
calculated using the comparative Ct method (∆∆Ct). 
Primers used for quantitative RT-PCR of miRNAs: 
- Mouse U6 miRCURY LNA UniRT PCR reference primer mix (Exiqon; 203907) 
- mmu-miR-1199-5p miRCURY LNA UniRT PCR primer mix (Exiqon; 206004) 
 
Immunoblotting 
Cells were lysed in RIPA buffer (50 mM Tris-HCl (pH 8.0), 150 mM NaCl, 10% 
Glycerol, 1 % NP40, 0.5 % NaDOC, 0.1 % SDS, 2 mM MgCl2, 2 mM CaCl2, 1 mM 
DTT, 1 mM NaF, 2 mM Na3VO4 and 1x protease inhibitor cocktail (Sigmal-Aldrich)) 
on ice for 20 minutes, centrifuged and protein concentrations were determined via 
Biorad Bradford solution according to the manufacturer’s instructions. Proteins were 
mixed with SDS-PAGE loading buffer (10% glycerol, 2% SDS, 65 mM Tris, 1 
mg/100ml bromophenol blue, 1 % β-mercaptoethanol) and equally loaded on a SDS 
polyacrylamide gel. After size fractionation, proteins were transferred on an 
Immobilon-P PVDF membrane (Millipore) using an electrophoretic transfer cell 
(Biorad) and blocked with 5 % skim milk powder dissolved in TBS/0.05 % Tween for 
one hour. The membrane was incubated with the primary antibody (listed above) 
over night at 4 °C or one hour at room temperature. HRP-conjugated secondary 
antibodies were used to visualize specific proteins by the Fusion Fx7 
chemoluminescence reader (Vilber Lourmat). 
 
Immunofluorescence 
Cells were grown on uncoated glas cover slips (Menzel-Glaser), fixed with 4 % 
paraformaldehyde/PBS for 20 minutes, permeabilized with 0.5 % NP40 for 5 minutes 
and blocked with 3 % BSA/0.01 % Triton-X-100/PBS for 30 minutes. The primary 
antibodies (listed above) were diluted in 3 % BSA/0.01 % Triton-X-100/PBS and 
incubated with the cells at room temperature for 1.5 hours, followed by an incubation 
with a fluorophore-coupled secondary antibody (Alexa Fluor, Invitrogen). Cell nuclei 
were visualized with DAPI (Sigma-Aldrich). After staining, the cells were mounted 
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with fluorescence mounting medium (Dako) on microscope slides and imaged using 
fluorescence microscopy (Leica DMI 4000). 
 
EMT phenotypic microscopy-based screen 
NMuMG/E9 cells were plated as duplicates in a 96-well plate and reverse 
transfected with 20 nM miRNA mimics using Lipofectamine RNAiMax (Invitrogen) 
prior to four days TGFβ treatment or not. For immunofluorescence analysis, cells 
were processed as described above and mesenchymal characteristics like formation 
of focal adhesions (Paxillin), actin stress fibers (Phalloidin) and secretion of 
Fibronectin were stained with antibodies described before. Images of cells in a 96-
well plate were taken with the fluorescence Operetta HCS microscope (Perkin 
Elmers). EMT features were quantified (Columbus software, version 2.5.0) and the 
median of two replicates was calculated, normalized to the number of nuclei (DAPI) 
and compared to the median value of miR-Ctr transfected cells. Standard deviations 
(SD) were estimated. MiRNAs showing an at least 3x SD for all three EMT read outs 
or 4x SD in two EMT read outs aside from the median value of miR-Ctr transfected 
cells were considered as hits to block or induce EMT. Some miRNAs, which turned 
out to be no hits in the EMT phenotypic microscopy-based screen, but maintained an 
epithelial cell morphology of NMuMG/E9 cells cultured in the presence of TGFβ 
(judged by eye), were also considered as hits. 
 
Transwell Assays 
Boyden Chamber migration and invasion Assay (24-well plate format) 
Mesenchymal Py2T and 4T1 cells were reverse transfected with 50 nM of 
miRNA mimics in a 6-well plate. Two days later, the cells were trypsinized, washed 
once with PBS and counted. 25`000 cells were plated as duplicates in a 24-trans-well 
migration (8 µm pore membrane) or invasion (8 µm pore membrane, covered with a 
layer of growth factor reduced matrigel) insert (BD Biosciences). After 18 hours, the 
cells were fixed with 4 % paraformaldehyde/PBS, nuclei were stained with DAPI 
(Sigma-Aldrich) and non-migrated/invaded cells on the upper surface of the 
membrane were removed with a cotton swab. Migrated/invaded cells on the bottom 
of the membrane were imaged with a fluorescence microscope (Leica DMI 4000) and 
quantified. As chemoattractant a gradient of 0.2 % - 20 % FCS was used. 
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Boyden Chamber migration Assay (96-well plate format) 
Mesenchymal Py2T cells were reverse-transfected with 50 nM of miRNA mimics 
in a 96-well plate. After two days, cells were trypsinized and washed with PBS in a 
round-bottom 96-well plate (Corning). MiR-Ctr-transfected cells were counted and 
6`000 cells were plated as duplicates in the inserts of a 96-well FluoroBlok 
fluorescent-blocking High Density PET insert (BD Biosciences) and, in parallel, in a 
96-well reference plate (Cell Carrier 96, Perkin Elmers). The same cell suspension 
volume was used to plate cells transfected with other miRNA mimics. As 
chemoattractant a gradient of 0.2 % - 20 % FCS was used. Migrated cells (bottom of 
membrane of migration insert) as well as cells in the reference plate were imaged 
with the Operetta HCS microscope (Perkin Elmers), quantified (Columbus software, 
version 2.5.0) and normalized to each other. 
 
Statistical analysis 
Statistical analyses and graphs were generated using GraphPad Prism software 
(version 6). Statistical analyses were performed by an unpaired, two-sided student t-
test with * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001. 
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3.2.6 Supplementary data 
 
Supplementary Figure 1: Identified miRNAs affecting TGFβ-induced EMT. (A) Bright field images of 
NMuMG/E9 cells transfected with the indicated miRNA mimics. Top: NMuMG/E9 cells cultured in the 
absence of TGFβ. Bottom: NMuMG/E9 cells cultured in the presence of TGFβ for 4 days. Scale bar: 100 µm. 
(B) Immunofluorescence images of NMuMG/E9 cells cultured and treated as described in A. Localization of 
the epithelial marker E-cadherin (green) was analyzed. DAPI was used to stain nuclei. Scale bar: 100 µm. 
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Supplementary Figure 2: 
Identification of miRNAs regulating 
mesenchymal tumor cell migration. 
(A) Quantification of migrated 
epithelial (no TGFβ) and 
mesenchymal (> 20 days TGFβ; LT) 
Py2T cells transfected with the 
indicated miRNA mimics in a 96-well 
plate format. Graph summarizes the 
number of migrated cells per insert 
normalized to the total cell number 
(input plate). Fold changes of migrated 
cells were calculated by normalization 
to the cell number of migrated Py2T 
LT cells transfected with miR-Ctr 
mimic (red dashed line). Data are 
shown as mean +/- S.E.M. of three 
independent experiments. (B) 
Representative immune-fluorescence 
images of migrated epithelial (no 
TGFβ) and mesenchymal (> 20 days 
TGFβ; LT) Py2T cells from the 
experiment described in A. Nuclei 
were visualized with DAPI and the 
bottom of the trans-well migration 
inserts were imaged by fluorescence 
microscopy. 
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Supplementary Figure 3: Ectopic expression of miR-1199-5p affects EMT in Py2T and MCF10A cells 
(A) Scheme of miR-1199 promoter luciferase reporters. miR-1199 promoter region (-1 à -800 bps) was 
cloned in front of a Firefly luciferase gene (pGL4 miR-1199 promoter). A construct without a promoter region 
was used as control (pGL4). (B) Bright field images of MCF10A cells transfected with miR-Ctr or miR-1199-
5p mimic. Cells were cultured in the absence (untreated) and presence (5 days) of TGFβ. Scale bar: 100 µm. 
(C) Immunofluorescence images of MCF10A cells transfected with the indicated miRNA mimics and treated 
with TGFβ for 5 days. Localization of E-cadherin (green) was analyzed. DAPI was used to stain nuclei. Scale 
bar: 100 µm. (D) mRNA levels of indicated EMT markers in MCF10A cells transfected with indicated miRNA 
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mimics and treated with TGFβ for 5 days. qRT-PCR analysis was used to determine mRNA expression and 
data are presented as mean fold change +/- S.E.M. of three independent experiments. (E) Immunoblot 
analysis for indicated EMT markers in MCF10A cells cultured as described in D. GAPDH was used as 
loading control. (F) Bright field images of Py2T cells transfected with miR-Ctr or miR-1199-5p mimic. Cells 
were cultured in the absence (untreated) and presence (3 days) of TGFβ. Scale bar: 100 µm. (G) 
Immunofluorescence images of Py2T cells transfected with the indicated miRNA mimics and treated with 
TGFβ for 3 days. Localization of E-cadherin (green) was analyzed. DAPI was used to stain cell nuclei. Scale 
bar: 100 µm. (H) mRNA levels of indicated EMT markers in Py2T cells transfected with the indicated miRNA 
mimics and treated with TGFβ for 3 days. qRT-PCR analysis was used for the measurement and data are 
presented as mean fold change +/- S.E.M. of three independent experiments. (I) Immunoblot analysis for 
indicated EMT markers in Py2T cells cultured as described in H. GAPDH was used as loading control. 
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Supplementary Figure 4: The transcription factor Zeb1 controls TGFβ-induced EMT and 
mesenchymal tumor cell migration and its expression is further controlled by miR-1199-5p in Py2T 
and MCF10A cells. (A) Zeb1 mRNA levels were determined during TGFβ-induced EMT in NMuMG/E9 (left), 
Py2T (middle) and MCF10A cells (right) by qRT-PCR analysis. Data are presented as mean fold changes +/- 
S.E.M. of one (MCF10A) or three (NMuMG/E9, Py2T) independent experiments. (B) Bright field images of 
MCF10A cells transfected with siRNAs against Zeb1 (siZeb1) or a negative control (siCtr) and cultured in the 
absence (untreated) and presence (5 days) of TGFβ. Scale bar: 100 µm. (C) Trans-well Boyden chamber 
migration assay. Mesenchymal Py2T (left) and 4T1 (right) cells were transfected with siRNAs against Zeb1 
or a negative control. Two days later, cells were replated in a trans-well migration insert (24-well plate format) 
and migrated cells were quantified after 18 hours. Data are represented as mean fold changes of migrated 
cells per insert +/- S.E.M. of three independent experiments. (D) miR-1199-5p regulates the protein levels of 
Zeb1 in Py2T cells. Immunofluorescence images of Py2T cells transfected with miR-Ctr or miR-1199-5p 
mimic. Cells were cultured in the absence (untreated; top) or presence of TGFβ (3 days TGFβ; bottom). 
Localization of E-cadherin (green) and levels of Zeb1 (red) were analyzed. DAPI was used to stain cell nuclei 
(blue). Scale bar: 100 µm. (E) Immunoblot analysis of Zeb1 protein levels in Py2T cells. Cells were cultured 
and treated as described in D. Zeb1 levels were quantified and normalized to GAPDH levels, which was 
used as loading control. (F) Immunoblot analysis of Zeb1 protein levels in MCF10A cells. Cells were 
transfected with miR-Ctr or miR-1199-5p mimics and cultured in the absence (untreated) or presence of 
TGFβ for 5 days. GAPDH was used as loading control. Zeb1 protein levels were quantified and normalized 
to GAPDH protein levels. 
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4 General conclusions and future plans 
The dynamic nature of cellular EMT and MET processes are essential during 
embryogenesis and wound healing since they promote organ formation and tissue 
regeneration. Upon diverse extracellular signals, interconnected molecular networks 
consisting of transcription factors, epigenetic regulators, splicing factors and non-
coding RNAs can orchestrate EMT/MET processes to endow the necessity of tissue 
plasticity in these contexts. However, during tumorigenesis aberrant (in)activation of 
these networks can induce oncogenic EMT, which promotes tumor cell invasion and 
malignant tumor progression. 
The work presented here has aimed to provide new insights into the molecular 
mechanisms orchestrating an EMT and its functional consequences in normal and 
tumorigenic mammary epithelial cells. We have reported the identification and 
characterization of the transcription factor Tead2. As a transcriptional effector of the 
Hippo pathway, Tead2 is required during TGFβ-induced EMT and promotes 
mesenchymal tumor cell migration, invasion and lung colonization in vivo. Since 
Tead2 induces an oncogenic EMT via direct binding to its cofactors Yap and Taz, 
pharmacological inhibition of the Tead2/Yap/Taz interface might be beneficial for 
breast cancer treatment. In this case, disruption of Tead2 binding to Yap and/or Taz 
would prevent oncogenic EMT and might reduce primary tumor cell invasion and 
their systemic dissemination. Considering the pro-proliferative and anti-apoptotic 
cellular effects induced by Tead/Yap/Taz transcriptional activity, their 
pharmacological inhibition might further restrict primary tumor as well as metastatic 
growth. Some molecules have been reported to disrupt the Tead/Yap/Taz 
transcriptional complex and future investigations will prove whether this strategy can 
be translated into the clinics and provide the expected beneficial outcome for cancer 
patients. 
Aside from transcriptional control of EMT by Tead2, we have further reported the 
identification and characterization of miR-1199-5p - a novel and critical EMT-
regulatory miRNA that mechanistically functions in a double-negative feedback 
regulation with the EMT transcription factor Zeb1. However, whether Zeb1 directly 
targets existing E-box sequences in the miR-1199 promoter and thereby represses 
its activity, will be tested by Zeb1 chromatin immunoprecipitation (ChIP) followed by 
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quantitative RT-PCR. Furthermore, transcriptional downregulation of miR-1199-5p 
seems to be required for a TGFβ-induced EMT and mesenchymal mammary tumor 
cell migration and invasion in vitro. However, whether its downregulation in epithelial 
cells is also sufficient to induce EMT and increase cell migration and invasion has to 
be examined. Additionally, RNA deep sequencing analysis of cells forced to express 
miR-1199-5p after TGFβ-treatment should help to identify other EMT-relevant targets 
of miR-1199-5p aside from Zeb1 and further embed miR-1199-5p in an EMT 
molecular network. Regarding miR-1199-5p's impact on breast cancer progression, 
the following questions arise and shall be addressed in the future: (a) What are the 
consequences of miR-1199-5p overexpression or its genetic deletion in the context of 
breast cancer progression in vivo? Does a stable overexpression of miR-1199-5p in 
breast tumor cells lead to a reduction and its loss to an increase in breast cancer 
metastases of orthotopically transplanted mouse 4T1 cells? (b) Does miR-1199-5p 
expression correlate with specific breast cancer subtypes in patients? (c) How is 
miR-1199 expression regulated during EMT and during tumor progression? Strikingly, 
the MIR-1199 gene is located within CpG islands in the mouse and human genome, 
therefore its transcription might be further controlled by DNA hypermethylation during 
TGFβ-induced EMT and/or in metastatic breast cancer cells. The identification and 
initial characterization of miR-1199-5p during EMT raises many exciting questions, 
which should be investigated in the future. 	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